document incorporate reference document proxy statement annual meeting iii shareholder hold file securities exchange commission day close fiscal year cover reporttable content table content item business item risk factor cautionary factor affect future result item unresolved staff comment item property item legal proceeding item safety disclosure executive officer registrant item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum financial statement note consolidated financial statement report independent register public accounting firm supplementary datum item change disagreement accountant account financial disclosure item control procedure management report item information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service item exhibit financial statement schedule signature consent independent register public accounting firm table content item business merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health consumer care product market directly joint venture company operation principally manage product basis comprise operating segment pharmaceutical animal health consumer care alliance segment reportable segment pharmaceutical segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer additionally company consumer care operation develop manufacture market overthecounter foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet financial information information pharmaceutical segment item management discussion analysis financial condition result operation item financial statement supplementary datum product service mark appear type form different surround text trademark service mark own license promote distribute merck subsidiary affiliate note trademark service mark respective owner overview company focus accelerate revenue growth reduce cost drive efficiency allocate resource drive future growth make strategic investment product launch emerge market advance augment research development pipeline worldwide sale total billion increase compare billion foreign exchange favorably affect global sale performance revenue increase drive largely growth januvia sitagliptin janumet sitagliptinmetformin hydrochloride hci treatment type diabete singulair montelukast sodium medicine chronic treatment asthma relief symptom allergic rhinitis isentress raltegravir antiretroviral therapy use combination therapy treatment hiv infection gardasil human papillomavirus quadrivalent type vaccine recombinant vaccine help prevent certain disease cause type human papillomavirus hpv simponi golimumab treatment inflammatory disease rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infant child zetia ezetimibe cholesterol absorption inhibitor pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease bridion sugammadex reversal certain muscle relaxant surgery addition revenue benefit high sale company animal health product launch victrelis boceprevir treatment chronic hepatitis increase partially offset low sale cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide treatment hypertension lose patent protection united states april number major european market march low sale caelyx subutex suboxone company long marketing right product revenue negatively affect low sale vytorin ezetimibesimvastatin cholesterol modify medicine temodar temozolomide treatment certain type brain tumor proquad measle mump rubella varicella virus vaccine live pediatric combination vaccine help protect measle mump rubella varicella varivax varicella virus vaccine live vaccine help table content prevent chickenpox varicella addition discuss ongoing implementation certain provision health care reform legislation result increase medicaid rebate impact reduce revenue additionally country european union undertake austerity measure aim reduce cost health care implement pricing action negatively impact sale april merck johnson johnson reach agreement amend agreement govern distribution right remicade infliximab simponi agreement conclude arbitration proceeding initiate term amend distribution agreement merck relinquish marketing right remicade simponi territory include canada central south america middle east africa asia pacific effective july merck retain exclusive marketing right europe russia turkey retain territory retain territory represent approximately merck revenue billion remicade simponi addition begin july profit derive merck exclusive distribution product retain territory equally divide merck receive onetime payment merck million april company continue advancement drug candidate pipeline victrelis company innovative oral medicine treatment chronic hepatitis approve food drug administration fda european commission fda approve juvisync sitagliptin simvastatin new treatment type diabetes combine active ingredient glucoselowere medication januvia cholesterollowere medication zocor simvastatin addition approve zoely nomace monophasic combine oral contraceptive tablet use woman prevent pregnancy cubicin antibacterial agent activity methicillinresistant staphylococcus aureus mrsa company license development distribution right japan approve use country february fda approve janumet sitagliptin metformin hci extendedrelease new treatment type diabetes combine sitagliptin active component januvia extendedrelease metformin oncedaily formulation cosopt dorzolamide hydrochloridetimolol maleate ophthalmic solution merck preservativefree formulation cosopt indicate reduction elevate intraocular pressure appropriate patient openangle glaucoma ocular hypertension zioptan tafluprost ophthalmic solution preservativefree prostaglandin analogue ophthalmic solution company receive additional indication exist product fda approve expand age indication zostavax zoster vaccine live vaccine help prevent shingles herpe zoster include adult age addition fda approve sylatron peginterferon alfab injection adjuvant treatment melanoma patient microscopic gross nodal involvement simponi receive indication use combination methotrexate adult severe active progressive rheumatoid arthritis previously treat methotrexate show reduce rate progression joint damage measure xray improve physical function january fda approve use isentress combination antiretroviral medicine treatment hiv infection pediatric patient year age old weighing company currently candidate review fda ridaforolimus treatment metastatic softtissue bone sarcoma patient favorable response chemotherapy mkc zetia combine atorvastatin treatment primary mixed hyperlipidemia review company currently candidate phase iii development anticipate file new drug application nda fda respect certain candidate include suvorexant investigational treatment insomnia bridion medication reversal certain muscle relaxant surgery ninevalent hpv vaccine company anticipate filing odanacatib investigational treatment osteoporosis mka tredaptive extendedrelease niacinlaropiprantsimvastatin development treatment atherosclerosis merck continue pursue opportunity potential drive near longterm growth company complete variety transaction include acquisition inspire table contents pharmaceuticals inc specialty pharmaceutical company focus develop commercialize ophthalmic product additionally company enter transaction design strengthen presence emerge market long term merck continue realize cost saving area company saving result action include merger restructuring program discuss previously announce ongoing cost reduction activity nonrestructuringrelate activity end company realize approximately billion annual net cost saving activity merger legacy merck inc scheringplough corporation scheringplough november merger july company announce late phase global restructuring program merger restructuring program initiate conjunction integration legacy merck legacy scheringplough business merger restructuring program intend optimize cost structure combine company late phase company expect reduce workforce measure time merger additional company worldwide majority workforce reduction phase merger restructuring program relate manufacture include animal health administrative headquarters organization previously announce workforce reduction approximately early phase program primarily reflect elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility company continue hire employee strategic growth area business necessary company continue pursue productivity efficiency evaluate manufacture supply chain capability ongoing basis result future restructuring action company record total pretax restructuring cost billion billion billion relate program restructuring action merger restructuring program expect substantially complete end exception certain action principally manufacturingrelate expect substantially complete total cumulative pretax cost estimate approximately billion billion company estimate approximately twothird cumulative pretax cost relate cash outlay primarily relate employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest company expect merger restructure program yield annual saving end approximately billion billion annual saving completion program approximately billion billion company continue affect health care reform legislation enact additional provision go effect begin law require pharmaceutical manufacturer pay discount medicare beneficiary medicare coverage gap socalle donut hole approximately million record reduction revenue relate estimate impact provision health care reform company record million expense annual health care reform fee company require pay beginning law increase mandate medicaid rebate reduce revenue approximately million million respectively effective december richard clark chairman retired company merck board director kenneth frazier mercks president chief executive officer elect board serve chairman follow clarks retirement november mercks board director raise company quarterly dividend share share earning common share assume dilution attributable common shareholder eps reflect net unfavorable impact result acquisitionrelate cost restructure cost charge relate settlement arbitration proceeding discuss partially offset favorable impact certain tax item gain disposition company interest johnson johnsonmerck consumer pharmaceutical company joint venture sale certain manufacturing facility relate asset nongaap eps exclude item nongaap income nongaap ep table content product sale sale company product follow year end december pharmaceutical cardiovascular zetia vytorin integrilin diabetes obesity januvia janumet diversify brand cozaarhyzaar zocor propecia claritin remeron vasotecvaseretic proscar infectious disease isentress pegintron cancidas primaxin invanz avelox noxafil crixivanstocrin rebetol victrelis neuroscience ophthalmology maxalt cosopttrusopt oncology temodar emend intron respiratory immunology singulair remicade nasonex clarinex arcoxia simponi asmanex proventil dulera vaccines gardasil proquadmmr iivarivax rotateq pneumovax zostavax womens health endocrine fosamax nuvare follistim implanon cerazette pharmaceutical total pharmaceutical segment sale segment sale total segment sale sale legacy scheringplough product include postmerger period addition prior merger substantially sale zetia vytorin recognize msp partnership result merck interest msp partnership record equity income affiliate result merger msp partnership wholly own company accordingly sale msp partnership product merger reflect table sale zetia vytorin reflect merck sale product latin america msp partnership sale product postmerger period amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate amount reflect supply sale sanofi pasteur msd pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately reflect nonreportable segment include animal health consumer care revenue company relationship azlp primarily relate sale nexium prilosec revenue azlp billion billion billion respectively revenue primarily comprise miscellaneous corporate revenue thirdparty manufacture sale sale relate divested product business supply sale include segment result table content pharmaceutical company pharmaceutical product include therapeutic preventive agent generally sell prescription treatment human disorder certain product companys franchise follow cardiovascular zetia market ezetrol outside united states vytorin market inegy outside united states integrilin eptifibatide injection treatment patient acute coronary syndrome diabete obesity januvia janumet treatment type diabete diversified brand cozaar hyzaar zocor propecia finasteride product treatment male pattern hair loss claritin loratadine treatment seasonal outdoor allergy yearround indoor allergy remeron mirtazapine antidepressant vasotec enalapril maleate vaseretic enalapril maleatehydrochlorothiazide hypertension andor heart failure product proscar finasteride urology product treatment symptomatic benign prostate enlargement infectious disease isentress pegintron peginterferon alphab treatment chronic hepatitis cancidas caspofungin acetate antifungal product primaxin imipenem cilastatin sodium antibacterial product invanz ertapenem sodium treatment certain infection avelox moxifloxacin company market united states broadspectrum fluoroquinolone antibiotic certain respiratory skin infection noxafil posaconazole prevention invasive fungal infection crixivan indinavir sulfate stocrin efavirenz antiretroviral therapy treatment hiv infection rebetol ribavirin usp capsule oral solution use combination pegintron intron interferon alphab recombinant treat chronic hepatitis victrelis neuroscience ophthalmology maxalt rizatriptan benzoate product acute treatment migraine cosopt trusopt dorzolamide hydrochloride ophthalmic solution ophthalmic product oncology temodar market temodal outside united states emend aprepitant prevention chemotherapyinduce post operative nausea vomit intron injection market chronic hepatitis numerous anticancer indication worldwide include adjuvant therapy malignant melanoma respiratory immunology singulair remicade nasonex mometasone furoate monohydrate inhaled nasal corticosteroid treatment nasal allergy symptom clarinex desloratadine nonsedate antihistamine arcoxia etoricoxib treatment arthritis pain simponi asmanex twisthaler mometasone furoate inhalation powder oral drypowder corticosteroid inhaler firstline maintenance treatment asthma patient old proventil hfa albuterol sulfate inhalation aerosol relief bronchospasm patient year old dulera inhalation aerosol mometasone furoateformoterol fumarate dihydrate fixeddose combination asthma treatment patient year age old vaccine gardasil proquad mmr measles mumps rubella virus vaccine live vaccine help prevent measle mump rubella varivax rotateq pneumovax zostavax vaccine help prevent shingles herpe zoster patient age old women health endocrine fosamax alendronate sodium treatment prevention osteoporosis nuvare etonogestrelethinyl estradiol vaginal ring vaginal contraceptive ring follistim follitropin beta injection biological fertility treatment implanon etonogestrel implant single rod subdermal contraceptive implant cerazette desogestrel progestin oral contraceptive animal health animal health segment discover develop manufacture market animal health product include vaccine principal market product segment include livestock product nuflor antibiotic range use cattle swine bovilisvista vaccine line infectious disease cattle banamine bovine swine antiinflammatory estrumate treatment fertility disorder cattle regumatematrix fertility management swine horse resflor combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zilmax revalor table content improve production efficiency beef cattle mpac swine pneumonia vaccine porcilis vaccine line infectious disease swine poultry product nobilisinnovax vaccine line poultry paracox coccivac coccidiosis vaccine companion animal product nobivaccontinuum vaccine line flexible dog cat vaccination otomaxmometamaxposatex ear ointments acute chronic otitis caninsulinvetsulin diabete mellitus treatment dog cat panacursafeguard broadspectrum anthelmintic dewormer use animal scaliborexspot protect bite flea tick mosquitoe sandfly aquaculture product slice parasiticide sea lice salmon aquavacnorvax vaccine bacterial viral disease fish compact vaccine salmon aquaflor antibiotic farmraised fish consumer care consumer care segment develop manufacture market overthecounter foot care sun care product principal product segment include overthecounter product claritin nondrowsy antihistamine miralax treatment occasional constipation coricidin hbp decongestantfree coldflu medicine people high blood pressure afrin nasal decongestant spray zegerid otc treatment frequent heartburn foot care scholl foot care product lotrimin topical antifungal product tinactin topical antifungal product foot sneaker odorwetness product sun care coppertone sun care lotion spray dry oil discussion sale company product item management discussion analysis financial condition result operation product approval february fda approve zioptan tafluprost preservativefree prostaglandin analog ophthalmic solution reduce elevated intraocular pressure patient openangle glaucoma ocular hypertension merck exclusive commercial right tafluprost western europe exclude germany north america south america africa middle east india australia zioptan market saflutan certain market outside united states february fda approve janumet new treatment type diabete combine sitagliptin active component januvia extendedrelease metformin janumet provide convenient oncedaily treatment option health care provider patient need help control blood sugar addition february fda approve cosopt mercks preservativefree formulation cosopt ophthalmic solution indicate reduction elevate intraocular pressure appropriate patient openangle glaucoma ocular hypertension october fda approve juvisync new treatment type diabetes combine glucoselowere medication sitagliptin cholesterollowere medication zocor juvisync treatment option health care provider help patient need blood sugarlowere benefit dpp inhibitor cholesterollowering benefit simvastatin convenience single tablet daily august zoely oral contraceptive grant marketing authorization use woman prevent pregnancy zoely combine oral contraceptive tablet contain unique monophasic combination hormone nomegestrol acetate highly selective progesteronederived progestin beta estradiol estrogen similar naturally present womans body marketing authorization zoely apply member states plus iceland liechtenstein norway teva pharmaceutical industries ltd hold exclusive marketing right zoely france italy belgium spain table content fda approve victrelis company innovative oral medicine treatment chronic hepatitis victrelis approve treatment chronic hepatitis genotype infection combination peginterferon alfa ribavirin adult patient year age old compensate liver disease include cirrhosis previously untreated fail previous interferon ribavirin therapy victrelis antiviral agent design interfere ability hepatitis virus replicate inhibit key viral enzyme july approve victrelis ec decision grant single marketing authorization valid country member unified labeling applicable iceland liechtenstein norway addition united states victrelis launch market include france germany canada brazil joint ventures astrazeneca merck enter agreement astra astra develop market astra product united states merck astra form equally own joint venture develop market astra new prescription medicine united states include prilosec omeprazole class medication know proton pump inhibitor slow production acid cell stomach lining merck astra restructure joint venture merck acquire astras interest joint venture rename kbi inc kbi contribute kbis operating asset new limited partnership name astra pharmaceutical partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca azlp astras merger zeneca group plc exclusive distributor product kbi retain right company earn certain partnership return ongoing revenue base sale current future kbi product partnership return include priority return provide partnership agreement preferential return represent company share undistribute partnership azlp generally accept accounting principle gaap earning variable return relate companys limited partner interest conjunction restructuring discuss astra purchase option asset option payment million record deferred income buy merck interest kbi product exclude gastrointestinal medicine nexium prilosec nonppi products april astrazeneca exercise asset option merck receive million astrazeneca represent net present value march project future pretax revenue receive merck nonppi products record reduction company investment azlp company recognize million defer income component income expense net addition merck grant astra option share option buy merck common stock interest kbi mercks interest nexium prilosec exercisable exercise price share option primarily base net present value project future pretax revenue receive merck nexium prilosec determine time exercise subject certain trueup mechanism company believe likely astrazeneca exercise share option sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur form joint venture market human vaccine europe collaborate development combination vaccine distribution thenexiste european free trade association merck sanofi pasteur contribute thing european vaccine business equal share joint venture know pasteur mrieux msd snc sanofi pasteur msd snc joint venture maintain presence directly affiliate branches belgium italy germany spain france austria ireland sweden portugal netherlands switzerland united kingdom distributor rest territory table content license subsidiary scheringplough enter licensing agreement centocor ortho biotech inc centocor company market remicade prescribe treatment inflammatory disease scheringplough subsidiary exercise option contract centocor license right develop commercialize simponi fully human monoclonal antibody company exclusive marketing right product outside united states japan certain asian market december scheringplough centocor revise distribution agreement development commercialization distribution remicade simponi extend company right exclusively market remicade match duration company exclusive marketing right simponi addition scheringplough centocor agree share certain development cost relate simponis autoinjector delivery system october approve simponi treatment rheumatoid arthritis immune system disorder presentation novel autoinjector prefille syringe result company marketing right product extend year commercial sale simponi follow receipt pricing reimbursement approval april merck reach agreement amend agreement govern distribution right remicade simponi agreement conclude arbitration proceeding initiate term amend distribution agreement merck relinquish marketing right remicade simponi territory include canada central south america middle east africa asia pacific effective july merck retain exclusive marketing right europe russia turkey retain territory addition begin july profit derive merck exclusive distribution product retain territory equally divide merck prior term distribution agreement contribution income profit split merck percent decline merck increase year equally divide receive onetime payment merck million april competition health care environment competition market company conduct business pharmaceutical industry highly competitive highly regulate company competitor include worldwide researchbase pharmaceutical company small research company limit therapeutic focus generic drug consumer health care manufacturer company operation affect technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor generic availability competitor brand product new information clinical trial market product postmarkete surveillance generic competition company product mature addition patent position increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result recognition impairment charge respect certain product competitive pressure intensify pressure industry grow effect operation competitive factor patent dispute predict pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively longstanding emphasis research development company position compete search technological innovation additional resource require meet market challenge include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product external alliance joint venture license refine sale marketing effort address change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number compound available treat particular disease typically increase time result slow sale growth company product therapeutic category table content highly competitive animal health business affect factor include regulatory legislative issue scientific technological advance product innovation quality price company product effective promotional effort frequent introduction generic product competitor company consumer care operation face competition consumer health care business retailer carry private label brand companys competitive position affect factor include regulatory legislative issue scientific technological advance quality price company product promotional effort growth low cost private label brand health care environment global effort health care cost containment continue exert pressure product pricing market access united states federal state government year pursue method reduce cost drug vaccine pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity disproportionate share hospital hospital meet certain criterion federal vaccine child entitlement program center disease control prevention fund purchase recommend pediatric vaccine public sector price immunization medicaid eligible uninsured native american certain underinsured child merck contract provide pediatric vaccine program backdrop united states enact major health care reform legislation began implement insurance market reform advance continue implementation new law expect expand access health care million americans end decade previously regular access health care respect effect law pharmaceutical industry law increase mandate medicaid rebate expand rebate medicaid manage care utilization increase type entity eligible federal drug discount program law require pharmaceutical manufacturer pay discount medicare beneficiary medicare coverage gap socalle donut hole pharmaceutical manufacturer require pay annual health care reform fee total annual industry fee billion billion fee assess company proportion share sale certain government program medicare medicaid company face increase pricing pressure globally manage care organization government agency program negatively affect company sale profit margin united states include practice manage care group institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure addition effort contain federal deficit pharmaceutical industry consider potential source saving legislative proposal debate enact prior year type revenue generating cost saving proposal include direct price control medicare prescription drug program addition congress consider proposal allow certain condition importation medicine country remain uncertain proposal include future federal budget deficit reduction proposal directly indirectly affect company global effort health care cost containment intense european country country announce austerity measure include implementation pricing action reduce price generic patent drug company take step mitigate impact austerity measure negatively affect company revenue performance company anticipate austerity measure continue negatively affect revenue performance additionally global economic downturn sovereign debt issue certain european country factor adversely impact foreign receivables certain european country table content company continue receive payment receivable condition result increase average length time take collect account receivable outstanding adversely affect cash flow impact health care reform continue budget pressure government world predict time address cost containment pressure company continue attempt demonstrate medicine provide value patient pay health care market historically low rate government health care spending company encourage government increase investment order improve citizen access appropriate health care include medicine operating condition challenge global pressure competition industry regulation cost containment effort predict effect factor company business company continually take measure evaluate adapt improve organization business practice well meet customer need believe position respond evolve health care environment market force government regulation pharmaceutical industry subject regulation regional country state local agency world governmental regulation legislation tend focus standard process determine drug safety effectiveness condition sale reimbursement especially relate pricing product particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement practice increase time resource necessary develop new product bring market united states adopt directive legislation concern classification label advertise wholesale distribution integrity supply chain enhance pharmacovigilance monitor approval marketing medicinal product human use provide mandatory standard supplemented implement additional regulation member states company policy procedure consistent substance directive consequently believe material effect company business company believe continue able conduct operation include launch new drug market regulatory environment access medicine global health care company merck primary role discover develop innovative medicine vaccine company recognize important role play helping improve access product world company effort regard wideranging example company recognize price product differential pricing framework take consideration factor country level economic development public health need addition merck patient assistance program provide medicine adult vaccine free people prescription drug health insurance coverage company assistance afford merck medicine vaccine building company effort merck undertake collaboration stakeholder improve access medicine enhance quality life people world example merck announce launch merck mother longterm effort global health partner create world woman die preventable complication pregnancy childbirth launch include year million initiative apply mercks scientific business expertise make prove solution widely available develop new technology improve public awareness policy effort private sector engagement maternal mortality merck past provide fund merck company foundation independent organization partner variety organization dedicate improve global health table content partnership african comprehensive hivaids partnership botswana collaboration government botswana bill melinda gates foundation renew support botswanas response hivaids comprehensive sustainable approach hiv prevention care treatment support privacy datum protection company subject number privacy datum protection law regulation globally legislative regulatory landscape privacy datum protection continue evolve increase attention privacy datum protection issue develop emerge market potential affect directly company business include recently enact law regulation united states europe asia latin america increase enforcement activity united states develop market distribution company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine sell primarily physician wholesaler physician distributor government entity company professional representative communicate effectiveness safety value company pharmaceutical vaccine product health care professional private practice group practice hospital manage care organization company sell animal health product veterinarian distributor animal producer companys overthecounter foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet raw material raw material supply generally available multiple source purchase worldwide normally available quantity adequate meet need company business patent trademark license patent protection consider aggregate material importance company marketing product united states major foreign market patent cover product pharmaceutical formulation process intermediate useful manufacture product use product protection individual product extend vary period accordance legal life patent country protection afford vary country country depend type patent scope coverage food drug administration modernization act fda modernization act include pediatric exclusivity provision provide additional month market exclusivity united states indication new currently market drug certain agree pediatric study complete applicant exclusivity provision reauthorize prescription drug user fee act pass september current patent law provide additional patent term patent term restoration period patent product regulatory review fda table content patent portfolio develop product introduce company normally provide market exclusivity company follow key patent protection include patent term restoration pediatric exclusivity major market product product year expiration maxalt singulair cancidas compound composition propecia formulationuse asmanex use formulation avelox dulera use combination integrilin compound useformulation nasonex useformulationformulation temodar emend follistim pegintron conjugate mature ifnalpha invanz compound composition zostavax use zetiavytorin zioptan nuvare delivery system noxafil rotateq clarinex formulation comvax method makingvector intron recombivax method makingvector saphrissycrest useformulation pende patent term restoration januviajanumetjuvisyncjanumet compound salt isentress victrelis pende patent term restoration gardasil method makinguseproduct process compound patent note company determine enforce additional patent set expire agreement generic manufacturer give right enter market january given right enter july agreement generic manufacturer launch generic early february month pediatric exclusivity extend date august agreement generic manufacturer launch generic august agreement generic manufacturer launch generic version zetia december application patent term restoration zioptan compound patent file prescribed time limit company expect year patent term restoration virtue litigation settlement certain generic manufacturer give right enter market expiration product patent normally result loss market exclusivity cover pharmaceutical product commercial benefit continue derive latergrante patent process intermediate relate economical method manufacture active ingredient product patent relate use product iii patent relate novel composition formulation united states certain country market exclusivity available relevant law effect product patent expiration pharmaceutical product depend factor nature market position product growth market complexity economic process manufacture active ingredient product requirement new drug provision federal food drug cosmetic act similar law regulation country table content patent provide market exclusivity singulair company large selling product expire august company expect year follow patent expiration lose substantially sale singulair decline come year follow patent expiration patent provide market exclusivity singulair expire number major european market february company expect sale singulair market decline significantly patent provide market exclusivity singulair japan expire addition patent provide market exclusivity maxalt expire december patent provide market exclusivity maxalt expire number major european market february company anticipate sales united states european market decline significantly patent expiry addition market exclusivity seek united states country relevant law include law increase patent life benefit increase patent life partially offset general increase number incentive use generic product additionally improvement intellectual property law seek united states country reform patent relevant law implementation international treaty company follow key patent protection drug candidate review currently anticipate review year expiration mkc ezetimibeatorvastatin ridaforolimus company follow key patent protection drug candidate phase iii development currently anticipate phase iii drug candidate year expiration grass pollen ragweed mka extendedrelease niacinlaropiprant mkb extendedrelease niacinlaropiprantsimvastatin anacetrapib vernakalant mka clostridium difficile infection mka nomace use mke sitagliptinatorvastatin compound salt corifollitropin alfa injection formulation vaniprevir inactivated varicella zoster virus vzv vaccine method use hpv vaccine valent compound method makinguse suvorexant bridion odanacatib preladenant pediatric hexavalent combination vaccine method makingvector vorapaxar compound patent note subject future patent term restoration year month pediatric market exclusivity available depend circumstance surround final regulatory approval compound list patent patent application pende relevance product finally approve relevance application depend claim ultimately grant nature final regulatory approval product regulatory exclusivity tie protection clinical data complementary patent protection case provide efficacious long last marketing exclusivity compound patent estate united states data protection generally run year marketing approval new chemical entity extend year orphan drug indication year marketing approval biological product year datum exclusivity marketing approval expect table content information respect company patent item risk factor item financial statement supplementary datum note contingency environmental liability worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely royalty income patent knowhow license right amount million merck incur royalty expense amount billion patent knowhow license hold research development company business characterize introduction new product new use exist product strong research development program approximately people employ company research activity research development expense billion billion billion include restructuring cost year million billion inprocess research development impairment charge respectively company maintain ongoing commitment research broad range therapeutic area clinical development support new product company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource disease area unmet medical need scientific opportunity commercial opportunity merck manage research development portfolio diverse approach discovery development balance investment appropriately novel innovative target potential major impact human health develop bestinclass approach deliver maximum value approve medicine vaccine new indication new formulation important component company sciencebase diversification base expand company portfolio modality include small molecule vaccine biologic peptide small protein antibodie rnai merck move diversify portfolio merck bioventure division potential harness market opportunity present biological medicine patent expiry deliver high quality followon biologic product enhance access patient worldwide company supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound new technology company clinical pipeline include candidate multiple disease area include atherosclerosis cancer cardiovascular disease diabete infectious disease inflammatoryautoimmune disease insomnia neurodegenerative disease ophthalmic osteoporosis respiratory disease women health development human health product industry practice government regulation united states foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug vaccine marketed united states record datum preclinical clinical experience include nda drug biologic license application bla vaccine biologic submit fda require approval company scientist discover new small molecule compound biologic molecule believe promise treat medical condition company commence preclinical testing compound preclinical testing include laboratory testing animal safety study gather data chemistry pharmacology immunogenicity toxicology pende acceptable preclinical datum company initiate clinical testing accordance establish regulatory requirement clinical testing begin phase study design assess safety tolerability pharmacokinetic preliminary pharmacodynamic activity compound human favorable additional large phase study initiate determine efficacy compound affect population define appropriate dosing compound identify adverse table content effect limit compound usefulness datum phase trial satisfactory company commence largescale phase iii trial confirm compound efficacy safety completion trial satisfactory company submit regulatory filing appropriate regulatory agency world product candidate approve marketing assurance compound result particular program obtain regulatory approval necessary market vaccine development follow general pathway drug preclinical testing focus vaccine safety ability elicit protective immune response immunogenicity premarkete vaccine clinical trial typically phase initial phase clinical study conduct normal subject evaluate safety tolerability immunogenicity vaccine candidate phase study doserange study finally phase iii trial provide necessary datum effectiveness safety successful company submit regulatory filing appropriate regulatory agency stage propose manufacturing facility undergo preapproval inspection production vaccine progress examine detail united states fda review process begin complete nda submit receive fda pursuant prescription drug user fee act fda review period target nda supplemental nda month priority review month standard review day receipt nda fda determine application sufficiently complete permit substantive review fda assess time application grant priority review standard review review timeline define fda generally act application timeline major amendment submit company initiative fda request pende application occur fda extend review period allow review new information month extension review period communicate company fda act application issue approval letter issue complete response letter state application approve present form describe deficiency fda identify company wish pursue application receive complete response letter resubmit application information address question issue identify fda order support approval resubmission subject review period target vary depend underlie submission type content resubmission research development update company currently candidate regulatory review united states internationally ridaforolimus investigational oral mtor mammalian target rapamycin inhibitor development treatment metastatic softtissue bone sarcoma patient favorable response chemotherapy accept standard review fda september august european medicine agency ema accept marketing authorization application ridaforolimus exclusive license agreement ariad pharmaceuticals inc ariad merck responsible development worldwide commercialization ridaforolimus ariad option copromote ridaforolimus sarcoma united states subject execution copromotion agreement mkc zetia combined atorvastatin accept standard review fda treatment primary mixed hyperlipidemia response notice company file pfizer inc pfizer file patent infringement lawsuit district court company assert certain pfizer patent right respect atorvastatin lawsuit potential bar fda approval company nda month january subject shorten lengthen court decision shorten agreement party addition candidate regulatory review company drug candidate phase iii development target broad range disease company plan file major product approval include suvorexant insomnia bridion reversal neuromuscular blockade cervical cancer vaccine odanacatib osteoporosis tredaptive atherosclerosis suvorexant investigational dual orexin receptor antagonist potential new approach treatment insomnia orexin neuropeptide chemical messenger release specialized table content neuron hypothalamus region brain believe important regulator brain sleepwake process february merck announce base positive result pivotal phase iii efficacy trial suvorexant company anticipate file nda fda bridion medication reversal certain muscle relaxant surgery bridion currently approve launch country outside united states prior merger scheringplough receive notapprovable letter fda bridion company conduct additional clinical trial address fdas comment plan file nda bridion fda ninevalent hpv vaccine development help protect certain hpvrelate disease incorporate antigen additional cancercause hpv type compare gardasil phase iii clinical program include eventdriven clinical trial ongoing merck continue anticipate file bla fda odanacatib oral onceweekly investigational treatment osteoporosis postmenopausal woman osteoporosis disease reduce bone density strength result increase risk bone fracture odanacatib cathepsin inhibitor selectively inhibit cathepsin enzyme cathepsin know play central role function osteoclast cell break exist bone tissue particularly protein component bone inhibition cathepsin novel approach treatment osteoporosis odanacatib continue study determine safety potential effect hip vertebral nonvertebral fracture eventdriven phase iii clinical trial company anticipate file nda fda mka drug candidate combine extendedrelease niacin novel flush inhibitor laropiprant mka demonstrate ability low ldlcholesterol ldlc bad cholesterol raise hdlcholesterol hdlc good cholesterol low triglyceride significantly flushing traditional extendedrelease niacin high ldlc low hdlc elevate triglyceride risk factor associate heart attack stroke april merck receive notapprovable letter fda response nda mka meet discuss letter fda state additional efficacy safety datum require suggest merck wait result hpsthrive treatment hdl reduce incidence vascular event eventdriven cardiovascular outcome study expect complete company anticipate file nda fda mka mka approve country outside united states treatment dyslipidemia particularly patient combine mixed dyslipidemia characterize elevated level ldlc triglyceride low hdlc patient primary hypercholesterolemia heterozygous familial nonfamilial market tredaptive cordaptive certain country tredaptive patient combination statin cholesterol lower effect statin monotherapy inadequate tredaptive monotherapy patient statin consider inappropriate tolerate elonva corifollitropin alpha injection approve control ovarian stimulation combination gnrh antagonist development multiple follicle woman participate assist reproductive technology program currently phase iii development united states base feedback fda additional datum ongoing phase iii trial require time filing merck anticipate file nda elonva fda vernakalant investigational candidate treatment atrial fibrillation market brinavess merck acquire exclusive right develop commercialize vernakalant exclusive worldwide right oral formulation vernakalant prior merck acquisition right vernakalant canada mexico united states program place clinical hold fda phase iii act trial suspend act terminate united states program remain hold company plan discussion fda mka nomace market zoely oral contraceptive use woman prevent pregnancy nomace combine oral contraceptive tablet contain unique monophasic combination hormone nomegestrol acetate highly selective progesteronederived progestin beta table content estradiol estrogen similar naturally present women body november merck receive complete response letter fda nomace company plan conduct additional clinical study request fda update application future vorapaxar thrombin receptor antagonist develop prevention thrombosis clot formation reduction cardiovascular event vorapaxar evaluate major clinical outcome study different patient group tracer thrombin receptor antagonist clinical event reduction acute coronary syndrome clinical outcome trial patient acute coronary syndrome trap thrombin receptor antagonist secondary prevention atherothrombotic ischemic event secondary prevention study patient previous heart attack ischemic stroke document peripheral vascular disease february merck announce topline result trap study trap show addition vorapaxar standard care significantly reduce risk protocolspecifie primary endpoint composite cardiovascular death heart attack myocardial infarction stroke urgent coronary revascularization compare standard care significant increase bleed include intracranial hemorrhage patient take vorapaxar addition standard care low risk intracranial hemorrhage patient history stroke result trap present american college cardiology scientific session march november researcher present result tracer outcome study american heart association scientific session result publish tracer achieve primary endpoint january merck external study investigator announce combined datum safety monitoring board dsmb clinical trial review available safety efficacy datum recommend patient tracer trial discontinue study drug investigator close study merck review datum trap tracer investigator outside expert help well understand profile investigational medicine specific patient population determine step include potential regulatory filing mkb drug candidate combine novel approach raise hdlc lower triglyceride extendedrelease niacin combine laropiprant prove benefit simvastatin combination product merck anticipate file nda mkb fda investigational allergy immunotherapy sublingual tablet ait phase iii development grass pollen allergy company north american right ait dissolvable oral tablet design prevent allergy symptom induce protective immune response allergy treat underlying cause disease merck investigate ait treatment grass pollen allergic rhinoconjunctivitis child adult company anticipate file nda fda ait ragweed allergy phase iii development north american market company anticipate file nda fda preladenant selective adenosine receptor antagonist phase iii development treatment parkinson disease company anticipate file nda preladenant fda mka investigational candidate treatment clostridium difficile infection combination monoclonal antibody treat patient single infusion company anticipate file nda mka fda inactivated varicellazoster virus vaccine development prevention herpe zoster company enrol phase iii trial autologous hematopoietic cell transplant patient patient solid tumor malignancy undergo chemotherapy hematological malignancy company anticipate file bla autologous hematopoietic cell transplant datum file second indication cancer patient later date investigational hexavalent pediatric combination vaccine contain component current vaccine design help protect potentially disease diphtheria tetanus whooping cough bordetella pertussis polio poliovirus type invasive disease cause haemophilus influenzae type hepatitis develop collaboration sanofipasteur company anticipate file bla fda table content mke combine januvia atorvastatin single tablet develop treatment diabete atherosclerosis company anticipate file nda mke fda vaniprevir investigational oral twice daily protease inhibitor treatment chronic hepatitis virus drug phase iii trial japan company anticipate file new drug application japan anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp investigate lipid management raise hdlc reduce ldlc base result phase iii define determine efficacy tolerability cetp inhibition anacetrapib safety study patient coronary heart disease coronary heart disease risk equivalent company initiate large eventdriven cardiovascular clinical outcome trial reveal randomize evaluation effect anacetrapib lipidmodification involve patient preexist vascular disease company continue anticipate file nda anacetrapib fda merck discontinue clinical development program telcagepant company investigational calcitonin generelate peptide receptor antagonist treatment acute migraine decision base assessment datum clinical program company discontinue clinical development program mkc combination sitagliptin pioglitazone treatment diabete base review regulatory commercial prospect combination drug candidate merck discontinue clinical development program mka zenhale fix dose combination previously approve drug treatment asthma mometasone furoate formoterol fumarate dehydrate market united states dulera inhalation aerosol table content chart reflect company research pipeline february candidate show phase iii include specific product date candidate enter phase iii development candidate show phase include advanced compound specific mechanism list compound mechanism currently intend commercialization give therapeutic area small molecule biologic give mknumber designation vaccine candidate give vnumber designation candidate phase additional indication therapeutic area additional claim line extension formulation inline product show phase phase iii phase iii entry date review allergy allergy atherosclerosis immunotherapy grass pollen march mkc ezetimibeatorvastatin cancer ragweed september sarcoma dalotuzumab atherosclerosis ridaforolimus mka extendedrelease niacinlaropiprant december dinaciclib mkb extendedrelease niacinlaropiprant contraception medicate ius simvastatin july anacetrapib diabete mellitus atrial fibrillation vernakalant august hepatitis clostridium difficile infection mka november insomnia contraception mka nomace june diabetes atherosclerosis overactive bladder mke sitagliptinatorvastatin october fertility pneumoconjugate vaccine corifollitropin alfa injection july footnote hepatitis north american right psoriasis vaniprevir june prior mercks acquisition right herpe zoster vernakalant canada mexico inactivated vzv vaccine december united states program place hpvrelate cancer clinical hold fda hpv vaccine valent september suspend phase iii trial act insomnia terminate program remain suvorexant december hold united states company neuromuscular blockade reversal plan discussion fda bridion november osteoporosis ino mlo mjap era ecly ve odanacatib september complete response letter fda parkinson disease nomace mka company preladenant july planning conduct additional clinical pediatric hexavalent combination vaccine study request fda update april application future thrombosis vorapaxar september employees december company approximately employee worldwide approximately employ united state include puerto rico approximately worldwide employee company represent collective bargaining group february company commence action merger restructuring program conjunction integration legacy merck legacy scheringplough business merger restructuring program intend optimize cost structure combine company additional action program continue july company announce late phase merger restructuring program company expect reduce workforce measure time table content merger additional company worldwide majority workforce reduction phase merger restructuring program relate manufacture include animal health administrative headquarters organization previously announce workforce reduction approximately early phase program primarily reflect elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility inception merger restructuring program december merck eliminate approximately position comprise employee separation elimination contractor position vacant time merger october merck announce global restructure program restructuring program reduce cost structure increase efficiency enhance competitiveness restructure program company expect eliminate approximately position active employee vacancy company worldwide inception restructuring program december merck eliminate approximately position comprise employee separation elimination contractor vacant position prior merger scheringplough commence productivity transformation program design reduce avoid cost increase productivity position elimination associate program largely complete environmental matter company believe compliance issue associate applicable environmental law regulation material adverse effect company company remediate environmental contamination result past industrial activity certain site expenditure remediation environmental liability million million million estimate million aggregate year amount consider potential recovery party company take active role identify provide cost management opinion liability environmental matter probable reasonably estimable accrue total million december possible predict certainty outcome environmental matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure material adverse effect company financial position result operation liquidity capital resource year merck believe climate change present risk business potential impact climate change business include increase operating cost additional regulatory requirement physical risk company facility water limitation disruption supply chain potential risk integrate company business planning include investment reduce energy water use greenhouse gas emission company believe risk material business time geographic area information company operation outside united states conduct primarily subsidiarie sale worldwide subsidiary outside united states sale sale sale increase proportion sale outside united states primarily inclusion result scheringplough follow close merger company worldwide business subject risk currency fluctuation governmental action governmental proceeding abroad company regard risk deterrent expansion operation abroad company closely review method operation adopt strategy responsive change economic political condition merck expand operation country locate latin america middle east africa eastern europe asia pacific business develop area stable offer important opportunity growth time table content financial information geographic area company business discuss item financial statement supplementary datum available information company internet website address wwwmerckcom company available free charge investor portion website annual report quarterly report form current report form amendment report file furnish pursuant section security exchange act amend soon reasonably practicable report electronically file furnish securities exchange commission sec companys corporate governance guideline charter board director stand committee available company website wwwmerckcomaboutleadership information available print stockholder request company item risk factor investor carefully consider information set forth include follow risk factor decide invest company security risk one company face additional risk currently know company company presently deem immaterial impair business operation company business financial condition result operation prospect materially adversely affect risk contain forwardlooke statement involve risk uncertainty company result materially differ anticipate forwardlooke statement result certain factor include risk face describe cautionary factor affect future result certain company major product go lose patent protection near future include singulair occur company expect significant decline sale product company depend patent provide exclusive marketing right product period time product patent company product recently expire united states country company face strong competition lower price generic drug loss patent protection company product typically lead rapid loss sale product lower price generic version drug available case product contribute significantly company sale loss patent protection material adverse effect company business cash flow result operation financial position prospect patent provide market exclusivity singulair company large selling product sale approximately billion expire august company expect year follow patent expiration lose substantially sale singulair decline come year follow patent expiration patent provide market exclusivity singulair expire number major european market february company expect sale singulair market decline significantly addition patent provide market exclusivity maxalt expire december patent provide market exclusivity maxalt expire number major european market february company anticipate sales united states approximately million european market decline significantly patent expiry addition previously disclose astrazeneca right exercise option acquire company interest subsidiary company interest nexium prilosec company believe likely astrazeneca exercise option chart list patent protection company major market product set forth item business patent trademark license company dependent patent right patent right invalidate circumvent business adversely affect patent protection consider aggregate material importance company market human health product united states major foreign market patent cover table content product introduce normally provide market exclusivity important successful marketing sale product company seek patent cover product market intend sell product meaningful patent protection available company succeed obtain patent cover product party government authority challenge seek invalidate circumvent patent patent application important company business defend successfully patent right provide market exclusivity product company involve patent dispute relate challenge patent infringement similar claim company company aggressively defend important patent outside united state include file claim infringement party item financial statement supplementary datum note contingency environmental liability particular manufacturer generic pharmaceutical product time time file abbreviate new drug application fda seek market generic form company product prior expiration relevant patent own company company normally respond vigorously defend patent include filing lawsuit allege patent infringement trial relate company patent nasonex expect place patent litigation challenge company patent costly unpredictable deprive company market exclusivity patent product case party patent prevent company marketing selling product particular geographic area additionally certain foreign government indicate compulsory license patent grant case national emergency diminish eliminate sale profit region negatively affect company result operation recent court decision relate company patent potential legislation relate patent reform regulatory initiative result erosion intellectual property protection important product lose patent protection profitable market sale product likely decline significantly result generic version product available case certain product loss result material noncash impairment charge company result operation adversely affect lost sale company successfully launch commercially successful replacement product key company product generate significant company profit cash flow event adversely affect market lead product material negative impact result operation cash flow company ability generate profit operate cash flow depend largely continue profitability company key product singulair januvia remicade zetia vytorin janumet isentress nasonex gardasil temodar result company dependence key product event adversely affect product market product significant impact result operation cash flow event include loss patent protection increase cost associate manufacturing generic overthecounter availability company product competitive product discovery previously unknown effect increase competition introduction new effective treatment discontinuation removal market product reason event material adverse effect sale certain product event result material noncash impairment charge company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequence company able replace sale successful product lose patent protection like major pharmaceutical company order remain competitive company continue launch new product year expect decline sale product singulair maxalt loss market exclusivity mean company future success dependent pipeline new product include new product develop joint venture product able obtain table content license acquisition accomplish company commit substantial effort fund resource research development dedicate resource collaboration party high rate failure inherent research develop new drug treat disease result high risk fund invest company research program generate financial return risk profile compound fact research long investment cycle bring pharmaceutical compound discovery phase market decade failure occur point process include later process significant fund invest description research development process item business research development phase test highly regulate phase substantial risk company encounter obstacle achieve goal company abandon product invest substantial amount time resource risk encounter research development process include follow preclinical testing new compound yield disappointing result clinical trial new drug successful new drug effective harmful effect new drug approve fda intend use possible obtain patent new drug sale new product disappointing company state certainty product development approve launch able develop license acquire compound product candidate product product launch commercially successful company maintain continuous flow successful new product successful new indication brand extension exist product sufficient cover substantial research development cost replace sale lose profitable product singular maxalt lose patent protection displace compete product therapie failure short term long term material adverse effect company business result operation cash flow financial position prospect company success dependent successful development marketing new product subject substantial risk product appear promise development fail reach market numerous reason include follow finding ineffectiveness superior safety efficacy compete product harmful effect clinical preclinical testing failure receive necessary regulatory approval include delay approval new product new indication increase uncertainty time require obtain regulatory approval benefitrisk standard apply regulatory agency determine grant approval lack economic feasibility manufacturing cost factor preclusion commercialization proprietary right future certain pipeline program cancel company believe commercial prospect reduce company recognize material noncash impairment charge program measure fair value capitalize connection merger non cash impairment charge company anticipate exclude company nongaap earning material company future gaap earning example company recognize noncash impairment charge billion respect vorapaxar legacy schering plough pipeline program company product include product development market company obtain maintain regulatory approval company activity include research preclinical testing clinical trial manufacturing marketing product subject extensive regulation numerous federal state local governmental authority unite states include fda foreign regulatory authority include united states fda particular importance company administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical table content case fda requirement increase time money necessary develop new product bring market united states regulation outside united states primarily focus drug safety effectiveness case cost reduction fda foreign regulatory authority substantial discretion require additional testing delay withhold registration marketing approval preclude distribution sale product company successful develop new product able market product obtain require regulatory approval jurisdiction propose market new product obtain company maintain approval long plan market new product jurisdiction approval require company failure obtain approval significant delay approval process failure maintain approval jurisdiction prevent sell new product jurisdiction approval obtain company able realize revenue new product jurisdiction approval development follow regulatory approval adversely affect sale company product product reach market certain development follow regulatory approval include result postmarkete phase trial study decrease demand company product include follow rereview product market new scientific information evolution scientific theory recall loss marketing approval product market change government standard public expectation safety efficacy labeling change great scrutiny advertising promotion past year clinical trial postmarkete surveillance certain market drug company competitor industry raise concern lead recall withdrawal adverse labeling market product clinical trial postmarkete surveillance certain market drug raise concern prescriber patient relate safety efficacy pharmaceutical product general negatively affect sale product addition increase scrutiny outcome clinical trial lead increase volatility market reaction matter attract litigation basis litigation groundless considerable resource need respond addition follow wake product withdrawal significant safety issue health authority fda ema japans pharmaceutical medical device agency increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication rereviewe select product market add uncertainty regulatory process great regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising previously unknown effect discover increase negative publicity know effect company product significantly reduce demand product require company action negatively affect sale include remove product market restrict distribution apply labeling change current environment pharmaceutical company operate company risk product liability consumer protection claim civil criminal governmental action relate product research andor marketing activity company face intense competition lowercost generic product general company face increase competition lowercost generic product patent right protect product vary strength duration addition country patent table content protection significantly weak united states united states political pressure reduce spending prescription drug lead legislation encourages use generic product company policy actively protect patent right generic challenge company product arise time able prevent emergence generic competition product loss patent protection product typically follow promptly generic substitute reduce company sale product availability generic substitute company drug adversely affect result operation cash flow addition proposal emerge time time united states country legislation encourage early rapid approval generic drug proposal enact law worsen substantial negative effect company sale potentially business cash flow result operation financial position prospect company face intense competition competitor product addition factor certain circumstance lead non cash impairment charge company product face intense competition competitor product competition increase new product enter market event competitor product safer effective effectively market sell company product alternatively case generic competition include generic availability competitor brand product equally safe effective product sell substantially low price company product result company fail maintain competitive position material adverse effect business cash flow result operation financial position prospect addition legacy scheringplough product measure fair value capitalize connection merger saphris merckschering plough partnership product vytorin zetia experience difficulty market negatively impact product cash flow company recognize material noncash impairment charge respect value product noncash impairment charge company anticipate exclude company nongaap earning material company future gaap earning company face pricing pressure respect product company face increase pricing pressure globally manage care organization government agency program negatively affect company sale profit margin united states include practice manage care group institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure addition company face risk litigation government pricing calculation outside united states numerous major market pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine product consequently market company subject government decision make budgetary action respect product company expect pricing pressure increase future health care industry continue subject increase regulation political action company believe health care industry continue subject increase regulation political legal action future proposal reform health care system consider congress state legislature major health care reform adopt law united states important market reform begin continue implementation new law expect expand access health care million americans end decade merck incur additional cost result new law include increase medicaid rebate impact reduce revenue minimum rebate state participate medicaid program table content increase company brand prescription drug medicaid rebate extend medicaid manage care organization eligibility federal drug discount program extend rural referral center sole community hospital critical access hospital certain free stand cancer hospital certain additional children hospital addition law require drug manufacturer pay discount medicare beneficiary medicare coverage gap socalle donut hole begin company require pay annual health care reform fee assess brand prescription drug manufacturer importer fee calculate base industry total sale brand prescription drug specify government program percentage manufacturer sale include determined tiere scale base manufacturers individual revenue manufacturers portion total annual fee base manufacturer proportion total includable sale prior year annual industry fee billion annual industry fee billion company predict likelihood future change health care industry general pharmaceutical industry particular impact company result operation financial condition business current uncertainty global economic condition austerity measure take certain government negatively affect company operating result current uncertainty global economic condition result slowdown global economy affect company business reduce price drug wholesaler retailer hospital government agency manage health care provider able willing pay company product reduce demand company product turn negatively impact company sale result material adverse effect company business cash flow result operation financial position prospect company brand experience positive growth trend environment europe continue challenge country announce austerity measure aim reduce cost area health care implementation pricing action vary country announce measure reduce price generic patent drug company take step mitigate immediate impact austerity measure negatively affect company revenue performance company anticipate midsingle digit pricing pressure europe furthermore european austerity measure negatively affect company revenue performance company anticipate lastly company subject biennial price reduction japan furthermore company believe credit economic condition greece spain italy portugal member deteriorate continue deteriorate condition inherent variability time cash receipt result continue result increase average length time take collect account receivable outstanding country impact likelihood collect outstanding account receivable december company account receivable greece italy spain portugal total approximately billion hospital public sector receivable approximately billion aggregate approximately relate greece italy spain portugal respectively december company total account receivable outstanding year approximately million approximately relate account receivable greece italy spain portugal comprise hospital public sector receivables condition europe worsen country euro zone exit euro zone reintroduce legacy currency result economic currency impact affect market globally material adverse effect company result table content company significant global operation expose additional risk adverse event material negative impact company result operation extent company operation outside united states significant risk inherent conduct global business include change medical reimbursement policy program price restriction key market multiple regulatory requirement restrict company ability manufacture sell product key market trade protection measure import export licensing requirement foreign exchange fluctuation diminish protection intellectual property country possible nationalization expropriation addition change company business political position instability disruption destruction significant geographic region regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease company experience difficulty delay manufacture certain product previously disclose merck past experienced difficulty manufacture certain vaccine product similarly company past experienced difficulty manufacture certain animal health product currently experience difficulty manufacture certain women health product company work manufacturing issue assurance issue finally resolve addition difficulty company experience currently company experience difficulty delay inherent manufacturing product failure company vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture construction delay relate construction new facility expansion exist facility include intended support future demand company product iii manufacture distribution problem include change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation impact continuous supply manufacturing difficulty result product shortage lead lose sale company face significant litigation relate vioxx september merck voluntarily withdraw vioxx arthritis acute pain medication market worldwide merck settle major portion product liability litigation company face material litigation arise voluntary withdrawal vioxx addition vioxx product liability lawsuit purport class action individual lawsuit bring merck current officer director merck allege merck false misleading statement vioxx violation federal security law state law suit refer vioxx security lawsuit vioxx security lawsuit transfer judicial panel multidistrict litigation jpml district court district new jersey district judge stanley chesler inclusion nationwide mdl shareholder mdl consolidated purpose vioxx security lawsuit discuss fully item financial statement supplementary datum note contingency environmental liability merck name defendant action country outside united states suit refer vioxx foreign lawsuit merck sue number state county private citizen qui tam lawsuit respect marketing vioxx table content previously disclose department justice doj issue subpoena request information relate merck research marketing selling activity respect vioxx federal health care investigation criminal statute company establish million reserve vioxx liability reserve connection anticipate resolution dojs investigation november company announce reach resolution federal state authority matter pende court approval civil settlement agreement sign united states individually state district columbia merck pay approximately twothird reserve charge resolve civil allegation relate vioxx result united states participate state release merck civil liability relate government allegation sale promotion vioxx company agree plead guilty count misdemeanor misbranding vioxx federal food drug cosmetic act promote drug treatment rheumatoid arthritis prior fda approval indication april company pay fine approximately onethird reserve federal government plea agreement regard nonparticipating state merck continue face lawsuit file state december united states district court district massachusetts conduct hear regard resolution hearing party advise court nature resolution core document comprise resolution court schedule subsequent hearing march court issue ruling concern accept merck plea resolution vioxx litigation discuss fully item financial statement supplementary datum note contingency environmental liability trial missouri state court action schedule begin company predict timing trial relate vioxx litigation company believe meritorious defense vioxx product liability lawsuit vioxx security lawsuit vioxx foreign lawsuit collectively vioxx lawsuit vigorously defend company insurance coverage respect vioxx lawsuit adequate cover defense cost loss company currently able estimate additional amount require pay connection vioxx lawsuit proceeding expect continue year company predict course proceeding view inherent difficulty predict outcome litigation particularly claimant claimant seek unspecified damage company unable predict outcome matter time reasonably estimate possible loss range loss respect remain vioxx lawsuit company establish reserve potential liability relate remain vioxx lawsuit vioxx liability reserve reserve relate settlement canadian vioxx litigation discuss item financial statement supplementary datum note contingency environmental liability series unfavorable outcome vioxx lawsuit result payment substantial damage material adverse effect company business cash flow result operation financial position prospect issue concern vytorin enhance clinical trial adverse effect sale vytorin zetia united states result ongoing trial adverse effect sale company sell vytorin zetia previously disclose january legacy company announce result enhance clinical trial image trial patient heterozygous familial hypercholesterolemia rare genetic condition cause high level ldl bad cholesterol greatly increase risk premature coronary artery disease previously report despite fact ezetimibesimvastatin vytorin significantly lower ldl bad cholesterol simvastatin significant difference treatment ezetimibesimvastatin simvastatin prespecifie primary endpoint change thickness carotid artery wall year measure ultrasound improve trial underway design provide cardiovascular outcome data ezetimibesimvastatin patient acute coronary syndrome incremental benefit ezetimibesimvastatin table content cardiovascular morbidity mortality demonstrate simvastatin establish january fda announce complete review final clinical study report enhance fda state result enhance change position elevate ldl cholesterol risk factor cardiovascular disease lower ldl cholesterol reduce risk cardiovascular disease discussion concern shareholder litigation arise enhance study item financial statement supplementary datum note contingency environmental liability improveit trial schedule completion improveit trial blind interim efficacy analysis conduct dsmb trial approximately endpoint accrue dsmb recommend continue trial change study protocol blind interim efficacy analysis plan dsmb quarter approximately primary event accrue base result interim analysis trial halt concern relate vytorin material adverse effect sale vytorin zetia issue concern enhance clinical trial adverse effect sale vytorin zetia continue adverse effect sale result improveit trial fail demonstrate incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrate simvastatin sale zetia vytorin materially adversely affect sale product materially adversely affect company business cash flow result operation financial position prospect materially adversely affect company require record material noncash impairment charge addition unfavorable outcome result shareholder litigation concern enhance clinical trial result material adverse effect company business cash flow result operation financial position prospect company fail realize anticipated cost saving revenue enhancement benefit expect merger adversely affect value company common stock success merger depend company ability successfully combine business merck scheringplough realize anticipated benefit cost saving combination company combine company able achieve objective anticipated time frame value company common stock adversely affect possible integration process result loss key employee result disruption company ongoing business identify inconsistency standard control procedure policy adversely affect ability maintain relationship customer supplier distributor creditor lessor clinical trial investigator manager achieve anticipate benefit merger specifically issue address integrate operation legacy company order realize anticipate benefit merger include thing integrate research development manufacturing distribution marketing promotion activity information technology system merck scheringplough conforming standard control procedure accounting policy business culture compensation structure company identify eliminate redundant underperform operation asset manage tax cost inefficiency associate integrate operation combine company integration effort company continue divert management attention resource company integration effort involve plan close sell certain facility worldwide implementation plan subject satisfaction local legal requirement include limited compliance relevant information consultation obligation applicable process result delay failure company realize anticipated synergy inability realize extent anticipate benefit merger delay encounter integration process adverse effect company business result operation affect value share company common stock table content addition actual integration result additional unforeseen expense new information technology system anticipate benefit integration plan realize actual cost sale synergy lower company expect long achieve anticipate company able adequately address challenge unable successfully integrate operation legacy company realize anticipated benefit integration legacy company delay encounter integration process material adverse effect revenue expense operating result financial condition company company expect significant benefit increase cost saving result merger assurance company realize anticipated benefit company able realize expect benefit investment emerge market company take step increase presence emerge market guarantee company effort expand sale emerge market succeed country emerge market especially vulnerable period global financial instability limited resource spend health care order company successfully implement emerge market strategy attract retain qualified personnel company require increase reliance thirdparty agent develop market addition country currency fluctuate substantially currency devalue offset devaluation company financial performance country adversely affect reason sale emerge market carry significant risk failure continue expand company business emerge market material adverse effect business financial condition result company operation company expose market risk fluctuation currency exchange rate interest rate company operate multiple jurisdiction virtually sale denominate currency local jurisdiction additionally company enter enter acquisition licensing borrowing financial transaction rise currency interest rate exposure company certainty foresee mitigate adverse fluctuation fluctuation currency exchange rate interest rate negatively affect company result operation financial position cash flow order mitigate adverse impact market fluctuation company time time enter hedge agreement hedge agreement currency option interest rate swap limit exposure exchange rate interest rate fluctuation attempt mitigate risk costly successful company subject evolve complex tax law result additional liability affect result operation company subject evolve complex tax law jurisdiction operate significant judgment require determine company tax liability company tax return periodically examine tax authority company believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority complexity tax contingency ultimate resolution tax matter result payment great amount accrue february president obamas administration repropose significant change international tax law include change tax company excess return attributable certain offshore intangible asset limit tax deduction expense relate unrepatriated foreignsource income table content modify foreign tax credit rule potentially significant change international law include territorial tax system set congressional committee company determine proposal enact law change proposal prior enact law change international tax law enact significant impact financial result company addition company impact change tax law include tax rate change change law relate remittance foreign earning deferral limitation impact tax treatment foreign earning new tax law revise tax law interpretation domestic foreign jurisdiction pharmaceutical product develop unexpected safety efficacy concern unexpected safety efficacy concern arise respect market product scientifically justified lead product recall withdrawal decline sale product liability consumer fraud andor claim include potential civil criminal governmental action change law regulation adversely affect company business aspect company business include research development manufacturing marketing pricing sale litigation intellectual property right subject extensive legislation regulation change applicable federal state law agency regulation material adverse effect company business reliance party relationship outsource arrangement adversely affect company business company depend party include supplier alliance pharmaceutical biotechnology company party service provider key aspect business include development manufacture commercialization product support information technology system failure party meet contractual regulatory obligation company development factor materially disrupt relationship company party material adverse effect company business company increasingly dependent sophisticated information technology infrastructure company increasingly dependent sophisticated information technology infrastructure significant breakdown intrusion interruption corruption system datum breach material adverse effect business addition company currently proceed multiyear implementation enterprise wide resource planning system certain operation united states began implement operation include modification design operation documentation internal control financial reporting company implement resource planning system major european market canada intends implement additional market material problem implementation material adverse effect company business negative event animal health industry negative impact future result operation future sale key animal health product adversely impact number risk factor include certain risk specific animal health business example outbreak disease carry animal bovine spongiform encephalopathy mad cow disease lead widespread death precautionary destruction reduce consumption demand animal adversely impact company result operation outbreak highly contagious disease near company main production site require company immediately halt production vaccine site force company incur substantial expense procure raw material vaccine risk specific animal health include epidemic pandemic government procurement pricing practice table content weather global agribusiness economic event animal health segment company business significant impact event future result operation significant biologic carry unique risk uncertainty negative impact future result operation successful development testing manufacturing commercialization biologic particularly human animal health vaccine long expensive uncertain process unique risk uncertaintie biologic include limited access supply normal diseased tissue sample cell line pathogen bacteria viral strain biological material addition government regulation multiple jurisdiction united states european country result restrict access transport use material company lose access sufficient source material tight restriction impose use material company able conduct research activity plan incur additional development cost development manufacturing marketing biologic subject regulation fda ema regulatory body regulation complex extensive regulation applicable pharmaceutical product example united states bla include preclinical clinical trial datum extensive datum manufacturing procedure require human vaccine candidate fda approval require release manufacture commercial lot manufacture biologic especially large quantity complex require use innovative technology handle living micro organism lot approve biologic undergo thorough testing identity strength quality purity potency manufacturing biologic require facility specifically design validate purpose sophisticated quality assurance quality control procedure necessary slight deviation manufacturing process include fill labeling packaging storage shipping quality control testing result lot failure product recall spoilage change manufacturing process company required provide preclinical clinical datum show comparable identity strength quality purity potency product change biologic frequently costly manufacture production ingredient derive live animal plant material biologic synthetically particular keeping demand vaccine difficult complexity produce vaccine use biologically derive ingredient lead allegation harm include infection allergic reaction closure product facility possible contamination event result substantial cost product liability insurance product limit cost prohibitive unavailable result number factor product liability insurance available cost increase significantly respect product liability company selfinsure substantially risk availability commercial insurance restrictive company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance certain product liability effective august include liability legacy merck product sell date company continually assess efficient mean address risk guarantee insurance coverage obtained obtain sufficient fully cover product liability arise table content cautionary factor affect future result cautionary statement private security litigation reform act report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement company caution place undue reliance forwardlooke statement possible predict identify factor include follow competition generic product company product lose patent protection increase brand competition therapeutic area important company longterm business performance difficulty uncertaintie inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level pricing pressure unite states abroad include rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general change government law regulation include law govern intellectual property enforcement thereof affect company business efficacy safety concern respect market product scientifically justified lead product recall withdrawal decline sale significant litigation relate vioxx vytorin zetia legal factor include product liability claim antitrust litigation governmental investigation include tax dispute environmental concern patent dispute brand generic competitor preclude commercialization product negatively affect profitability exist product lose market opportunity result delay uncertaintie approval process fda foreign regulatory authority increase focus privacy issue country world include united states legislative regulatory landscape privacy datum protection continues evolve increase focus privacy datum protection issue potential affect directly company business include recently enact law majority state united states require security breach notification change tax law include change relate taxation foreign earning table content change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board sec adverse company economic factor company control include change inflation interest rate foreign currency exchange rate list consider exhaustive statement potential risk uncertainty risk factor item unresolved staff comment item property companys corporate headquarters locate whitehouse station new jersey company commercial operation headquarter upper gwynedd pennsylvania company pharmaceutical business conduct divisional headquarters locate upper gwynedd whitehouse station company vaccine business conduct divisional headquarters locate west point pennsylvania company worldwide strategic plan merck animal health global headquarters function currently locate boxmeer netherland centralized new jersey principal research facility locate rahway kenilworth summit new jersey west point pennsylvania palo alto california elkhorn nebraska animal health principal research facility outside locate netherlands company production facility human health product location united states puerto rico outside united states subsidiary company own interest manufacturing plant property australia canada japan singapore south africa countries western europe central south america asia capital expenditure billion united states amount billion million abroad expenditure amount million million company subsidiarie principal facility manufacturing plant title consider satisfactory company consider property good operating condition machinery equipment maintain plant manufacture product suitable intend purpose capacity project capacity adequate current project need exist company product capacity plant convert need modification requirement newly introduce future product item legal proceeding information call item incorporate reference note contingency environmental liability include item financial statement supplementary datum item safety disclosure applicable executive officer registrant age february time merger november certain executive officer assume position newly merge company note kenneth frazi age december chairman president chief executive officer merck inc january president chief executive officer merck inc president merck inc responsible company large worldwide division global human health merck manufacturing division merck research laboratory table content november executive vice president president global human health merck inc responsible company market sale organization worldwide include global pharmaceutical vaccine franchise august executive vice president president global human health merck inc responsible company market sale organization worldwide include global pharmaceutical vaccine franchise november executive vice president general counsel merck inc responsible legal public affair function merck company foundation notforprofit charitable organization affiliate company adele ambrose age november senior vice president chief communication officer merck inc responsible global communication organization december vice president chief communication officer merck inc responsible global communication organization richard bowles iii age november executive vice president chief ethic compliance officer merck inc responsible company compliance function include global safety environment system assurance ethic privacy prior november bowles senior vice president global quality operation scheringplough corporation march john canan age november senior vice president financeglobal controller merck inc responsible company global controller organization include accounting control external reporting financial standard policy january senior vice president controller merck inc responsible corporate controller group september vice president controller merck inc responsible corporate controller group willie deese age november executive vice president president merck manufacturing division merck inc responsible company global manufacturing procurement distribution logistic function january executive vice president president merck manufacturing division merck inc responsible company global manufacturing procurement distribution logistic function president merck manufacturing division merck inc responsible company global manufacturing procurement operational excellence function richard deluca age september executive vice president president merck animal health merck inc responsible merck animal health organization prior september deluca chief financial officer becton dickinson bioscience medical technology company president wyeths fort dodge animal health division serve chief operating officer fort dodge executive vice president chief financial officer table content cuong viet age october executive vice president chief strategy officer merck inc responsible leading formulation execution company long term strategic plan prior october senior vice president corporate strategy business development connectivity global company design manufacture market product customer variety industry senior vice president chief strategy officer lenovo personal technology company mirian graddickweir age november executive vice president human resource merck inc responsible global human resource organization january executive vice president human resource merck inc responsible global human resource organization september senior vice president human resource merck inc bridgette heller age march executive vice president president merck consumer care merck inc responsible merck consumer care organization prior march heller president johnson johnsons baby global business unit president global baby kid wind care peter kellogg age november executive vice president chief financial officer merck inc responsible company worldwide financial organization investor relation corporate development licensing company joint venture relationship august executive vice president chief financial officer merck inc responsible company worldwide financial organization investor relation corporate development licensing company joint venture relationship prior august kellogg executive vice president finance chief financial officer biogen idec biotechnology company merger biogen inc idec pharmaceuticals corporation november peter kim age november executive vice president president merck research laboratories merck inc responsible company research development effort worldwide january executive vice president president merck research laboratories merck inc responsible company research development effort worldwide january president merck research laboratories merck inc responsible company research development effort worldwide bruce kuhlik age november executive vice president general counsel merck inc responsible legal communication public policy function merck company foundation notforprofit charitable organization affiliate company january executive vice president general counsel merck inc responsible legal communication public policy function merck company foundation notforprofit charitable organization affiliate company table content august senior vice president general counsel merck inc responsible legal communication public policy function merck company foundation notforprofit charitable organization affiliate company vice president associate general counsel merck inc primary responsibility company vioxx litigation defense michael rosenblatt age december executive vice president chief medical officer merck inc company primary voice global medical community critical issue patient safety oversight company global center scientific affair prior december rosenblatt dean tufts university school medicine chris scalet age november executive vice president global services chief information officer merck inc responsible global share service human resource finance site service information service function enterprise business process redesign initiative january executive vice president global services chief information officer merck inc responsible global share service human resource finance site service information service function enterprise business process redesign initiative january senior vice president global services chief information officer merck inc responsible global share service human resource finance site service information service function enterprise business process redesign initiative adam schechter age executive vice president president global human health merck inc responsible company pharmaceutical vaccine worldwide business november president global human health marketintegration leader merck inc commercial responsibility united states company portfolio prescription medicine leader integration effort merckscheringplough merger division function august president global pharmaceuticals global human health merck inc global responsibility company atherosclerosiscardiovascular diabetesobesity oncology specialtyneuroscience respiratory bone arthritis analgesia franchise commercial responsibility united states company portfolio prescription medicine july president human health merck inc commercial responsibility united states company portfolio prescription medicine officer list serve pleasure board director officer elect pursuant arrangement understand officer board table content item market registrant common equity relate stockholder matter issuer purchase equity security principal market trading company common stock new york stock exchange nyse symbol mrk common stock market price information set forth table base historical nyse market price follow table set forth calendar period indicate dividend share information cash dividend pay common share year common stock market price high low high low january approximately shareholder record table content equity compensation plan information follow table summarize information option warrant right equity compensation company equity compensation plan close business december table include information tax qualified plan msd employee saving security plan scheringplough employee saving plan number weight security remain number average available future security exercise issuance equity issue price compensation plan exercise outstanding exclude outstanding option security option warrant warrant reflect column right right plan category equity compensation plan approve security holder equity compensation plan approve security holder total include option purchase share company common stock right follow shareholderapprove plan merck sharp dohme incentive stock plan merck inc nonemployee directors stock option plan merck inc scheringplough stock incentive plan exclude approximately share restrict stock unit performance share unit assume maximum payout merck sharp dohme incentive stock plan share restrict stock unit performance share unit exclude accrue dividend merck inc scheringplough stock incentive plan exclude share phantom stock defer msd deferral program table include information equity compensation plan option warrant right assume company connection merger acquisition pursuant remain outstanding option warrant right collectively assume plan include rosetta inpharmatics inc employee stock option plan total share merck common stock purchase assume plan weight average exercise price grant assume plan table content performance graph follow graph assume investment december reinvestment dividend companys common share index composite peer group major usbased pharmaceutical company abbott laboratories bristolmyers squibb company johnson johnson eli lilly company pfizer inc comparison fiveyear cumulative total return merck inc composite peer group index end period value cagr merck peer grp merck peer grp performance graph reflect scheringplough stock performance december close merger merck stock performance november december assume cash component merger consideration reinveste merck stock closing price november compound annual growth rate october wyeth pfizer inc complete previously announce merger pfizerwyeth merger wyeth whollyowne subsidiary pfizer inc discuss november merck scheringplough complete merger pfizerwyeth merger transaction merck subsequently rename merck sharp dohme corp msd whollyowne subsidiary scheringplough subsequently rename merck inc result transaction wyeth msd long exist publicly trade entity cease trade common stock close business respective merger date wyeth msd permanently remove peer group index table content item select financial datum follow select financial datum read conjunction item management discussion analysis financial condition result operation consolidate financial statement note thereto contain item financial statement supplementary datum report merck inc subsidiarie million share amount result year sale material production marketing administrative research development restructuring cost equity income affiliate income expense net income taxis tax income net income net income attributable noncontrolle interest net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder cash dividend declare cash dividend pay common share capital expenditure depreciation average common share outstanding million average common share outstanding assume dilution million yearend position work capital property plant equipment net total asset longterm debt total equity yearend statistic number stockholder record number employee amount include amortization purchase accounting adjustment inprocess research development impairment charge reflect research development expense impact restructuring action arbitration settlement charge favorable impact certain tax item include net favorable impact approximately million relate settlement federal income tax audit amount include amortization purchase accounting adjustment inprocess research development impairment charge billion reflect research development expense impact restructuring action reserve relate vioxx gain recognize astrazeneca lps exercise option acquire certain asset company favorable impact certain tax item amount include reclassification million expense market administrative research development amount include impact merger scheringplough corporation november include recognition gain represent fair value stepup merck previously hold interest merckscheringplough partnership result obtain control interest amortization purchase accounting adjustment record postmerger period include gain sale merck interest merial limited favorable impact certain tax item impact restructuring action amount include gain distribution astrazeneca gain relate sale remain worldwide right aggrastat favorable impact certain tax item impact restructure action expense contribution merck company foundation amount include impact vioxx settlement agreement charge restructuring action civil governmental investigation charge insurance arbitration settlement gain inprocess research development expense result acquisition gain sale asset product divestiture net gain settlement certain patent dispute reflect dividend pay common shareholder merck addition approximately million dividend pay subsequent merger scheringplough million pay prior merger relate common stock prefer stock dividend declare scheringplough table content item management discussion analysis financial condition result operation description merck business merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health consumer care product market directly joint venture company operation principally manage product basis comprise operating segment pharmaceutical animal health consumer care alliance segment reportable segment pharmaceutical segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer additionally company consumer care operation develop manufacture market overthecounter foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet november legacy merck inc scheringplough corporation scheringplough merged merger result scheringplough business include merck financial statement period subsequent completion merger merck financial result reflect year scheringplough operation overview company focus accelerate revenue growth reduce cost drive efficiency allocate resource drive future growth make strategic investment product launch emerge market advance augment research development pipeline worldwide sale total billion increase compare billion foreign exchange favorably affect global sale performance revenue increase drive largely growth januvia janumet treatment type diabete singulair medicine chronic treatment asthma relief symptom allergic rhinitis isentress antiretroviral therapy use combination therapy treatment hiv infection gardasil vaccine help prevent certain disease cause type human papillomavirus hpv simponi treatment inflammatory disease rotateq vaccine help protect rotavirus gastroenteritis infant child zetia cholesterol absorption inhibitor pneumovax vaccine help prevent pneumococcal disease bridion reversal certain muscle relaxant surgery addition revenue benefit high sale company animal health product launch victrelis treatment chronic hepatitis increase partially offset low sale cozaar hyzaar treatment hypertension lose patent protection united states april number major european market march low sale caelyx subutex suboxone company long marketing right product revenue negatively affect low sale vytorin cholesterol modify medicine temodar treatment certain type brain tumor proquad pediatric combination vaccine help protect measle mump rubella varicella varivax vaccine help prevent chickenpox varicella addition discuss ongoing implementation certain provision health care reform legislation result increase medicaid rebate impact reduce revenue additionally country european union undertake austerity measure aim reduce cost health care implement pricing action negatively impact sale april merck johnson johnson reach agreement amend agreement govern distribution right remicade simponi agreement conclude arbitration proceeding table content initiate term amend distribution agreement merck relinquish marketing right remicade simponi territory include canada central south america middle east africa asia pacific effective july merck retain exclusive marketing right europe russia turkey retain territory retain territory represent approximately merck revenue billion remicade simponi addition begin july profit derive merck exclusive distribution product retain territory equally divide merck receive onetime payment merck million april company continue advancement drug candidate pipeline victrelis company innovative oral medicine treatment chronic hepatitis approve food drug administration fda european commission fda approve juvisync new treatment type diabetes combine active ingredient glucoselowere medication januvia cholesterollowere medication zocor addition approve zoely monophasic combine oral contraceptive tablet use woman prevent pregnancy cubicin antibacterial agent activity methicillinresistant staphylococcus aureus mrsa company license development distribution right japan approve use country february fda approve janumet new treatment type diabete combine sitagliptin active component januvia extendedrelease metformin oncedaily formulation cosopt mercks preservativefree formulation cosopt ophthalmic solution indicate reduction elevate intraocular pressure appropriate patient openangle glaucoma ocular hypertension zioptan preservativefree prostaglandin analogue ophthalmic solution company receive additional indication exist product fda approve expand age indication zostavax vaccine help prevent shingles herpe zoster include adult age addition fda approve sylatron adjuvant treatment melanoma patient microscopic gross nodal involvement simponi receive indication use combination methotrexate adult severe active progressive rheumatoid arthritis previously treat methotrexate show reduce rate progression joint damage measure xray improve physical function january fda approve use isentress combination antiretroviral medicine treatment hiv infection pediatric patient year age old weighing company currently candidate review fda ridaforolimus treatment metastatic softtissue bone sarcoma patient favorable response chemotherapy mkc zetia ezetimibe combine atorvastatin treatment primary mixed hyperlipidemia review company currently candidate phase iii development anticipate file new drug application nda fda respect certain candidate include suvorexant investigational treatment insomnia bridion medication reversal certain muscle relaxant surgery ninevalent hpv vaccine company anticipate filing odanacatib investigational treatment osteoporosis mka tredaptive development treatment atherosclerosis merck continue pursue opportunity potential drive near longterm growth company complete variety transaction include acquisition inspire pharmaceuticals inc specialty pharmaceutical company focus develop commercialize ophthalmic product additionally company enter transaction design strengthen presence emerge market long term merck continue realize cost saving area company saving result action include merger restructuring program discuss previously announce ongoing cost reduction activity nonrestructuringrelate activity end company realize approximately billion annual net cost saving activity merger july company announce late phase global restructuring program merger restructuring program initiate conjunction integration legacy merck legacy table content scheringplough business merger restructuring program intend optimize cost structure combine company late phase company expect reduce workforce measure time merger additional company worldwide majority workforce reduction phase merger restructuring program relate manufacture include animal health administrative headquarters organization previously announce workforce reduction approximately early phase program primarily reflect elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility company continue hire employee strategic growth area business necessary company continue pursue productivity efficiency evaluate manufacture supply chain capability ongoing basis result future restructuring action company record total pretax restructuring cost billion billion billion relate program restructuring action merger restructuring program expect substantially complete end exception certain action principally manufacturingrelate expect substantially complete total cumulative pretax cost estimate approximately billion billion company estimate approximately twothird cumulative pretax cost relate cash outlay primarily relate employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest company expect merger restructure program yield annual saving end approximately billion billion annual saving completion program approximately billion billion company continue affect health care reform legislation enact additional provision go effect begin law require pharmaceutical manufacturer pay discount medicare beneficiary medicare coverage gap socalle donut hole approximately million record reduction revenue relate estimate impact provision health care reform company record million expense annual health care reform fee company require pay beginning law increase mandate medicaid rebate reduce revenue approximately million million respectively effective december richard clark chairman retired company merck board director kenneth frazier mercks president chief executive officer elect board serve chairman follow clarks retirement november mercks board director raise company quarterly dividend share share earning common share assume dilution attributable common shareholder eps reflect net unfavorable impact result acquisitionrelate cost restructure cost charge relate settlement arbitration proceeding discuss partially offset favorable impact certain tax item gain disposition company interest johnson johnsonmerck consumer pharmaceutical company jjmcp joint venture sale certain manufacturing facility relate asset nongaap eps exclude item nongaap income nongaap eps competition health care environment competition market company conduct business pharmaceutical industry highly competitive highly regulate company competitor include worldwide researchbase pharmaceutical company small research company limit therapeutic focus generic drug consumer health care manufacturer company operation affect technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor generic availability competitor brand product new information clinical trial market product postmarkete surveillance generic competition company product table content mature addition patent position increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result recognition impairment charge respect certain product competitive pressure intensify pressure industry grow effect operation competitive factor patent dispute predict pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively longstanding emphasis research development company position compete search technological innovation additional resource require meet market challenge include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product external alliance joint venture license refine sale marketing effort address change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number compound available treat particular disease typically increase time result slow sale growth company product therapeutic category highly competitive animal health business affect factor include regulatory legislative issue scientific technological advance product innovation quality price company product effective promotional effort frequent introduction generic product competitor company consumer care operation face competition consumer health care business retailer carry private label brand companys competitive position affect factor include regulatory legislative issue scientific technological advance quality price company product promotional effort growth low cost private label brand health care environment global effort health care cost containment continue exert pressure product pricing market access united states federal state government year pursue method reduce cost drug vaccine pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity disproportionate share hospital hospital meet certain criterion federal vaccine child entitlement program center disease control prevention cdc fund purchase recommend pediatric vaccine public sector price immunization medicaideligible uninsured native american certain underinsured child merck contract provide pediatric vaccine program backdrop united states enact major health care reform legislation began implement insurance market reform advance continue implementation new law expect expand access health care million americans end decade previously regular access health care respect effect law pharmaceutical industry law increase mandate medicaid rebate expand rebate medicaid manage care utilization increase type entity eligible federal drug discount program law require pharmaceutical manufacturer pay discount medicare beneficiary medicare coverage gap socalle donut hole pharmaceutical manufacturer require pay annual health care reform fee total annual industry fee billion billion fee assess company proportion share sale certain government program medicare medicaid company face increase pricing pressure globally manage care organization government agency program negatively affect company sale profit margin united states include practice manage care group institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug table content improvement modernization act patient protection affordable care act change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure addition effort contain federal deficit pharmaceutical industry consider potential source saving legislative proposal debate enact prior year type revenue generating cost saving proposal include direct price control medicare prescription drug program addition congress consider proposal allow certain condition importation medicine country remain uncertain proposal include future federal budget deficit reduction proposal directly indirectly affect company global effort health care cost containment intense european country country announce austerity measure include implementation pricing action reduce price generic patent drug company take step mitigate impact austerity measure negatively affect company revenue performance company anticipate austerity measure continue negatively affect revenue performance additionally global economic downturn sovereign debt issue certain european country factor adversely impact foreign receivables certain european country company continue receive payment receivable condition result increase average length time take collect account receivable outstanding adversely affect cash flow impact health care reform continue budget pressure government world predict time address cost containment pressure company continue attempt demonstrate medicine provide value patient pay health care market historically low rate government health care spending company encourage government increase investment order improve citizen access appropriate health care include medicine operating condition challenge global pressure competition industry regulation cost containment effort predict effect factor company business company continually take measure evaluate adapt improve organization business practice well meet customer need believe position respond evolve health care environment market force government regulation pharmaceutical industry subject regulation regional country state local agency world governmental regulation legislation tend focus standard process determine drug safety effectiveness condition sale reimbursement especially relate pricing product particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement practice increase time resource necessary develop new product bring market united states adopt directive legislation concern classification label advertise wholesale distribution integrity supply chain enhance pharmacovigilance monitor approval marketing medicinal product human use provide mandatory standard supplemented implement additional regulation member states company policy procedure consistent substance directive consequently believe material effect company business company believe continue able conduct operation include launch new drug market regulatory environment table content access medicine global health care company merck primary role discover develop innovative medicine vaccine company recognize important role play helping improve access product world company effort regard wideranging example company recognize price product differential pricing framework take consideration factor country level economic development public health need addition merck patient assistance program provide medicine adult vaccine free people prescription drug health insurance coverage company assistance afford merck medicine vaccine building company effort merck undertake collaboration stakeholder improve access medicine enhance quality life people world example merck announce launch merck mother longterm effort global health partner create world woman die preventable complication pregnancy childbirth launch include year million initiative apply mercks scientific business expertise make prove solution widely available develop new technology improve public awareness policy effort private sector engagement maternal mortality merck past provide fund merck company foundation independent organization partner variety organization dedicate improve global health partnership african comprehensive hivaids partnership botswana collaboration government botswana bill melinda gates foundation renew support botswanas response hivaids comprehensive sustainable approach hiv prevention care treatment support privacy datum protection company subject number privacy datum protection law regulation globally legislative regulatory landscape privacy datum protection continue evolve increase attention privacy datum protection issue develop emerge market potential affect directly company business include recently enact law regulation united states europe asia latin america increase enforcement activity united states develop market operating result segment composition reflect certain managerial change implement consumer care product sale outside united states canada previously include pharmaceutical segment include consumer care segment segment disclosure prior year recast comparable basis sale worldwide sale total billion increase compare billion foreign exchange favorably affect global sale performance revenue increase drive largely growth januvia janumet singulair isentress gardasil simponi rotateq zetia pneumovax bridion addition revenue benefit high sale company animal health product launch victrelis increase partially offset low sale cozaar hyzaar lose patent protection united states april number major european market march low sale caelyx subutex suboxone company long marketing right product revenue negatively affect low sale vytorin temodar proquad varivax addition discuss ongoing implementation certain provision health care reform legislation result increase medicaid rebate impact reduce revenue domestic sale billion increase compare billion domestic sale increase drive high sale singulair januvia gardasil janumet isentress launch victrelis increase partially offset low sale cozaar hyzaar vytorin varivax proquad table content foreign sale billion increase compare billion drive growth japan emerge market foreign exchange favorably affect foreign sale performance foreign sale growth reflect strong performance januvia janumet singulair simponi isentress zetia nasonex high sale animal health product partially offset low sale cozaar hyzaar temodar foreign sale represent total sale total sale company brand experience positive growth trend environment continue challenge country announce austerity measure include implementation pricing action reduce price generic patent drug company take step mitigate impact austerity measure negatively affect company revenue performance company anticipate midsingle digit pricing pressure europe biennial price reduction japan worldwide sale total billion compare billion foreign exchange favorably affect global sale performance revenue increase drive largely incremental sale result inclusion year result legacy scheringplough product remicade nasonex temodar pegintron clarinex inclusion year result merckscheringplough partnership msp partnership product zetia vytorin prior merger substantially sale zetia vytorin recognize msp partnership result merck interest msp partnership record equity income affiliate result merger msp partnership wholly own company revenue product reflect sale additionally company recognize year sale legacy scheringplough animal health consumer care product sale include revenue legacy scheringplough msp partnership product postmerger period december contribute sale increase growth januvia janumet isentress singulair increase partially offset low sale cozaar hyzaar fosamax fosamax plus low revenue company relationship azlp product experience decline include gardasil zocor addition implementation certain provision health care reform legislation result increase medicaid rebate impact reduce revenue table content sale company product follow year end december pharmaceutical cardiovascular zetia vytorin integrilin diabete obesity januvia janumet diversify brand cozaarhyzaar zocor propecia claritin remeron vasotecvaseretic proscar infectious disease isentress pegintron cancidas primaxin invanz avelox noxafil crixivanstocrin rebetol victrelis neuroscience ophthalmology maxalt cosopttrusopt oncology temodar emend intron respiratory immunology singulair remicade nasonex clarinex arcoxia simponi asmanex proventil dulera vaccines gardasil proquadmmr iivarivax rotateq pneumovax zostavax womens health endocrine fosamax nuvare follistim implanon cerazette pharmaceutical total pharmaceutical segment sale segment sale total segment sale sale legacy scheringplough product include postmerger period addition prior merger substantially sale zetia vytorin recognize msp partnership result merck interest msp partnership record equity income affiliate result merger msp partnership wholly own company accordingly sale msp partnership product merger reflect table sale zetia vytorin reflect merck sale product latin america msp partnership sale product postmerger period amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate amount reflect supply sale sanofi pasteur msd pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately reflect nonreportable segment include animal health consumer care revenue company relationship azlp primarily relate sale nexium prilosec revenue azlp billion billion billion respectively revenue primarily comprise miscellaneous corporate revenue thirdparty manufacture sale sale relate divested product business supply sale include segment result table content pharmaceutical segment sale cardiovascular worldwide sale zetia market ezetrol outside united states cholesterol absorption inhibitor increase billion reflect high sale international market particularly japan positive impact foreign exchange partially offset volume decline united states global sale vytorin market outside united states inegy combination product contain active ingredient zetia zocor decline billion reflect volume decline united states partially offset increase international market sale zetia vytorin million million respectively postmerger period prior merger substantially sale product recognize msp partnership result merck interest msp partnership record equity income affiliate result merger msp partnership wholly own company revenue product reflect sale total sale zetia vytorin include sale recognize msp partnership billion billion respectively january fda approve update label vytorin include result sharp study heart renal protection clinical trial sharp vytorin lower ldl lowdensity lipoprotein cholesterol patient moderate severe chronic kidney disease major vascular event reduce treatment group compare placebo trial demonstrate treatment vytorin versus placebo reduce risk major vascular event chronic kidney disease population sharp study combination simvastatin ezetimibe compare placebo design assess independent contribution drug observe effect reason fda approve new indication vytorin zetia studys efficacy result incorporate label zetia previously disclose datum safety monitoring board dsmb improveit large cardiovascular outcome study evaluate zetiavytorin patient acute coronary syndrome plan conduct second interim analysis efficacy approximately prespecifie primary clinical endpoint occur september merck advise improveit executive committee decide schedule studys second interim analysis quarter previously anticipate late product contain cardiovascular franchise include integrilin injection treatment patient acute coronary syndrome sell company united states canada diabetes obesity global sale januvia mercks dipeptidyl peptidase dpp inhibitor treatment type diabete rise billion reflect volume growth united states international market particularly japan europe sale januvia grow billion reflect continued growth united states internationally dpp inhibitor represent class prescription medication improve blood sugar control patient type diabete enhance natural body system call incretin system help regulate glucose affect beta cell alpha cell pancrea worldwide sale janumet merck oral antihyperglycemic agent combine sitagliptin januvia metformin single tablet target key defect type diabete billion million million reflect growth internationally ongoing launch certain market growth united states october fda approve juvisync new treatment type diabetes combine glucoselowere medication sitagliptin active component januvia cholesterollowere medication zocor juvisync treatment option health care provider help patient need blood sugarlowere benefit dpp inhibitor cholesterollowering benefit simvastatin convenience single tablet daily table content february fda approve janumet new treatment type diabetes combine sitagliptin extendedrelease metformin janumet provide convenient oncedaily treatment option health care provider patient need help control blood sugar february fda send warning letter company relate januvia janumet state company fulfill post marketing requirement month pancreatic safety study diabetic rodent model treat sitagliptin merck communication fda study merck effort complete timely satisfactory manner term warn letter day date letter company submit fda final study protocol new month rodent study satisfy fdas requirement propose revise timetable completion study month date letter fda expect company obtain agreement fda adequate study protocol initiate study letter state failure correct violation result regulatory action fda include limited civil money penalty merck remain fully commit fulfil fda requirement diversify brand mercks diversified brand human health pharmaceutical product approach expiration marketing exclusivity long protect patent develop market continue core company offer market world global sale cozaar companion agent hyzaar combination cozaar hydrochlorothiazide treatment hypertension decline billion fall billion patent provide market exclusivity cozaar hyzaar expire april addition cozaar hyzaar lose patent protection number major european market march accordingly company experience significant decline cozaar hyzaar sale company expect decline continue product contain diversified brand franchise include zocor statin modifying cholesterol propecia product treatment male pattern hair loss prescription claritin treatment seasonal outdoor allergy yearround indoor allergy remeron antidepressant vasotec vaseretic hypertension andor heart failure proscar urology product treatment symptomatic benign prostate enlargement remeron lose market exclusivity united states january lose market exclusivity major european market formulationuse patent provide market exclusivity propecia expire october previously disclose agreement generic manufacturer give right enter market january give right enter july infectious disease worldwide sale isentress hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection treatmentnave treatmentexperience adult grow billion reflect volume growth united states internationally partially offset unfavorable pricing european market sale isentress increase billion primarily positive performance united states internationally result continued uptake launch isentress work inhibit insertion hiv dna human dna integrase enzyme inhibit integrase perform essential function help limit ability virus replicate infect new cell january fda approve use isentress combination antiretroviral medicine treatment hiv infection pediatric patient year age old weighing worldwide sale pegintron treatment chronic hepatitis million decline compare million sale reflect competitive pressure addition company believe sale decline attributable patient treatment delay health care provider anticipation new therapeutic option available september company initiate voluntary recall pegintron single dose redipen injection united states consultation fda recall globally result reduction revenue approximately million represent estimate sale return addition company recognize charge approximately million material table content production primarily inventory discard cost recall conduct precautionary measure thirdparty manufacturing issue affect small number redipen recall specific pegintron redipen affect pegintron vial product sale pegintron million postmerger period fda approve victrelis company innovative oral medicine treatment chronic hepatitis victrelis approve treatment chronic hepatitis genotype infection combination peginterferon alfa ribavirin adult patient year age old compensate liver disease include cirrhosis previously untreated fail previous interferon ribavirin therapy victrelis antiviral agent design interfere ability hepatitis virus replicate inhibit key viral enzyme july approve victrelis ec decision grant single marketing authorization valid country member unified labeling applicable iceland liechtenstein norway addition united states victrelis launch market include france germany canada brazil sale victreli million sale primaxin antibacterial product decline million decrease million result primarily reflect low volume unfavorable pricing competitive pressure patent primaxin expire worldwide multiple generic launch europe accordingly company experience decline sale primaxin company expect decline continue product contain infectious disease franchise include cancida antifungal product invanz treatment certain infection avelox fluoroquinolone antibiotic treatment certain respiratory skin infection noxafil prevention certain invasive fungal infection crixivan stocrin antiretroviral therapy treatment hiv infection rebetol use combination pegintron treat chronic hepatitis compound patent provide market exclusivity cancida expire september neuroscience ophthalmology global sale maxalt mercks tablet acute treatment migraine increase million reflect high inventory level favorable pricing united states sale maxalt decline million reflect generic availability compete product patent provide market exclusivity maxalt expire december sale maxalt million addition patent provide market exclusivity maxalt expire number major european market february company anticipate sales united states european market decline significantly patent expiry worldwide sale ophthalmic product cosopt trusopt decline million reflect unfavorable pricing volume decline europe mitigate positive impact foreign exchange partially offset high cosopt sale japan sale cosopt trusopt decrease million patent provide market exclusivity cosopt trusopt expire trusopt lose market exclusivity number major european market patent cosopt expire number major european market march company expect sale market decline significantly february fda approve cosopt mercks preservativefree formulation cosopt ophthalmic solution indicate reduction elevate intraocular pressure appropriate patient openangle glaucoma ocular hypertension company plan launch cosopt end bridion reversal certain muscle relaxant surgery currently approve launch country outside united states sale bridion million million bridion phase iii development united states fda approve saphris asenapine antipsychotic treatment schizophrenia adult acute treatment monotherapy adjunctive therapy lithium valproate manic mixed episode associate bipolar disorder adult asenapine sell brand sycrest receive marketing approval treatment moderate severe manic episode associate bipolar disorder adult merck lundbeck lundbeck announce worldwide table content commercialization agreement sycr sublingual tablet term agreement lundbeck pay fee make product supply payment exchange exclusive commercial right sycr market outside united states china japan merck sales saphris million merck continue focus build brand awareness saphris united states company continue monitor assess saphrissycrest relate intangible asset increase brand awareness lundbeck launch product successful company noncash impairment charge respect saphrissycr charge material neuroscience ophthalmology franchise include product subutexsuboxone treatment opiate addiction march merck sell right subutexsuboxone nearly market reckitt benckiser group plc reckitt right product major market revert reckitt july remainder revert reckitt exception small market sale subutexsuboxone million february fda approve zioptan tafluprost preservativefree prostaglandin analog ophthalmic solution reduce elevated intraocular pressure patient openangle glaucoma ocular hypertension merck exclusive commercial right tafluprost western europe exclude germany north america south america africa middle east india australia zioptan market saflutan certain market outside united states oncology sale temodar market temodal outside united states treatment certain type brain tumor decline million billion primarily reflect generic competition europe sale temodar million postmerger period temodar lose patent exclusivity previously disclose agreement generic manufacturer give right enter market august patent exclusivity period expire february global sale emend treatment chemotherapyinduce nausea vomit increase million primarily reflect growth international market sale emend increase million drive increase united states launch japan product oncology franchise include intron adjuvant treatment melanoma marketing right caelyx treatment ovarian cancer metastatic breast cancer kaposis sarcoma transition december sale caelyx million march fda approve sylatron onceweekly subcutaneous injection indicate adjuvant treatment melanoma microscopic gross nodal involvement day definitive surgical resection include complete lymphadenectomy respiratory immunology worldwide sale singulair onceaday oral medicine chronic treatment asthma relief symptom allergic rhinitis grew reach billion drive favorable pricing united states volume growth japan emerge market beneficial impact foreign exchange global sale singulair rise billion reflect price increase positive performance japan patent provide market exclusivity singulair expire august company expect year follow patent expiration lose substantially sale singulair decline come year follow patent expiration sale singulair billion addition patent provide market exclusivity singulair expire number major european market february company expect sale singulair market decline significantly patent provide market exclusivity singulair japan expire sale remicade treatment inflammatory disease billion decline compare foreign exchange favorably affect sale performance prior july remicade market company outside united states japan certain asian market result agreement reach april amend agreement govern distribution right remicade simponi discuss effective july merck relinquish marketing right product certain territory include canada central south america middle east africa table content asia pacific sale performance reflect change retain territory remicade sale grow reflect favorable impact foreign exchange sale remicade million postmerger period simponi oncemonthly subcutaneous treatment certain inflammatory disease approve october january simponi approve use combination methotrexate adult severe active progressive rheumatoid arthritis previously treat methotrexate show reduce rate progression joint damage measure xray improve physical function sale simponi million million revenue increase drive growth retain territory ongoing launch global sale nasonex inhale nasal corticosteroid treatment nasal allergy symptom billion increase compare sale billion drive largely volume growth japan latin america positive effect foreign exchange partially offset volume decline united states sales nasonex million postmerger period global sale clarinex market aerius country outside united states nonsedate antihistamine million compare sale million sale clarinex million postmerger period product include respiratory immunology franchise include arcoxia treatment arthritis pain asmanex inhale corticosteroid asthma proventil inhalation aerosol relief bronchospasm dulera inhalation aerosol combination medicine treatment asthma january merck receive complete response letter fda supplemental new drug application snda dulera treatment chronic obstructive pulmonary disease company plan discussion fda regard complete response letter vaccine follow discussion vaccine include sale vaccine sell major european market sanofi pasteur msd spmsd company joint venture sanofi pasteur result reflect equity income affiliate select joint venture affiliate information supply sale spmsd include worldwide sale gardasil record merck grow billion drive increase vaccination male year age united states high sale conjunction launch japan growth emerge market partially offset low government order canada sale gardasil decline million drive largely decline united states australia sale include million result government purchase cdcs strategic national stockpile gardasil world topselle hpv vaccine indicate girl woman year age prevention cervical vulvar vaginal anal cancer cause hpv type certain precancerous dysplastic lesion cause hpv type genital wart cause hpv type gardasil approve united states use boy man year age prevention anal cancer cause hpv type anal dysplasia precancerous lesion cause hpv type genital wart cause hpv type company party certain thirdparty license agreement respect gardasil include crosslicense settlement agreement glaxosmithkline result agreement company pay royalty worldwide gardasil sale vary country include material production cost recent year company experience difficulty produce varicella zoster virus vzvcontaine vaccine difficulty result supply constraint proquad varivax zostavax company manufacture bulk varicella produce dose varivax zostavax limit quantity proquad pediatric combination vaccine help protect measle mump rubella varicella vzv contain vaccine available united states order second quarter supply exhausted proquad long available order merck sale proquad million million proquad available order supply constraint merck sale varivax vaccine help prevent chickenpox varicella million million billion sale reflect million million table content respectively revenue result government purchase cdcs strategic national stockpile merck sale mmr vaccine help protect measle mump rubella million million million sale varivax mmr affect unavailability proquad note merck sale rotateq vaccine help protect rotavirus gastroenteritis infant child grow million reflect favorable public sector inventory fluctuation growth emerge market sale rotateq decline million sale benefit modestly temporary competitor supply issue sale pneumovax vaccine help prevent pneumococcal disease million million million increase compare primarily positive performance united states favorable pricing japan mercks sale zostavax vaccine help prevent shingles herpe zoster million million million sale year affect supply issue company fill backorder resume normal supply schedule united states zostavax company increase promotional effort zostavax united states broad international launch immunization program currently plan march fda approve expand age indication zostavax prevention shingle include adult age zostavax indicate prevention herpe zoster individual year age old merck adult formulation vaqta vaccine hepatitis currently unavailable womens health endocrine worldwide sale fosamax fosamax plus market fosavance fosamac japan treatment case fosamax prevention osteoporosis decline million decrease million medicine lose market exclusivity united states lose market exclusivity major european market accordingly company experience sale decline fosamax product franchise company expect decline continue worldwide sale nuvare contraceptive product grow million million drive positive performance united states internationally include beneficial impact foreign exchange sale nuvare million postmerger period global sale follistim market country outside united states puregon biological fertility treatment million compare million reflect growth emerge market offset decline europe primarily supply constraint sale follistim million postmerger period puregon lose market exclusivity august product contain women health endocrine franchise include implanon singlerod subdermal contraceptive implant cerazette progestin oral contraceptive company currently experience difficulty manufacture certain women health product company work resolve issue august zoely oral contraceptive grant marketing authorization use woman prevent pregnancy zoely combine oral contraceptive tablet contain unique monophasic combination hormone nomegestrol acetate highly selective progesteronederived progestin beta estradiol estrogen similar naturally present womans body marketing authorization zoely apply member states plus iceland liechtenstein norway teva pharmaceutical industries ltd hold exclusive marketing right zoely france italy belgium spain november merck receive complete response letter fda nomace mka market zoely company planning conduct additional clinical study request fda update application future table content animal health animal health include pharmaceutical vaccine product prevention treatment control disease major farm companion animal species animal health sale affect intense competition frequent introduction generic product global sale animal health product grow billion billion foreign exchange favorably affect global sale performance increase sale drive positive performance cattle swine poultry companion animal product global sale animal health product million post merger period consumer care consumer care product include overthecounter foot care sun care product claritin nondrowsy antihistamine scholl foot care product coppertone sun care product miralax treatment occasional constipation global sale consumer care product increase billion reflect strong performance coppertone offset decline scholl claritin consumer care product sale million postmerger period consumer care product sale affect competition consumer spending pattern alliance astrazeneca option buy merck interest subsidiary merck interest nexium prilosec exercisable company believe likely astrazeneca exercise option select joint venture affiliate information astrazeneca exercise option company long record equity income azlp supply sale azlp decline substantially cost expense million change change material production marketing administrative research development restructuring cost equity income affiliate income expense net great amount include reclassification million expense market administrative research development include million billion iprd impairment charge respectively material production material production cost billion billion billion material production cost include expense relate sale legacy scheringplough msp partnership product postmerger period cost unfavorably affect billion billion billion respectively expense amortization intangible asset record connection merger acquisition additionally expense include billion billion respectively amortization purchase accounting adjustment scheringplough inventory recognize result merger cost include intangible asset impairment charge million company recognize additional noncash impairment charge future relate product intangible measure fair value capitalize connection merger acquisition charge material include material production cost associate restructuring activity amount million million million respectively include accelerate depreciation asset writeoff relate plan sale closure manufacturing facility separation cost associate manufacturingrelate headcount reduction incur reflect restructure cost discuss table content gross margin compare amortization intangible asset purchase accounting adjustment inventory restructuring impairment charge note unfavorable impact gross margin percentage point percentage point percentage point gross margin improvement compare reflect change product mix manufacturing efficiency benefit foreign exchange marketing administrative marketing administrative expense billion billion billion increase compare unfavorable effect foreign exchange strategic investment emerge market additionally market administrative expense include million expense annual health care reform fee require health care reform legislation expense include restructure cost million million respectively primarily relate accelerated depreciation facility close divest separation cost associate sale force reduction incur reflect restructure cost discuss expense include million million acquisitionrelate cost respectively consist largely integration cost relate merger consist severance cost associate acquisition inspire pharmaceuticals inc company formal restructuring program market administrative expense include expense relate scheringplough activity postmerger period include acquisition relate cost million largely comprise transaction cost directly related merger include advisory legal fee integration cost research development research development expense billion billion billion expense include expense relate scheringplough activity postmerger period research development expense comprise cost directly incur merck research lab mrl company research development division focus human healthrelated activity approximately billion billion respectively include research development expense cost incur division support research development activity include depreciation production general administrative certain cost operate segment include pharmaceutical animal health consumer care billion billion aggregate respectively research development expense favorably affect cost saving result restructure activity research development expense include inprocess research development iprd impairment charge research development relate restructuring charge company record iprd impairment charge million primarily pipeline program abandon determined alternative use expect delay launch timing change cash flow assumption certain compound addition impairment charge relate pipeline program previously deprioritize deem alternative use period outlicense party consideration related asset carry value company record billion iprd impairment charge billion relate writedown intangible asset vorapaxar result development clinical program compound research development remain million iprd impairment charge attributable compound abandon determine alternative use return respective licensor expect delay launch timing change cash flow assumption certain compound company recognize additional noncash impairment charge future cancellation delay pipeline program measure fair value capitalize connection merger acquisition charge material research development expense reflect million million million respectively accelerate depreciation asset abandonment cost associate restructuring activity sharebase compensation total pretax sharebase compensation expense million million million december million total pretax unrecognized compensation table content expense relate nonveste stock option restrict stock unit performance share unit award recognize weighted average period year segment report sharebased compensation cost unallocated expense restructure cost restructure cost billion million billion respectively nearly cost record relate merger restructuring program restructuring cost record million relate merger restructuring program million relate global restructure program initiate restructuring program remain activity relate legacy scheringplough program include gain sale manufacturing facility restructuring cost record billion relate merger restructure program million related restructuring program million relate legacy scheringplough program separation cost billion million billion respectively incur associate actual headcount reduction estimate expense exist severance program headcount reduction probable reasonably estimate merck eliminate position relate merger restructuring program relate restructuring program relate legacy scheringplough program position relate merger restructuring program relate restructuring program remainder legacy scheringplough program position relate restructuring program position elimination comprise actual headcount reduction elimination contractor vacant position include restructuring cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation plan costs contract termination shutdown cost segment report restructuring cost unallocated expense additional cost associate company restructuring activity include material production marketing administrative research development discuss equity income affiliate equity income affiliate reflect performance company joint venture equity method affiliate increase million primarily high partnership return azlp company divest interest jjmcp joint venture equity income affiliate decline million billion equity income affiliate long include equity income msp partnership wholly own company result merger merial limited merial sale merck interest addition low partnership return azlp low equity income spmsd result restructure charge record joint venture contribute decline select joint venture affiliate information income expense net income expense net million expense reflect million charge relate resolution arbitration proceeding involve company right market remicade simponi note consolidated financial statement million gain disposition company interest jjmcp joint venture note consolidated financial statement million gain sale certain manufacturing facility relate asset note consolidated financial statement income expense net billion expense reflect million charge vioxx liability reserve note consolidated financial statement charge relate settlement certain pende awp litigation million exchange loss venezuelan currency devaluation discuss partially offset million income recognize astrazenecas asset option exercise note consolidated financial statement million income recognize settlement certain dispute royalty income expense net billion income primarily reflect billion gain result recognize merck previously hold equity interest msp partnership fair value result obtain control msp partnership merger billion gain sale merck interest merial note consolidated financial statement table content note exchange loss reflect loss relate venezuelan currency devaluation effective january venezuelan government devalue currency bsf dollar twotiere official exchange rate essential rate bsf dollar nonessential rate bsf dollar january company require remeasure local currency operation venezuela dollar venezuelan economy determine hyperinflationary company settle transaction essential rate remeasure monetary asset liability utilize essential rate december venezuelan government announce eliminate essential rate effective january transaction settle official rate bsf dollar result announcement company remeasure december monetary asset liabilitie new official rate segment profit million pharmaceutical segment profit nonreportable segment profit income income taxis segment profit comprise segment revenue certain element material production cost operating expense include component equity income loss affiliate depreciation amortization expense internal management reporting present chief operating decision maker merck allocate production cost standard cost research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit exclude determination segment profit arbitration settlement charge gain divestiture jjmcp joint venture gain sale certain manufacturing facility relate asset record charge vioxx liability reserve income recognize astrazenecas asset option exercise recognize gain relate msp partnership disposition merial addition amortization purchase accounting adjustment acquisitionrelate cost intangible asset impairment charge restructure cost taxis pay joint venture level portion equity income exclude determination segment profit additionally segment profit reflect expense corporate manufacturing cost center miscellaneous income expense unallocated item reflect table include miscellaneous corporate profit operate profit relate thirdparty manufacturing sale divest product business supply sale pharmaceutical segment profit rose drive largely increase sale gross margin improvement discuss pharmaceutical segment profit increased drive largely inclusion legacy scheringplough result taxis income effective income tax rate reflect impact purchase accounting adjustment restructure cost partially offset beneficial impact foreign earning addition effective tax rate reflect net favorable impact approximately million relate settlement merck federal income tax audit favorable impact certain foreign state tax rate change result net million reduction defer tax liability intangible establish purchase accounting impact million charge relate resolution arbitration proceeding effective tax rate reflect impact vioxx liability reserve tax impact record million charge associate change tax law require taxation prescription drug subsidy company retiree health benefit plan enact quarter health care reform legislation impact astrazenecas asset option exercise unfavorable impact partially offset million tax benefit change foreign table content entitys tax rate result reduction defer tax liability product intangible record conjunction merger favorable impact enactment tax extender legislation include tax credit favorable impact foreign earning dividend companys foreign subsidiary effective tax rate reflect favorable impact increase income low tax jurisdiction include favorable impact msp partnership gain tax settlement include previously announce settlement canada revenue agency cra favorable impact partially offset unfavorable effect gain sale merck interest merial taxable united states combine federal state tax rate approximately net income earning common share net income attributable merck inc billion million billion eps increase net income ep compare primarily lower iprd impairment charge amortization inventory stepup low legal reserve favorable impact tax settlement partially offset arbitration settlement charge record income recognize astrazenecas asset option exercise decline net income ep compare primarily gain recognize associated msp partnership result merger disposition merial incremental cost result merger include recognition year amortization intangible asset inventory stepup addition iprd impairment charge charge establish vioxx liability reserve low equity income affiliate impact health care reform legislation contribute decline net income ep compare income recognize astrazenecas asset option exercise benefit net income ep eps affect dilutive impact share issue merger nongaap income nongaap ep nongaap income nongaap eps alternative view company performance management merck provide management believe information enhance investor understand company result nongaap income nongaap eps exclude certain item nature item impact analysis underlie business performance trend exclude item consist acquisitionrelate cost restructure cost certain item exclude item significant component understand assess financial performance information nongaap income nongaap eps consider addition lieu net income ep prepared accordance generally accept accounting principle united states gaap additionally nongaap income nongaap ep measure determine accordance gaap standardize mean prescribed gaap comparable calculation similar measure company nongaap income nongaap ep important internal measure company senior management receive monthly analysis operating result include nongaap income nongaap ep performance company measure basis performance metric senior management annual compensation derive nongaap income nongaap ep table content reconciliation gaap financial measure nongaap financial measure follow million share amount pretax income report gaap increase decrease exclude item acquisitionrelate cost restructure cost item arbitration settlement charge gain disposition interest jjmcp joint venture gain sale manufacturing facility relate asset vioxx liability reserve income recognize astrazenecas asset option exercise gain related msp partnership gain disposition interest merial taxis income report gaap estimate tax benefit expense exclude item tax benefit settlement federal income tax audit tax benefit foreign state tax rate change tax charge relate health care reform legislation nongaap net income net income attributable noncontrolle interest nongaap net income attributable merck inc eps assume dilution report gaap ep difference nongaap ep assume dilution represent difference calculate gaap ep calculate nongaap eps different calculate dividing impact exclude item weightedaverage share applicable year acquisitionrelate cost nongaap income nongaap eps exclude ongoing impact certain amount record connection merger acquisition amount include amortization intangible asset inventory stepup intangible asset impairment charge exclude integration transaction cost associate merger cost associate merger acquisition severance cost company formal restructuring program cost exclude management believe cost representative ongoing normal business activity restructure cost nongaap income nongaap eps exclude cost relate restructuring action include restructuring activity relate merger note consolidated financial statement amount include employee separation cost accelerate depreciation associate facility close divested accelerated depreciation cost represent difference depreciation expense recognize revise useful life site base anticipate date site close divest depreciation table content expense determine utilize useful life prior restructure action company undertake restructuring different type cover period charge consider nonrecurre management exclude amount nongaap income non gaap ep believe helpful understanding performance continue business certain item nongaap income nongaap eps exclude certain item item represent substantive unusual item evaluate individual basis evaluation consider quantitative qualitative aspect unusual nature generally represent item result nature magnitude management anticipate occur company normal business regular basis certain item comprise arbitration settlement charge gain disposition company interest jjmcp joint venture gain associate sale certain manufacturing facility relate asset charge establish vioxx liability reserve income recognize astrazenecas asset option exercise gain result recognize merck previously hold equity interest msp partnership fair value result obtain control interest merger gain divestiture merck interest merial exclude nongaap income nongaap eps tax benefit settlement federal income tax audit favorable impact certain foreign state tax rate change result net reduction defer tax liability intangible establish purchase accounting tax charge relate health care reform legislation research development chart reflect company current research pipeline february set forth item business research development research development update company currently candidate regulatory review united states internationally ridaforolimus investigational oral mtor mammalian target rapamycin inhibitor development treatment metastatic softtissue bone sarcoma patient favorable response chemotherapy accept standard review fda september august european medicine agency accept marketing authorization application ridaforolimus exclusive license agreement ariad pharmaceuticals inc ariad merck responsible development worldwide commercialization ridaforolimus ariad option promote ridaforolimus sarcoma united states subject execution copromotion agreement mkc zetia ezetimibe combine atorvastatin accept standard review fda treatment primary mixed hyperlipidemia response notice company file pfizer inc pfizer file patent infringement lawsuit district court company assert certain pfizer patent right respect atorvastatin lawsuit potential bar fda approval company nda month january subject shorten lengthen court decision shorten agreement party addition candidate regulatory review company drug candidate phase iii development target broad range disease company plan file major product approval include suvorexant insomnia bridion reversal neuromuscular blockade cervical cancer vaccine odanacatib osteoporosis tredaptive atherosclerosis suvorexant investigational dual orexin receptor antagonist potential new approach treatment insomnia orexin neuropeptide chemical messenger release specialized neuron hypothalamus region brain believe important regulator brain sleepwake process february merck announce base positive result pivotal phase iii efficacy trial suvorexant company anticipate file nda fda table content bridion medication reversal certain muscle relaxant surgery bridion currently approve launch country outside united states prior merger scheringplough receive notapprovable letter fda bridion company conduct additional clinical trial address fdas comment plan file nda bridion fda ninevalent hpv vaccine development help protect certain hpvrelate disease incorporate antigen additional cancercause hpv type compare gardasil phase iii clinical program include eventdriven clinical trial ongoing merck continue anticipate file biologic license application bla fda odanacatib oral onceweekly investigational treatment osteoporosis postmenopausal woman osteoporosis disease reduce bone density strength result increase risk bone fracture odanacatib cathepsin inhibitor selectively inhibit cathepsin enzyme cathepsin know play central role function osteoclast cell break exist bone tissue particularly protein component bone inhibition cathepsin novel approach treatment osteoporosis odanacatib continue study determine safety potential effect hip vertebral nonvertebral fracture eventdriven phase iii clinical trial company anticipate file nda fda mka drug candidate combine extendedrelease niacin novel flush inhibitor laropiprant mka demonstrate ability low ldlcholesterol ldlc bad cholesterol raise hdlcholesterol hdlc good cholesterol low triglyceride significantly flushing traditional extend release niacin high ldlc low hdlc elevate triglyceride risk factor associate heart attack stroke april merck receive notapprovable letter fda response nda mka meet discuss letter fda state additional efficacy safety datum require suggest merck wait result hpsthrive treatment hdl reduce incidence vascular event eventdriven cardiovascular outcome study expect complete company anticipate file nda fda mka mka approve country outside united states treatment dyslipidemia particularly patient combine mixed dyslipidemia characterize elevated level ldlc triglyceride low hdlc patient primary hypercholesterolemia heterozygous familial nonfamilial market tredaptive cordaptive certain country tredaptive patient combination statin cholesterol lower effect statin monotherapy inadequate tredaptive monotherapy patient statin consider inappropriate tolerate elonva corifollitropin alpha injection approve control ovarian stimulation combination gnrh antagonist development multiple follicle woman participate assist reproductive technology program currently phase iii development united states base feedback fda additional datum ongoing phase iii trial require time filing merck anticipate file nda elonva fda vernakalant investigational candidate treatment atrial fibrillation market brinavess merck acquire exclusive right develop commercialize vernakalant exclusive worldwide right oral formulation vernakalant prior merck acquisition right vernakalant canada mexico united states program place clinical hold fda phase iii act trial suspend act terminate united states program remain hold company plan discussion fda mka nomace market zoely oral contraceptive use woman prevent pregnancy nomace combine oral contraceptive tablet contain unique monophasic combination hormone nomegestrol acetate highly selective progesteronederived progestin beta estradiol estrogen similar naturally present women body november merck receive complete response letter fda nomace company plan conduct additional clinical study request fda update application future table content vorapaxar thrombin receptor antagonist develop prevention thrombosis clot formation reduction cardiovascular event vorapaxar evaluate major clinical outcome study different patient group tracer thrombin receptor antagonist clinical event reduction acute coronary syndrome clinical outcome trial patient acute coronary syndrome trap thrombin receptor antagonist secondary prevention atherothrombotic ischemic event secondary prevention study patient previous heart attack ischemic stroke document peripheral vascular disease february merck announce topline result trap study trap show addition vorapaxar standard care significantly reduce risk protocolspecifie primary endpoint composite cardiovascular death heart attack myocardial infarction stroke urgent coronary revascularization compare standard care significant increase bleed include intracranial hemorrhage patient take vorapaxar addition standard care low risk intracranial hemorrhage patient history stroke result trap present american college cardiology scientific session march november researcher present result tracer outcome study american heart association scientific session result publish tracer achieve primary endpoint january merck external study investigator announce combine dsmb clinical trial review available safety efficacy datum recommend patient tracer trial discontinue study drug investigator close study merck review datum trap tracer investigator outside expert help well understand profile investigational medicine specific patient population determine step include potential regulatory filing mkb drug candidate combine novel approach raise hdlc lower triglyceride extendedrelease niacin combine laropiprant prove benefit simvastatin combination product merck anticipate file nda mkb fda investigational allergy immunotherapy sublingual tablet ait phase iii development grass pollen allergy company north american right ait dissolvable oral tablet design prevent allergy symptom induce protective immune response allergy treat underlying cause disease merck investigate ait treatment grass pollen allergic rhinoconjunctivitis child adult company anticipate file nda fda ait ragweed allergy phase iii development north american market company anticipate file nda fda preladenant selective adenosine receptor antagonist phase iii development treatment parkinson disease company anticipate file nda preladenant fda mka investigational candidate treatment clostridium difficile infection combination monoclonal antibody treat patient single infusion company anticipate file nda mka fda inactivated varicellazoster virus vaccine development prevention herpe zoster company enrol phase iii trial autologous hematopoietic cell transplant patient patient solid tumor malignancy undergo chemotherapy hematological malignancy company anticipate file bla autologous hematopoietic cell transplant datum file second indication cancer patient later date investigational hexavalent pediatric combination vaccine contain component current vaccine design help protect potentially disease diphtheria tetanus whooping cough bordetella pertussis polio poliovirus type invasive disease cause haemophilus influenzae type hepatitis develop collaboration sanofipasteur company anticipate file bla fda mke combine januvia atorvastatin single tablet develop treatment diabete atherosclerosis company anticipate file nda mke fda table content vaniprevir investigational oral twice daily protease inhibitor treatment chronic hepatitis virus drug phase iii trial japan company anticipate file new drug application japan anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp investigate lipid management raise hdlc reduce ldlc base result phase iii define determine efficacy tolerability cetp inhibition anacetrapib safety study patient coronary heart disease coronary heart disease risk equivalent company initiate large eventdriven cardiovascular clinical outcome trial reveal randomize evaluation effect anacetrapib lipidmodification involve patient preexist vascular disease company continue anticipate file nda anacetrapib fda merck discontinue clinical development program telcagepant company investigational calcitonin generelate peptide receptor antagonist treatment acute migraine decision base assessment datum clinical program company discontinue clinical development program mkc combination sitagliptin pioglitazone treatment diabete base review regulatory commercial prospect combination drug candidate merck discontinue clinical development program mka zenhale fix dose combination previously approve drug treatment asthma mometasone furoate formoterol fumarate dehydrate market united states dulera inhalation aerosol company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource disease area unmet medical need scientific opportunity commercial opportunity merck manage research development portfolio diverse approach discovery development balance investment appropriately novel innovative target potential major impact human health develop bestinclass approach deliver maximum value approve medicine vaccine new indication new formulation important component company sciencebase diversification base expand company portfolio modality include small molecule vaccine biologic peptide small protein antibodie rnai merck move diversify portfolio merck bioventure division potential harness market opportunity present biological medicine patent expiry deliver high quality followon biologic product enhance access patient worldwide company supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound new technology company clinical pipeline include candidate multiple disease area include atherosclerosis cancer cardiovascular disease diabete infectious disease inflammatoryautoimmune disease insomnia neurodegenerative disease ophthalmic osteoporosis respiratory disease women health inprocess research development connection merger company record fair value human animal health research project underway schering plough msp partnership fair value project allocate pharmaceutical animal health operating segment billion billion respectively significant project include victrelis bridion vorapaxar ezetimibeatorvastatin combination product victreli medicine treatment hepatitis approve fda note company file nda fda ezetimibeatorvastatin combination product company anticipate file nda fda bridion approximately million million respectively iprd project receive marketing approval major market company begin amortize asset base estimate useful life company recognize intangible asset fair value research project underway connection smartcells inc acquisition note consolidated financial statement insme inc acquisition table content iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate time period receive approval fda regulatory agency subject uncertainty significant delay approval process company failure obtain approval delay prevent company realize revenue product additionally certain iprd program fail abandon development company realize future cash flow estimate record iprd merger acquisition date company recover research development expenditure merger develop program circumstance occur company future operating result adversely affect company recognize impairment charge charge material company record million iprd impairment charge research development expense primarily pipeline program abandon determined alternative use expect delay launch timing change cash flow assumption certain compound addition impairment charge relate pipeline program previously deprioritize deem alternative use period outlicense party consideration related asset carry value company record billion iprd impairment charge company determine development clinical research program vorapaxar discuss constituted trigger event require company evaluate vorapaxar intangible asset impairment utilize market participant assumption consider different scenario company conclude good estimate current fair value intangible asset relate vorapaxar million result recognition impairment charge billion february merck announce topline result trap study result merck evaluate vorapaxar intangible asset impairment conclude impairment necessary december note merck continue review data trap tracer investigator outside expert help well understand profile investigational medicine specific patient population determine step include potential regulatory filing process company require impairment charge relate vorapaxar remain million iprd impairment charge record attributable compound abandon determine alternative use return respective licensor expect delay launch timing change cash flow assumption certain compound additional research development require remain program reach technological feasibility cost complete research project depend project bring final stage development ultimately submit fda regulatory agency approval december estimate cost complete project acquire connection merger phase iii development human health analogous stage development animal health approximately billion acquisition research collaboration license agreement merck continue remain focused pursue opportunity potential drive near longterm growth company complete transaction broad range therapeutic category include earlystage technology transaction merck actively monitor landscape growth opportunity meet company strategic criterion merck complete acquisition inspire pharmaceuticals inc inspire specialty pharmaceutical company focus develop commercialize ophthalmic product term merger agreement merck acquire outstanding share common stock inspire price share cash total approximately million transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value acquisition date determination fair value require management significant estimate assumption connection acquisition substantially purchase price allocate inspire table content product product right intangible asset relate deferred tax liability defer tax asset relate inspire net operating loss carryforward goodwill transaction close accordingly result operation acquire business include company result operation acquisition date pro forma financial information include inspire historical financial result significant compare company financial result select joint venture affiliate information expand research base realize synergy combine capability opportunity asset previous year merck form number joint venture astrazeneca merck enter agreement astra astra develop market astra product royaltybeare license merck total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami merck astra own share joint venture form develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach lining merck astra complete restructure ownership operation joint venture merck acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca azlp astras merger zeneca group plc exclusive distributor product kbi retain right maintain limited partner interest azlp merck consent protective right intend preserve business economic interest include restriction power general partner certain distribution disposition furthermore limit event default additional right grant company include power direct action remove replace partnership chief executive officer chief financial officer merck earn ongoing revenue base sale kbi product revenue billion billion billion respectively primarily relate sale nexium prilosec addition merck earn certain partnership return record equity income affiliate return include priority return provide partnership agreement preferential return represent merck share undistribute azlp gaap earning variable return relate companys limited partner interest return aggregate million million million respectively conjunction restructuring discuss astra purchase option asset option payment million record deferred income buy merck interest kbi product exclude gastrointestinal medicine nexium prilosec nonppi products april astrazeneca exercise asset option merck receive million astrazeneca represent net present value march project future pretax revenue receive merck nonppi products record reduction company investment azlp company recognize million defer income component income expense net addition merck grant astra option share option buy merck common stock interest kbi mercks interest nexium prilosec exercisable exercise price share option primarily base net present value project future pretax revenue receive merck nexium prilosec determine time exercise subject certain trueup mechanism company believe likely astrazeneca exercise share option astrazeneca exercise option company long record equity income azlp supply sale azlp decline substantially table content sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur establish equallyowne joint venture market vaccine europe collaborate development combination vaccine distribution europe sale joint venture product follow million gardasil influenza vaccine viral vaccine rotateq hepatitis vaccine vaccine johnson johnsonmerck consumer pharmaceutical company september merck sell interest jjmcp joint venture venture merck form develop manufacture market distribute certain overthecounter otc consumer product united states canada merck receive onetime payment million recognize pretax gain million reflect income expense net merck right pepcid brand outside united states canada affect transaction follow transaction own venture asset include exclusive right market otc pepcid mylanta mylicon local otc brand currently sell united states canada partnership asset include manufacture facility termination jjmcp joint venture provide merck great flexibility allow company capitalize pipeline potential prescription tootc switch actively pursue otc licensing activity united states canada sale product market joint venture million period january september divestiture date million million merckscheringplough partnership merck scheringplough collectively partner enter agreement create equally own partnership develop market united states new prescription medicine cholesterol management ezetimibe new class cholesterollowere agent launch united states zetia market ezetrol outside united states combination product contain active ingredient zetia zocor approve united states vytorin market inegy outside united states cholesterol agreement provide share operating income generate msp partnership base percentage varied product sale level country operating income include expense partner contractually agree share expense incur support msp partnership share partner include equity income affiliate cost reflect overall result partner result merck interest msp partnership prior merger reflect equity income affiliate billion result merger msp partnership wholly own company activity result sale msp partnership product merger consolidate merck result discussion performance product sale table content sale joint venture product follow million premerger postmerger total vytorin zetia amount exclude sale product partner outside msp partnership merial limited merck sell interest merial limited merial joint venture sanofiaventis merck sanofiaventis rhnepoulenc form merial combine animal health business fully integrate animal health company standalone joint venture equally own party merck receive billion cash record billion pretax gain reflect income expense net sale product market joint venture billion january september divestiture date march merck sanofiaventis mutually terminate agreement form new animal health joint venture termination agreement penalty party capital expenditure capital expenditure billion billion billion expenditure united states billion million million depreciation expense billion billion billion billion billion billion respectively apply location united states total depreciation expense include accelerate depreciation million million million respectively associate restructuring activity note consolidated financial statement analysis liquidity capital resource merck strong financial profile enable fully fund research development focus external alliance support inline product maximize upcoming launch provide significant cash return shareholder select datum millions work capital total debt total liability equity cash provide operation total debt cash provide operating activity billion billion billion increase cash provide operating activity compare reflect increase result operation partially offset million payment result arbitration settlement net payment approximately million internal revenue service irs result conclusion examination certain merck federal income tax return discuss increase cash provide operating activity compare primarily reflect inclusion year legacy scheringplough operation billion payment vioxx settlement fund million payment connection previously disclose settlement canada revenue agency cra cash provide operating activity continue company primary source fund finance operating need capital expenditure treasury stock purchase dividend pay shareholder global economic downturn sovereign debt issue factor adversely impact foreign receivables certain european country note consolidated financial statement company table content continues receive payment receivable condition result increase average length time take collect account receivable outstanding adversely affect cash provide operating activity cash investing activity billion compare billion primarily reflect high proceed sale security investment proceed disposition certain business partially offset high purchase security investment addition proceed astrazenecas asset option exercise decrease restrict asset contribute cash flow invest activity cash investing activity billion compare cash provide investing activity billion change reflect low proceed sale security investment high purchase security investment decrease restrict asset proceed disposition merck interest merial partially offset use cash fund merger proceed receive related astrazenecas asset option exercise cash financing activity billion compare billion high use cash financing activity primarily drive low proceed issuance debt high purchase treasury stock high payment debt partially offset increase shortterm borrowing cash financing activity billion compare billion reflect low proceed issuance debt purchase treasury stock increase dividend pay stockholder high payment debt partially offset increase shortterm borrowing dividend pay stockholder billion billion billion effort implement merck strategy expand product offering capabilitie emerge market company anticipate future allocate capital resource region december total worldwide cash investment billion include billion cash cash equivalent shortterm investment billion longterm investment substantial majority cash investment hold foreign subsidiary subject significant tax payment cash investment repatriate cash provide operating activity united states continue company primary source fund finance domestic operating need capital expenditure treasury stock purchase dividend pay shareholder april irs conclude examination merck federal income tax return result company require net payment approximately million company unrecognized tax benefit year examination exceed adjustment relate examination period company record net million tax provision benefit net benefit reflect decrease unrecognized tax benefit year examination partially offset increase unrecognize tax benefit year subsequent examination period result settlement company disagree irs treatment issue raise examination appeal matter irs administrative process previously disclose october cra issue merck notice reassessment contain adjustment relate certain intercompany pricing matter february merck cra negotiate settlement agreement regard matter accordance settlement merck pay additional tax approximately million interest approximately million additional amount penalty assessment settlement account quarter merck previously establish reserve matter portion taxis pay expect creditable tax purpose addition previously disclose cra propose adjustment relate intercompany pricing matter july cra issue assessment miscellaneous audit issue tax year adjustment increase canadian tax approximately million plus approximately million interest december company disagree position take cra believe merit company continue contest assessment cra appeal process cra expect prepare similar adjustment later year management believe resolution matter material effect company financial position liquidity irs finalize examination scheringplough tax year audit cycle company reach agreement irs adjustment income relate intercompany pricing table content matter income adjustment reduce nols tax credit carryforward additionally company seek resolution issue raise examination irs administrative appeal process company reserve uncertain tax position adequate cover adjustment relate examination period irs begin examination tax year company company contractual obligation december follow payment period million total purchase obligation loan payable current portion longterm debt longterm debt interest relate debt obligation vioxx liability reserve relate interest unrecognized tax benefit operating lease merck enter transaction require company future bulk supply purchase million maximum fouryear period commence occurrence certain predetermine event reflect table predetermine event occur time result payment give year determine december company consolidate balance sheet reflect liability unrecognize tax benefit interest penalty billion include million reflect current liability high degree uncertainty time future cash outflow liability unrecognize tax benefit year reasonable estimate period cash settlement year purchase obligation enforceable legally bind obligation purchase good service include minimum inventory contract research development advertising amount reflect research development obligation include contingent milestone payment loan payable current portion longterm debt reflect million longdate note subject repayment option holder require funding obligation relate company pension postretirement benefit plan expect material company currently anticipate contribute approximately million million respectively pension plan postretirement benefit plan company enter new billion day credit facility new billion fouryear credit facility mature company terminate exist billion day credit facility expire billion revolve credit facility schedule mature august outstanding facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility december merck close underwritten public offer billion senior unsecured note consist million aggregate principal note billion aggregate principal note interest note payable semiannually note series redeemable time company option vary redemption price proceed note general corporate purpose include reduction shortterm debt december company file security registration statement security exchange commission sec automatic shelf registration process available wellknown seasoned issuer effective year connection merger effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent merger table content company longterm credit rating assign moodys investor service standard poor stable outlook stable outlook respectively rating continue allow access capital market flexibility obtain fund competitive term company continue maintain conservative financial profile company place cash investment instrument meet high credit quality standard specify investment policy guideline guideline limit credit exposure issuer despite strong financial profile certain contingent event realize discuss note consolidated financial statement material adverse impact company liquidity capital resource company participate offbalance sheet arrangement involve unconsolidated subsidiary provide financing potentially expose company unrecorde financial obligation november board director declare quarterly dividend share company common stock quarter april merck announce board director approve additional purchase billion merck common stock treasury company purchase billion common stock million share treasury company approximately billion remain program previous november treasury stock purchase authorization treasury stock purchase time limit time open market block transaction privately negotiate transaction company purchase billion common stock purchase treasury stock financial instrument market risk disclosure company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management significant portion company revenue denominate foreign currency company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange rate decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale expect occur planning cycle typically year future company layer hedge time increase portion thirdparty intercompany distributor entity sale hedge get close expect date forecast foreign currency denominate sale probable hedge transaction occur portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged currency risk manner company manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow offset decline expect future dollar equivalent cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow table content connection company revenue hedging program purchase collar option strategy utilize purchase collar option strategy company write local currency option purchase local currency option compare purchase option strategy purchase collar strategy reduce upfront cost associate purchasing put collection premium write option dollar weaken relative currency hedge anticipate sale purchase option value collar strategy reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow benefit cap strike level write dollar strengthen relative currency hedge anticipate sale write option value collar strategy reduce zero change purchase cash flow collar strategy offset decline expect future dollar equivalent cash flow hedge foreign currency sale company utilize forward contract revenue hedging program dollar strengthen relative currency hedge anticipate sale increase fair value forward contract offset decrease expect future dollar cash flow hedge foreign currency sale conversely dollar weaken decrease fair value forward contract offset increase value anticipate foreign currency cash flow weak dollar result net benefit market value merck hedge decline estimate million million respectively uniform weaken dollar december market value determine foreign exchange option pricing model hold factor exchange rate constant merck principally use purchase local currency option uniform weaken dollar yield large overall potential loss market value option sensitivity measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow primary objective balance sheet risk management program mitigate exposure foreign currency denominate net monetary asset foreign subsidiary dollar functional currency effect volatility foreign exchange instance merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange monetary asset merck routinely enter contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument company minimize effect exchange monetary asset liability manage operating activity net asset position local level company future use forward contract hedge change fair value certain foreign currency denominate availableforsale security attributable fluctuation foreign currency exchange rate derivative contract designate fair value hedge sensitivity analysis change value dollar foreign currency denominate derivative investment monetary asset liability indicate dollar uniformly strengthen currency exposure company december income taxis decline approximately million company net long position relative major foreign currency consideration forward contract uniform strengthen dollar yield large overall potential net loss earning exchange december company net short position relative major foreign currency consideration forward contract uniform weaken dollar reduce income taxis million measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe table content threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow effective january venezuelan government devalue currency bsf dollar twotiere official exchange rate essential rate bsf dollar nonessential rate bsf dollar january company require remeasure local currency operation venezuela dollar venezuelan economy determine hyperinflationary company settle transaction essential rate remeasure monetary asset liability utilize essential rate december venezuelan government announce eliminate essential rate effective january transaction settle official rate bsf dollar result announcement company remeasure december monetary asset liabilitie new official rate company use forward exchange contract hedge net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation company hedge portion net investment certain foreign operation measure ineffectiveness base change spot foreign exchange rate effective portion unrealize gain loss contract record foreign currency translation adjustment comprehensive income oci remain accumulated comprehensive income aoci sale complete substantially complete liquidation subsidiary cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk february company enter payfloate receivefixe interest rate swap contract notional amount billion aggregate designate fair value hedge fixedrate note notional amount match hedge fixedrate note interest rate swap contract designate fair value hedge fixedrate note mature notional amount million effectively convert company million fixedrate note float rate instrument interest rate swap contract designate hedge fair value change note attributable change benchmark london interbank offer rate libor swap rate fair value change note attributable change benchmark interest rate record interest expense offset fair value change swap contract company terminate payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note swap effectively convert billion fixedrate note maturity date vary march june float rate instrument interest rate swap contract designate hedge fair value change note attributable change benchmark libor swap rate result swap termination company receive million cash include million accrue interest unamortized adjustment carry value debt associate interest rate swap contract million amortize reduction interest expense respective term note cash flow contract report operating activity consolidate statement cash flow company investment portfolio include cash equivalent shortterm investment market value significantly affect change interest rate market value company table content medium longterm fixedrate investment modestly affect change interest rate change medium longterm interest rate significant impact market value company fixedrate borrowing generally long maturity sensitivity analysis measure potential change market value merck investment debt relate swap contract change interest rate indicate percentage point increase interest rate december positively affect net aggregate market value instrument billion billion respectively percentage point decrease december negatively affect net aggregate market value billion billion respectively fair value merck debt determine pricing model reflect percentage point shift appropriate yield curve fair value merck investment determine combination pricing duration model critical accounting policy company consolidated financial statement prepare conformity gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection merger acquisition include initial fair value determination asset liability primarily iprd intangible asset subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate application follow accounting policy result accounting estimate potential significant impact financial statement merger acquisition business combination acquisition method accounting require asset acquire liability assume record date merger acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency recognize fair value fair value reasonably estimate acquisition date fair value asset acquire liability assume arise contingency determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date merger acquisition company determine asset acquire meet definition business acquisition method accounting transaction account acquisition asset business combination goodwill record fair value intangible asset include acquire iprd determine utilize information available near merger acquisition date base expectation assumption deem reasonable management give considerable judgment involve determine fair value company typically obtain assistance thirdparty valuation specialist significant item amount allocate acquire iprd capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project merck separate determination useful life asset begin amortization judgment determine estimate fair value assign asset acquire liability assume business combination asset life materially affect company result operation fair value identifiable intangible asset relate currently market product product right primarily determined income approach fair value estimate base asset discount project net cash flow company estimate market participant net cash flow consider table content historical project pricing margin expense level performance compete product applicable relevant industry therapeutic area growth driver factor current expect trend technology product life cycle time investment require develop product technology ability obtain market regulatory approval ability manufacture commercialize product extent time potential new product introduction company competitor life asset underlie patent net cash flow probabilityadjuste appropriate consider uncertainty associate underlie assumption risk profile net cash flow utilize valuation probabilityadjuste future net cash flow product discount present value utilize appropriate discount rate fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probability adjust future net cash flow reflect different stage development product associate probability successful completion net cash flow discount present value appropriate discount rate revenue recognition revenue sale product recognize time delivery title risk loss pass customer recognition revenue require reasonable assurance collection sale proceed completion performance obligation domestically sale discount issue customer direct discount pointofsale indirectly intermediary wholesaler know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition revenue record net time value money discount customer collection account receivable expect excess year provision aggregate indirect customer discount cover chargeback rebate chargeback discount occur contract customer purchase directly intermediary wholesaler contract customer generally purchase product contract price plus markup wholesaler wholesaler turn charge company difference price initially pay wholesaler contract price pay wholesaler customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product pharmacy benefit plan participant provision base expect payment drive patient usage contract performance benefit provider customer company use historical customer segment mix adjust know event order estimate expect provision amount accrue aggregate indirect customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager customer amount accrue adjustment record trend significant event indicate change estimate provision appropriate company continually monitor provision aggregate indirect customer discount material adjustment estimate associate aggregate indirect customer discount provision summarize information change aggregate indirect customer discount accrual follow millions balance january current provision adjustment prior year payment balance december table content accrual chargeback reflect direct reduction account receivable accrual rebate current liability accrue balance relative provision include account receivable accrue current liability million billion respectively december million billion respectively december company maintain return policy allow pharmaceutical customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market additional generic competition change formulary launch overthecounter product product return provision pharmaceutical sale approximately net sale distribution program wholesaler company encourage wholesaler align purchase underlie demand maintain inventory specify level term program allow wholesaler earn fee provide visibility inventory level achieve certain performance parameter inventory management customer service level reduce shortage claim reduce product return information provide wholesaler distribution program include item sale trend inventory onhand onorder quantity product return wholesaler generally provide mention datum company regulatory requirement report lot level information manufacturer level information need determine remain shelf life original sale date inventory give current wholesaler inventory level generally month company believe collection order lot information wholesale customer limited use estimate sale discount return inventory produce preparation product launch company capitalize inventory produce preparation product launch sufficient support estimate initial market demand typically capitalization inventory begin relate product candidate phase iii clinical trial consider high probability regulatory approval company monitor status respective product regulatory approval process company generally disclose specific timing regulatory approval company aware specific risk contingency normal regulatory approval process specific issue identify research process relate safety efficacy manufacturing marketing label relate inventory generally capitalize expiry date inventory affect stage completion company manage level inventory stage optimize shelf life inventory relation anticipate market demand order avoid product expiry issue inventory capitalize anticipated future sale shelf live support realization inventory value inventory shelf life sufficient meet initial product launch requirement inventory produce preparation product launch capitalize december million december million contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action note consolidated financial statement company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company table content cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust site investigation feasibility study relate cost assessment remedial technique complete extent potentially responsible party jointly severally liable expect contribute determine company remediate environmental contamination result past industrial activity certain site take active role identify provide cost past merck perform worldwide survey assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate definitive information available course investigation andor remedial effort site estimate refined accrual establish adjust accordingly estimate related accrual continue refine annually company believe compliance issue associate applicable environmental law regulation material adverse effect company expenditure remediation environmental liability million estimate million aggregate year management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year sharebase compensation company expense sharebase payment award employee include grant stock option requisite service period base grant date fair value award company determine fair value certain sharebased award blackschole optionprice model use historical current market datum estimate fair value method incorporate assumption riskfree interest rate expect volatility expect dividend yield expect life option pension postretirement benefit plan net periodic benefit cost pension postretirement benefit plan total million million million high cost compare primarily incremental cost associate merger pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption include discount rate plan benefit obligation expect rate return plan asset company reassesse benefit plan assumption regular basis pension postretirement benefit plan discount rate evaluate measurement date modify reflect table content prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come december discount rate company pension postretirement benefit plan range compare range december expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company consider longterm compound annualize return historical market datum actual return company plan asset reference information company develop forwardlooke return expectation asset category weightedaverage expect longterm rate return target portfolio allocate investment category expect portfolio performance reflect contribution active management appropriate result analysis company expect rate return range compare range pension postretirement benefit plan company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest nonus pension plan target investment portfolio vary base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline actuarial assumption base management good estimate judgment reasonably possible change plus minus basis point discount rate assumption assumption hold constant estimate million favorable unfavorable impact net periodic benefit cost reasonably possible change plus minus basis point expect rate return assumption assumption hold constant estimate million favorable unfavorable impact net periodic benefit cost require funding obligation relate company pension postretirement benefit plan expect material precede hypothetical change discount rate expect rate return assumption impact company funding requirement net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption record component aoci expect return pension plan base calculate marketrelated value asset methodology asset gainslosse result actual return differ company expect return recognize marketrelated value asset ratably fiveyear period net loss amount aoci excess certain threshold amortize net periodic benefit cost average remain service life employee amortization net loss companys plan december expect increase net periodic benefit cost approximately million annually restructure cost restructuring cost record connection restructuring program design reduce cost structure increase efficiency enhance competitiveness result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place accrue cost company recognize range cost good estimate range range well estimate company recognize minimum range connection action management assess recoverability longlive asset employ business certain instance asset life shorten base change expect useful life affect asset table content severance relate cost reflect restructuring cost assetrelate charge reflect material production cost market administrative expense research development expense depend nature asset impairment longlive asset company assess change economic regulatory legal condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset company periodically evaluate current fact circumstance indicate carry value longlive asset hold recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow approach goodwill represent excess consideration transfer fair value net asset business purchase assign reporting unit company test goodwill impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying factor consider assessment include general macro economic condition condition specific industry market cost factor significant effect earning cash flow overall financial performance report unit sustained decline company share price additionally company evaluate extent fair value exceed carry value reporting unit date valuation perform company conclude likely fair value report unit carrying quantitative fair value test perform acquire intangible exclude iprd record fair value assign estimate useful life amortize primarily straightline basis estimate useful life event circumstance warrant review company assess recoverability future operation pretax undiscounte cash flow derive low appropriate asset grouping impairment recognize operating result extent carry value intangible asset exceed fair value determine base net present value estimate future cash flow iprd represent fair value assign incomplete research project company acquire business combination time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project company test iprd impairment annually frequently impairment indicator exist onestep test compare fair value iprd intangible asset carry value impairment testing purpose company combine separately record iprd intangible asset unit account base relevant fact circumstance generally company combine iprd intangible asset testing purpose operate single asset essentially inseparable fair value carrying impairment loss recognize company operate result impairment investment company review investment impairment base determination decline market value investment carrying value otherthantemporary company consider available evidence evaluate potential impairment investment include duration extent fair value cost equity security company ability intent hold investment debt security otherthan temporary impairment occur company expect recover entire amortize cost basis debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning limited portion attribute credit loss remain portion otherthantemporary impairment relate factor recognize oci table content tax income company effective tax rate base pretax income statutory tax rate tax planning opportunity available jurisdiction company operates estimate effective tax rate year apply company quarterly operating result event significant unusual onetime item recognize expect recognize company quarterly operating result tax attributable item separately calculate record time unusual onetime item company consider resolution prior year tax matter item significant judgment require determine company tax provision evaluate tax position recognition measurement tax position base management good judgment give fact circumstance information available reporting date company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement likely threshold meet period tax position take company subsequently recognize benefit tax position tax matter effectively settle statute limitation expire likely threshold meet subsequent period note consolidated financial statement tax regulation require item include tax return different time item reflect financial statement time difference create defer tax asset liability defer tax asset generally represent item tax deduction credit tax return future year company record tax benefit financial statement company establish valuation allowance defer tax asset expect future taxable income likely support use deduction credit defer tax liability generally represent tax expense recognize financial statement payment defer expense company take deduction tax return recognize expense financial statement december foreign earning billion retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability recently issue accounting standard june fasb issue amend guidance presentation comprehensive income financial statement amendment provide company option present component net income comprehensive income continuous statement comprehensive income separate consecutive statement eliminate option present component comprehensive income statement change stockholder equity provision new guidance effective interim annual period begin adoption new guidance impact company financial position result operation cash flow cautionary factor affect future result report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially table content company assume obligation update forwardlooke statement carefully evaluate statement light factor include risk factor describe company filing securities exchange commission especially form item risk factor annual report company discuss detail important risk factor cause actual result differ expect historic result company note factor investor permit private security litigation reform act understand possible predict identify factor consequently reader consider list complete statement potential risk uncertaintie item quantitative qualitative disclosure market risk information require item incorporate reference discussion financial instrument market risk disclosure item management discussion analysis financial condition result operation table content item financial statement supplementary datum financial statement consolidate balance sheet merck inc subsidiary december relate consolidated statement income equity cash flow year period end december note consolidated financial statement report date february pricewaterhousecooper llp independent register public accounting firm follow consolidated statement income merck inc subsidiary year end december millions share amount sale cost expense material production marketing administrative research development restructuring cost equity income affiliate income expense net income taxis tax income net income net income attributable noncontrolle interest net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder accompany note integral consolidated financial statement table content consolidate balance sheet merck inc subsidiary december millions share amount asset current asset cash cash equivalent shortterm investment account receivable net allowance doubtful account inventory exclude inventory classify asset note defer income taxis current asset total current asset investment property plant equipment cost land building machinery equipment office furnishing construction progress accumulate depreciation goodwill intangible net asset liabilitie equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable total current liability longterm debt defer income taxis noncurrent liability merck inc stockholders equity common stock par value authorize share issue share paidin capital retain earning accumulate comprehensive loss treasury stock cost share share total merck inc stockholders equity noncontrolle interest total equity accompany note integral consolidated financial statement table content consolidate statement equity merck inc subsidiary year end december millions share amount accumulate non common paidin retain comprehensive treasury control stock capital earning loss stock interest total balance january net income attributable merck inc total comprehensive loss net tax comprehensive income net tax scheringplough merger cancellation treasury stock prefer stock conversion cash dividend declare common stock share net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc total comprehensive loss net tax comprehensive income net tax cash dividend declare common stock share mandatory conversion convertible prefer stock treasury stock share purchase net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc total comprehensive income net tax comprehensive income net tax cash dividend declare common stock share treasury stock share purchase net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december accompanying note integral consolidated financial statement table content consolidate statement cash flow merck inc subsidiary year end december million cash flow operating activity net income adjustment reconcile net income net cash provide operating activity depreciation amortization intangible asset impairment charge gain disposition interest equity method investment gain astrazeneca asset option exercise gain related merckscheringplough partnership equity income affiliate dividend distribution equity affiliate defer income taxis sharebase compensation net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability net cash provide operating activity cash flow invest activity capital expenditure purchase security investment proceed sale security investment proceed sale interest equity method investment acquisition business net cash acquire disposition business net cash divest scheringplough merger net cash acquire proceed astrazeneca asset option exercise decrease restrict asset net cash provide investing activity cash flow financing activity net change shortterm borrowing payment debt proceed issuance debt purchase treasury stock dividend pay stockholder dividend pay proceed exercise stock option net cash financing activity effect exchange rate change cash cash equivalent net increase cash cash equivalent cash cash equivalent begin year cash cash equivalent end year supplemental cash flow information note accompany note integral consolidated financial statement table content note consolidated financial statement merck inc subsidiarie million share amount nature operation merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health consumer care product market directly joint venture company operation principally manage product basis comprise operating segment pharmaceutical animal health consumer care alliance segment reportable segment pharmaceutical segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer additionally company consumer care operation develop manufacture market overthecounter foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet november legacy merck inc scheringplough corporation scheringplough merged merger result scheringplough business include merck financial statement period subsequent completion merger merck financial result reflect year scheringplough operation summary accounting policy principle consolidation consolidated financial statement include account company subsidiary control interest maintain intercompany balance transaction eliminate control interest determine majority ownership interest absence substantive thirdparty participate right case variable interest entity majority exposure expect loss residual return consolidate subsidiary merck ownership outside shareholder interest show noncontrolle interest equity investment affiliate company significant influence control interest interest entity own equally company party share control carry equity basis merger acquisition business combination acquisition method accounting require asset acquire liability assume record date merger acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency recognize fair value fair value reasonably estimate acquisition date fair value asset acquire liability assume arise contingency determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date merger acquisition company determine asset acquire meet definition business acquisition method accounting transaction account acquisition asset business combination goodwill record table content foreign currency translation net asset international subsidiary local currency determine functional currency translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation account include accumulate comprehensive income loss aoci reflect separate component equity subsidiary operate highly inflationary economy subsidiarie dollar determine functional currency nonmonetary foreign currency asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include income expense net result merger functional currency operation company international subsidiary reevaluate result change functional currency certain subsidiary cash equivalent cash equivalent comprise certain highly liquid investment original maturity month inventory inventory value low cost market cost substantial majority domestic pharmaceutical vaccine inventory determine lastin firstout lifo method financial report tax purpose cost inventory determine firstin firstout fifo method inventory consist currently market product certain product await regulatory approval evaluate recoverability inventory produce preparation product launch company consider probability revenue obtain future sale relate inventory status product regulatory approval process investment investment marketable debt equity security classify availableforsale report fair value fair value company investment determine quote market price active market identical asset liability quote price similar asset liability input observable corroborate observable market datum substantially term asset liability change fair value consider temporary report net tax comprehensive income oci decline fair value equity security consider thantemporary impairment loss charge income expense net company consider available evidence evaluate potential impairment investment include duration extent fair value cost equity security company ability intent hold investment debt security otherthantemporary impairment occur company expect recover entire amortize cost basis debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning record income expense net limited portion attribute credit loss remain portion otherthantemporary impairment relate factor recognize oci realize gain loss debt equity security include income expense net revenue recognition revenue sale product recognize time delivery title risk loss pass customer recognition revenue require reasonable assurance collection sale proceed completion performance obligation domestically sale discount issue customer direct discount pointofsale indirectly intermediary wholesaler know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition revenue record net time value money discount customer collection account receivable expect excess year accrual chargeback reflect direct reduction account receivable accrual rebate record current liability accrue balance relative provision chargeback rebate include account receivable accrue current liability million billion respectively december million billion respectively december company recognize revenue sale vaccine federal government placement vaccine stockpile accordance security exchange commission sec interpretation commission guidance accounting sale vaccine bioterror countermeasure federal government placement pediatric vaccine stockpile strategic national stockpile table content depreciation depreciation provide estimate useful life asset principally straightline method tax purpose accelerate tax method estimate useful life primarily range year building year machinery equipment office furnishing software capitalization company capitalize certain cost incur connection obtain develop internaluse software include external direct cost material service payroll cost employee directly involve software development capitalize software cost include property plant equipment amortize begin software project substantially complete asset ready intend use capitalize software cost associate company multiyear implementation enterprisewide resource planning system amortize year december approximately million million respectively remain unamortized capitalize software cost associate initiative capitalize software cost amortize period range year cost incur preliminary project stage postimplementation stage maintenance training cost expense incur goodwill goodwill represent excess consideration transfer fair value net asset business purchase goodwill assign reporting unit evaluate impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying company conclude likely fair value report unit carrying quantitative fair value test perform base company recent annual impairment test complete october likely fair value report unit excess carrying value acquire intangible acquire intangible include product product right tradename patent record fair value assign estimate useful life amortize primarily straightline basis estimate useful life range year note event circumstance warrant review company assess recoverability acquire intangible future operation pretax undiscounte cash flow derive low appropriate asset grouping impairment recognize operating result extent carry value intangible asset exceed fair value determine base net present value estimate future cash flow inprocess research development inprocess research development iprd represent fair value assign incomplete research project company acquire business combination time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project merck determination useful life intangible asset generally determine period substantially cash flow expect generate begin amortization company test iprd impairment annually frequently impairment indicator exist onestep test compare fair value iprd intangible asset carrying value fair value carrying impairment loss recognize company operating result research development research development expense incur upfront milestone payment party connection research development collaboration prior regulatory approval expense incur payment party subsequent regulatory approval capitalize amortize shorter remaining license product patent life nonrefundable advance payment good service future research development activity expense activity perform good receive payment research development expense include restructure cost period iprd impairment charge million billion respectively sharebase compensation company expense sharebased payment employee requisite service period base grant date fair value award table content restructuring cost company record liability cost associate exit disposal activity period liability incur accordance exist benefit arrangement employee termination cost accrue restructuring action probable estimable accrue cost company recognize range cost good estimate range range well estimate company recognize minimum range cost onetime termination benefit employee require render service termination order receive benefit recognize ratably future service period contingency legal defense cost company record accrual contingency legal defense cost expect incur connection loss contingency probable liability incur reasonably estimate taxis income defer taxis recognize future tax effect temporary difference financial income tax reporting base enact tax law rate company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement company recognize interest penalty associate uncertain tax position component taxis income consolidate statement income use estimate consolidated financial statement prepare conformity accounting principle generally accept united states gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection merger acquisition include initial fair value determination asset liability primarily iprd intangible asset subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate reclassification certain reclassification prior year amount conform current year presentation recently adopt accounting standard follow new accounting standard issue fasb adopt company january company prospectively adopt new guidance revenue recognition multiple deliverable revenue arrangement enter materially modify adoption date guidance eliminate residual method current guidance replace relative sell price method allocate revenue multiple deliverable arrangement sell price deliverable shall determine vendor specific objective evidence sell price exist thirdparty evidence sell price shall exist deliverable vendor shall use good estimate sell price deliverable effect adoption company financial position result operation material october conjunction annual goodwill impairment testing company early adopt amend guidance simplifie entity test goodwill impairment amend guidance allow company assess qualitative factor determine likely fair value report unit carrying value perform step twostep goodwill impairment test table content recently issue accounting standard june fasb issue amend guidance presentation comprehensive income financial statement amendment provide company option present component net income comprehensive income continuous statement comprehensive income separate consecutive statement eliminate option present component comprehensive income statement change stockholder equity provision new guidance effective interim annual period begin adoption new guidance impact company financial position result operation cash flow merger november merck scheringplough complete merger merger scheringplough acquire share merck whollyowne subsidiary scheringplough rename merck sharp dohme corp msd scheringplough continue survive public company rename merck inc accounting purpose merger treat acquisition merck consider accounting acquirer term merger agreement issue outstanding share scheringplough common stock convert right receive combination cash share common stock company issue outstanding share merck common stock automatically convert share common stock newly combine company base closing price merck stock november consideration receive scheringplough shareholder value share billion aggregate cash portion consideration fund combination exist cash include sale merck interest merial limited sale redemption investment issuance debt completion merger issue outstanding share scheringplough mandatory convertible preferred stock scheringplough preferred stock convert accordance term prefer stock remain outstanding share merck mandatory convertible preferred stock prefer stock right set forth merck certificate incorporation right substantially similar right schere plough preferred stock august outstanding preferred stock automatically convert term right receive cash share merck common stock note merger expand company pipeline product candidate broaden company commercial portfolio expand global presence increase manufacturing capability additionally company expect realize substantial cost saving synergy include opportunity consolidation sale marketing research development table content calculation consideration transfer million shareunit amount scheringplough common stock share outstanding november net treasury share unit merger consideration arise conversion prefer stock share unit eligible cash shareunit cash consideration outstanding sharesunit prefer stock makewhole dividend payment value scheringplough defer stock unit settle cash total cash consideration share unit eligible common stock exchange ratio shareunit equivalent merck share share issue settle certain performancebase award merck share issue merck common stock share price november common stock equity consideration fair value prefer stock convert fair value sharebase compensation award employee benefit relate amount payable result merger total consideration transfer completion merger period day holder prefer stock entitle convert share prefer stock number unit merger consideration equal makewhole conversion rate determine accordance term prefer stock represent unit merger consideration relate preferred stock convert holder day period follow merger represent present value remain dividend payment conversion date mandatory conversion date august pay holder prefer stock elect convert connection merger discount rate stipulate term prefer stock represent cash consideration pay holder scheringplough defer stock unit issue prior convert right receive cash specify merger agreement attributable precombination service represent fair value scheringplough stock option performance share unit defer stock unit replacement awards attributable precombination service issue holder award merger fair value outstanding scheringplough stock option performance share unit award issue prior immediately vest effective time merger attribute precombination service include consideration transfer stock option performance share unit defer stock unit award immediately vest completion merger award fair value award attribute precombination service include consideration transfer fair value attribute postcombination service recognize compensation cost requisite service period postcombination financial statement merck table content supplemental pro forma datum scheringplough result operation include merck financial statement period subsequent completion merger scheringplough contribute revenue billion estimate loss billion merck period consummation merger december follow unaudited supplemental pro forma datum present consolidated information merger complete january year end december unaudited sale net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder unaudite supplemental pro forma datum reflect application follow adjustment consolidation merckscheringplough partnership msp partnership wholly own company additional depreciation amortization expense recognize assume fair value adjustment inventory property plant equipment intangible asset additional interest expense financing cost incur borrowing arrangement loss interest income cash shortterm investment fund merger transaction cost associate merger conversion portion outstanding preferred stock unaudite supplemental pro forma financial information reflect potential realization cost saving relate integration company pro forma datum consider indicative result occur merger relate borrowing consummate january indicative future result restructure merger restructuring program february company commence action global restructuring program merger restructuring program conjunction integration legacy merck legacy scheringplough business merger restructuring program intend optimize cost structure combine company additional action program continue july company announce late phase merger restructuring program company expect reduce workforce measure time merger additional company worldwide majority workforce reduction phase merger restructuring program relate manufacture include animal health administrative headquarters organization previously announce workforce reduction approximately early phase program primarily reflect elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility company continue hire employee strategic growth area business necessary company continue pursue productivity efficiency evaluate manufacture supply chain capability ongoing basis result future restructuring action company record total pretax restructuring cost billion billion billion relate program inception merger restructuring program december merck record total pretax accumulate cost approximately billion eliminate approximately position comprise employee separation elimination table content contractor position vacant time merger restructuring action merger restructuring program expect substantially complete end exception certain action principally manufacturingrelate expect substantially complete total cumulative pretax cost estimate approximately billion billion company estimate approximately third cumulative pretax cost relate cash outlay primarily relate employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest global restructuring program october merck announce global restructure program restructuring program reduce cost structure increase efficiency enhance competitiveness restructure program company expect eliminate approximately position active employee vacancy company worldwide pretax restructuring cost million million million record respectively relate restructuring program inception restructuring program december merck record total pretax accumulate cost billion eliminate approximately position comprise employee separation elimination contractor vacant position restructure program substantially complete end exception certain manufacturingrelated action expect complete total cumulative pretax cost estimate billion company estimate twothird cumulative pretax cost relate cash outlay primarily employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest segment report restructuring charge unallocated expense table content follow table summarize charge related merger restructuring program restructuring program activity type cost separation accelerate year end december cost depreciation total merger restructuring program material production marketing administrative research development restructuring cost restructure program material production research development restructuring cost year end december merger restructuring program material production marketing administrative research development restructuring cost restructure program material production marketing administrative research development restructuring cost year end december merger restructuring program material production restructuring cost restructure program material production research development restructuring cost table content separation cost associate actual headcount reduction headcount reduction probable reasonably estimate approximately position eliminate merger restructuring program approximately position eliminate restructure program approximately position eliminate merger restructuring program approximately position eliminate restructure program approximately position eliminate restructure program approximately position eliminate merger restructuring program position elimination comprise actual headcount reduction elimination contractor vacant position certain employee anticipate separate plan restructuring action restructure program instead transfer buyer conjunction sale facility accordingly accrual separation cost associate employee reverse result reduction expense accelerate depreciation cost primarily relate manufacture research administrative facility equipment sell closed program accelerate depreciation cost represent difference depreciation expense recognize revise useful life site base anticipate date site close divest depreciation expense determine utilize useful life prior restructure action site continue operate respective closure date future cash flow sufficient recover respective book value merck require accelerate depreciation site asset write immediately activity include million million million respectively asset abandonment shutdown relate cost approximately million contract termination cost additionally activity include million million million respectively employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan note sharebased compensation cost activity reflect net pretax gain loss result sale facility relate asset million million million respectively adjustment record amount material period table content follow table summarize charge spend relate merger restructuring program restructuring program activity separation accelerate cost depreciation total merger restructuring program restructuring reserve january expense payment receipt net noncash activity restructuring reserve december expense payment receipt net noncash activity restructure reserve december restructure program restructure reserve january expense payment receipt net noncash activity restructuring reserve december expense payment receipt net noncash activity restructure reserve december cash outlay associate merger restructuring program expect substantially complete end exception certain action principally manufacturingrelate expect substantially complete cash outlay associate remain restructure reserve restructure program primarily manufacturingrelate expect complete end legacy scheringplough program prior merger scheringplough commence productivity transformation program design reduce avoid cost increase productivity company record million million million respectively accelerate depreciation cost include material production cost addition restructure cost reflect million net gain primarily relate sale manufacture facility million separation cost remain reserve relate plan substantially complete million million december respectively acquisition divestiture research collaboration license agreement merck complete acquisition inspire pharmaceuticals inc inspire specialty pharmaceutical company focus develop commercialize ophthalmic product term merger agreement merck acquire outstanding share common stock inspire price share cash total approximately million transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value acquisition date determination fair value require management significant estimate assumption connection acquisition substantially purchase price allocate inspire product product right intangible asset relate deferred tax liability defer tax asset relate inspire net operating loss carryforward goodwill transaction close accordingly table content result operation acquire business include company result operation acquisition date pro forma financial information include inspire historical financial result significant compare company financial result march company sell merck biomanufacture network provider contract manufacturing development service biopharmaceutical industry wholly own merck fujifilm corporation fujifilm term agreement fujifilm purchase equity interest merck subsidiary own asset merck biomanufacture network comprise facility locate research triangle park north carolina billingham united kingdom agreement fujifilm merck commit certain continue development manufacturing activity company transaction result gain million reflect income expense net company acquire facility locate billingham united kingdom complete acquisition avecia biologic limited february december company acquire outstanding stock smartcells inc smartcell private company develop glucose responsive insulin formulation treatment diabete mellitus total purchase consideration company determine fair value acquisition date million include upfront cash payment contingent consideration consist future clinical development regulatory milestone contingent consideration future sale product result acquisition transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value acquisition date determination fair value require management significant estimate assumption connection acquisition substantially preliminary purchase price allocate iprd remain net asset acquire significant fair value contingent consideration determine utilize probability weight estimate cash flow stream adjust expect timing payment subsequent acquisition date quarterly basis contingent consideration liability remeasure current fair value change record earning minimis transaction close december accordingly result operation acquire business include company result operation acquisition date pro forma financial information include smartcell historical financial result significant compare company financial result merck announce restructure codevelopment cocommercialization agreement ariad pharmaceuticals inc ariad ridaforolimus investigational orally available mtor inhibitor currently evaluate treatment multiple cancer type exclusive license agreement restructure agreement merck acquire control development worldwide commercialization ridaforolimus ariad receive million upfront fee company record research development expense eligible receive milestone payment associate regulatory filing approval ridaforolimus multiple cancer indication achievement significant sale threshold lieu profit split sale provide previous agreement ariad receive royalty global net sale ridaforolimus sale record merck merck assume responsibility activity acquire decision right matter relate development manufacturing commercialization ridaforolimus investigational new drug application transfer merck merck leading interaction regulatory agency ridaforolimus accept review food drug administration fda european medicine agency agreement ariad terminable merck month notice immediately good faith determination safety issue agreement terminable party result insolvency party uncured material breach party ariad failure merck perform certain product development responsibility collaborative arrangement company continue strategy establish external alliance complement substantial internal research capability include research collaboration license preclinical clinical compound technology platform drive near longterm growth company supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound new technology broad range therapeutic area arrangement table content include upfront payment royalty profit share payment contingent occurrence certain future event link success asset development expense reimbursement payment party cozaarhyzaar merck dupont nemour company dupont agree form longterm research marketing collaboration develop class therapeutic agent high blood pressure heart disease discover dupont call angiotensin receptor antagonist include cozaar hyzaar return merck provide dupont marketing right united states canada prescription medicine sinemet sinemet company regain global marketing right sinemet sinemet pursuant agreement dupont company exclusive licensing agreement market cozaar hyzaar return royalty profit share payment dupont patent provide market exclusivity united states cozaar hyzaar expire april addition cozaar hyzaar lose patent protection number major european market march remicadesimponi subsidiary scheringplough enter licensing agreement centocor ortho biotech inc centocor johnson johnson company market remicade prescribe treatment inflammatory disease scheringplough subsidiary exercise option contract centocor license right develop commercialize simponi golimumab fully human monoclonal antibody company exclusive marketing right product outside united states japan certain asian market december scheringplough centocor revise distribution agreement development commercialization distribution remicade simponi extend company right exclusively market remicade match duration company exclusive marketing right simponi addition scheringplough centocor agree share certain development cost relate simponis autoinjector delivery system october european commission approve simponi treatment rheumatoid arthritis immune system disorder presentation novel autoinjector prefille syringe result company marketing right product extend year commercial sale simponi european union follow receipt pricing reimbursement approval april merck reach agreement amend agreement govern distribution right remicade simponi term amend distribution agreement merck relinquish marketing right remicade simponi territory include canada central south america middle east africa asia pacific effective july merck retain exclusive marketing right europe russia turkey retain territory addition begin july profit derive merck exclusive distribution product retain territory equally divide merck prior term distribution agreement contribution income profit split merck decline merck increase year equally divide receive onetime payment merck million april company record charge income expense net financial instrument derivative instrument hedging activity company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss table content foreign currency risk management significant portion company revenue denominate foreign currency company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange rate decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale expect occur planning cycle typically year future company layer hedge time increase portion thirdparty intercompany distributor entity sale hedge get close expect date forecast foreign currency denominate sale probable hedge transaction occur portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged currency risk manner company manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow offset decline expect future dollar equivalent cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow connection company revenue hedging program purchase collar option strategy utilize purchase collar option strategy company write local currency option purchase local currency option compare purchase option strategy purchase collar strategy reduce upfront cost associate purchasing put collection premium write option dollar weaken relative currency hedge anticipate sale purchase option value collar strategy reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow benefit cap strike level write dollar strengthen relative currency hedge anticipate sale write option value collar strategy reduce zero change purchase cash flow collar strategy offset decline expect future dollar equivalent cash flow hedge foreign currency sale company utilize forward contract revenue hedging program dollar strengthen relative currency hedge anticipate sale increase fair value forward contract offset decrease expect future dollar cash flow hedge foreign currency sale conversely dollar weaken decrease fair value forward contract offset increase value anticipate foreign currency cash flow fair value derivative contract record asset gain position liability loss position consolidate balance sheet change fair value derivative contract record period current earning oci depend derivative designate hedge transaction type hedge transaction derivative designate cash flow hedge effective portion unrealize gain loss contract record aoci reclassify sale hedge anticipate revenue recognize hedge relationship highly effective hedge ineffectiveness minimis derivative designate cash flow hedge unrealize gain loss record sale period cash flow contract report operating activity consolidate statement cash flow company enter derivative trade speculative purpose primary objective balance sheet risk management program mitigate exposure foreign currency denominate net monetary asset foreign subsidiary dollar functional table content currency effect volatility foreign exchange instance merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange monetary asset merck routinely enter contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument company minimize effect exchange monetary asset liability manage operating activity net asset position local level monetary asset liability denominate currency functional currency give subsidiary remeasure spot rate effect balance sheet date effect change spot rate report income expense net forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception year company future use forward contract hedge change fair value certain foreign currency denominate availableforsale security attributable fluctuation foreign currency exchange rate derivative contract designate fair value hedge accordingly change fair value hedge security fluctuation spot rate record income expense net offset fair value change forward contract attributable spot rate fluctuation change contract fair value spotforward difference exclude designate hedge relationship recognize income expense net amount hedge ineffectiveness significant cash flow contract report operating activity consolidate statement cash flow company use forward exchange contract hedge net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation company hedge portion net investment certain foreign operation measure ineffectiveness base change spot foreign exchange rate effective portion unrealize gain loss contract record foreign currency translation adjustment oci remain aoci sale complete substantially complete liquidation subsidiary cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci include cumulative translation adjustment pretax gain million million million postmerger period eurodenominate note designate effective economic hedge net investment foreign operation interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk february company enter payfloate receivefixe interest rate swap contract notional amount billion aggregate designate fair value hedge fixedrate note notional amount match hedge fixedrate note interest rate swap contract designate fair value hedge fixedrate note mature notional amount million effectively convert company million fixedrate note float rate instrument interest rate swap contract designate hedge fair table content value change note attributable change benchmark london interbank offer rate libor swap rate fair value change note attributable change benchmark interest rate record interest expense offset fair value change swap contract company terminate payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note swap effectively convert billion fixedrate note maturity date vary march june float rate instrument interest rate swap contract designate hedge fair value change note attributable change benchmark libor swap rate result swap termination company receive million cash include million accrue interest unamortized adjustment carry value debt associate interest rate swap contract million amortize reduction interest expense respective term note cash flow contract report operating activity consolidate statement cash flow present table fair value derivative segregate derivative designate hedge instrument designate hedge instrument december fair value fair value derivative dollar derivative dollar millions balance sheet caption asset liability notional asset liability notional derivative designate hedge instrument foreign exchange contract defer income taxis current current asset foreign exchange contract non current asset foreign exchange contract current accrue current liability foreign exchange contract non defer income taxis current noncurrent liability interest rate swap noncurrent asset interest rate swap defer income taxis noncurrent noncurrent liability derivative designate hedge instrument foreign exchange contract defer income taxis current current asset foreign exchange contract current accrue current liability table content table provide information location pretax gain loss amount derivative designate fair value hedge relationship designate cash flow hedging relationship iii designate foreign currency net investment hedge relationship designate hedge relationship year end december derivative designate fair value hedge relationship interest rate swap contract gain recognize income expense net derivative loss recognize income expense net hedge item derivative designate foreign currency cash flow hedging relationship foreign exchange contract loss reclassify aoci sale loss gain recognize oci derivative derivative designate foreign currency net investment hedging relationship foreign exchange contract gain recognize income expense net derivative loss recognize oci deriviative derivative designate hedge relationship foreign exchange contract gain recognize income expense net derivative gain recognize sale ineffectiveness hedge represent exclude hedge effectiveness testing derivative contract mitigate change value remeasure foreign currency denominate monetary asset liability attributable change foreign currency exchange rate december company estimate million pretax net unrealize loss derivative mature month hedge foreign currency denominate sale period reclassify aoci sale ultimately reclassify sale differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity investment debt equity security information availableforsale investment december follow gross unrealized gross unrealize fair amortize fair amortize value cost gain loss value cost gain loss corporate note bond commercial paper government agency security municipal security assetbacke security mortgagebacke security foreign government bond debt security equity security availableforsale debt security include shortterm investment total billion december remain debt security billion mature year december debt security pledge collateral table content fair value measurement fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date company use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity company level asset value determine pricing model discount cash flow methodology similar technique significant unobservable input instrument determination fair value require significant judgment estimation input measure financial asset liability fall level describe categorization base low level input significant fair value measurement instrument table content financial asset liability measure fair value recur basis financial asset liability measure fair value recur basis december summarize fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total asset investment corporate note bond commercial paper government agency security municipal security assetbacke security mortgagebacke security foreign government bond equity security debt security asset security hold employee compensation derivative asset purchase currency option forward exchange contract interest rate swap total asset liability derivative liability forward exchange contract write currency option interest rate swap total liability primarily assetbacke security highlyrate standard poor rate aaa moodys investor service rating aaa secure primarily credit card auto loan home equity receivables weightedaverage live primarily year mortgagebacked security represent aaarate security issue unconditionally guarantee payment principal interest government agency fair value determination derivative include impact credit risk counterpartie derivative companys credit risk effect significant significant transfer level level december cash cash equivalent billion include billion cash equivalent consider level fair value hierarchy level valuation technique company level investment security include certain mortgagebacked security value primarily pricing model incorporate transaction detail contractual term maturity timing future cash inflow assumption liquidity credit valuation adjustment marketplace participant table content table provide summary change fair value financial asset measure fair value recur basis significant unobservable input level year end december beginning balance january sale total realize unrealized gain loss include earning comprehensive income end balance december loss record earning level asset hold december amount record income expense net financial instrument measure fair value company financial instrument measure fair value recur basis record amount approximate fair value liquid shortterm nature cash cash equivalent receivables payable estimate fair value loan payable longterm debt include current portion december billion compare carry value billion december billion compare carry value billion fair value estimate quote dealer price concentration credit risk ongoing basis company monitor concentration credit risk associate corporate government issuer security financial institution conduct business credit exposure limit establish limit concentration single issuer institution cash investment place instrument meet high credit quality standard specify company investment policy guideline approximately threequarter companys cash cash equivalent invest highly rate money market fund majority company account receivable arise product sale united states europe primarily drug wholesaler retailer hospital government agency manage health care provider pharmacy benefit manager company monitor financial performance creditworthiness customer properly assess respond change credit profile company continue monitor economic condition include volatility associate international sovereign economy associate impact financial market business take consideration global economic downturn sovereign debt issue certain european country company continue monitor credit economic condition greece spain italy portugal member deteriorate economic condition inherent variability time cash receipt result continue result increase average length time take collect account receivable outstanding time value money discount record customer collection account receivable expect excess year company expect writeoff adjustment account receivable material adverse effect financial position liquidity result operation december company account receivable greece italy spain portugal total approximately billion hospital public sector receivable approximately billion aggregate approximately relate greece italy spain portugal respectively december company total account receivable outstanding year approximately million approximately relate account receivable greece italy spain portugal comprise hospital public sector receivables table content previously disclose company receive zero coupon bond greek government settlement receivables relate certain government sponsor institution company sell portion bond company record impairment charge reduce remain bond fair value company sell remain bond company continue receive payment greek hospital public sector receivables company factor approximately million hospital public sector account receivable nonrecourse basis spain italy december company execute factor approximately million hospital public sector account receivable italy factoring subject certain closing condition company large customer cardinal health inc mckesson corporation amerisourcebergen corporation alliance healthcare zuellig pharma ltd represent aggregate approximately onefourth account receivable december company monitor creditworthiness customer grant credit term normal course business bad debt minimal company normally require collateral security support credit sale derivative financial instrument execute international swap derivative association master agreement master agreement company financial institution counterpartie include credit support annexe annexe contain provision require collateral exchange depend value derivative asset liability company credit rating credit rating counterparty december company receive cash collateral million million respectively counterpartie obligation return collateral record accrue current liability company advanced cash collateral counterpartie december inventory inventory december consist finished good raw material work process supply total approximate current cost reduction lifo cost recognize inventory asset inventory value lifo method comprise approximately inventory december respectively amount recognize asset comprise entirely raw material work process inventory december amount include billion billion respectively inventory expect sell year largely vaccine addition amount include million million december respectively inventory produce preparation product launch table content goodwill intangible follow table summarize goodwill activity segment pharmaceutical total goodwill balance january addition goodwill balance december addition goodwill balance december include cumulative translation adjustment goodwill balance reclassification goodwill pharmaceutical segment consumer care segment result segment change occur note certain adjustment intangible december consist gross gross carrying accumulate carry accumulate amortization net amortization net product product right inprocess research development tradename total identifiable intangible asset company record impairment charge million relate market product amount capitalize inprocess research development account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project company separate determination useful life asset begin amortization approximately million million respectively iprd reclassify product product right receipt marketing approval major market connection merger company record fair value human animal health research project underway schering plough msp partnership significant project include victrelis bridion vorapaxar ezetimibeatorvastatin combination product victreli approve fda company file nda fda ezetimibeatorvastatin combination product vorapaxar phase iii clinical development bridion approve country outside united states remain phase iii clinical development united states company record million iprd impairment charge research development expense primarily pipeline program abandon determined alternative use expect delay launch timing change cash flow assumption certain compound addition impairment charge relate pipeline program previously deprioritize deem alternative use period outlicense party consideration related asset carry value company record billion iprd impairment charge research development expense billion relate writedown vorapaxar intangible asset company determine development clinical research program vorapaxar include termination clinical trial constitute trigger event require company evaluate vorapaxar intangible asset table content impairment company continue monitor remain million asset value vorapaxar impairment remain million iprd impairment charge record attributable compound abandon determine alternative use return respective licensor expect delay launch timing change cash flow assumption certain compound iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate aggregate amortization expense primarily record material production cost billion billion million estimate aggregate amortization expense year follow billion billion billion billion billion joint venture equity method affiliate equity income affiliate reflect performance company joint venture equity method affiliate comprise follow year end december astrazeneca merckscheringplough completion merger msp partnership wholly own company primarily reflect result sanofi pasteur msd johnson johnsonmerck consumer pharmaceutical company dispose september merial limited dispose september astrazeneca merck enter agreement astra astra develop market astra product royaltybeare license merck total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami merck astra own share joint venture form develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach lining merck astra complete restructure ownership operation joint venture merck acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca azlp astras merger zeneca group plc exclusive distributor product kbi retain right maintain limited partner interest azlp merck consent protective right intend preserve business economic interest include restriction power general partner certain distribution disposition furthermore limit event default additional right grant company include power direct action remove replace partnership chief executive officer chief financial officer merck earn ongoing revenue base sale kbi product revenue billion billion billion respectively primarily relate sale nexium prilosec addition merck earn certain partnership return record equity income affiliate reflect table return include priority return provide partnership agreement preferential return represent merck share undistribute azlp gaap earning variable return relate companys limited partner interest table content conjunction restructuring discuss astra purchase option asset option payment million record deferred income buy merck interest kbi product exclude gastrointestinal medicine nexium prilosec nonppi products april astrazeneca exercise asset option merck receive million astrazeneca represent net present value march project future pretax revenue receive merck nonppi products record reduction company investment azlp company recognize million defer income component income expense net addition merck grant astra option share option buy merck common stock interest kbi mercks interest nexium prilosec exercisable exercise price share option primarily base net present value project future pretax revenue receive merck nexium prilosec determine time exercise subject certain trueup mechanism company believe likely astrazeneca exercise share option summarize financial information azlp follow year end december sale material production cost expense net income taxis december current asset noncurrent asset current liability merck partnership return azlp generally contractually determine note base percentage income azlp respect mercks limited partnership interest sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur establish equallyowne joint venture market vaccine europe collaborate development combination vaccine distribution europe joint venture vaccine sale billion billion billion johnson johnsonmerck consumer pharmaceutical company september merck sell interest johnson johnsonmerck consumer pharmaceutical company jjmcp joint venture venture merck form develop manufacture market distribute certain overthecounter otc consumer product united states canada merck receive onetime payment million recognize pretax gain million reflect income expense net merck right pepcid brand outside united states canada affect transaction follow transaction own venture asset include exclusive right market otc pepcid mylanta mylicon local otc brand currently sell united states canada partnership asset include manufacture facility sale product market joint venture million period january september divestiture date million million merckscheringplough partnership merck scheringplough collectively partner enter agreement create equally own partnership develop market united states new prescription medicine cholesterol management ezetimibe new class cholesterollowere agent launch united states zetia market ezetrol outside united states combination product contain active ingredient zetia zocor approve united states vytorin market inegy outside table content united states cholesterol agreement provide share operating income generate msp partnership base percentage varied product sale level country operating income include expense partner contractually agree share expense incur support msp partnership share partner include equity income affiliate cost reflect overall result partner result merger msp partnership wholly own company merck share result msp partnership date merger reflect equity income affiliate activity result sale msp partnership product merger consolidated merck result note information respect litigation involve msp partnership partner relate sale promotion zetia vytorin summarize financial information msp partnership follow period january november sales vytorin zetia material production cost expense net income taxis merck share income taxis merck share msp partnership income taxis differ equity income recognize msp partnership primarily time recognition certain transaction merck msp partnership include milestone payment merial limited merck sell interest merial limited merial joint venture sanofiaventis merck sanofiaventis rhnepoulenc form merial combine animal health business fully integrate animal health company standalone joint venture equally own party merck receive billion cash record billion pretax gain reflect income expense net sale product market joint venture billion january september divestiture date march merck sanofiaventis mutually terminate agreement form new animal health joint venture termination agreement penalty party investment affiliate account equity method include joint venture total million december million december amount report asset amount joint venture include defer income taxis current asset million december million december table content summarize information affiliate exclude msp partnership azlp disclose separately follow year end december sale material production cost expense net income taxis december current asset noncurrent asset current liability noncurrent liability include information jjmcp divestiture september include information merial divestiture september loan payable longterm debt commitment loan payable december include billion commercial paper million shortterm foreign borrowing million long date note subject repayment option holder loan payable december include billion note million commercial paper million shortterm foreign borrowing million longdate note subject repayment option holder longterm debt december consist eurodenominate note note note note note note note note note note note note debenture note debenture debenture present table include million borrowing variable rate average include foreign borrowing million million december respectively vary rate table content exception note debenture note list table redeemable merck option time vary redemption price connection merger effective november company execute unconditional guarantee exist debt subsidiary msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent merger certain company borrowing require merck comply financial covenant include requirement total debt capitalization ratio define applicable agreement exceed december company compliance covenant aggregate maturity longterm debt year follow million billion billion billion million company enter new billion day credit facility new billion fouryear credit facility mature company terminate exist billion day credit facility expire billion revolve credit facility schedule mature august outstanding facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility rental expense operating lease net sublease income million million million minimum aggregate rental commitment noncancellable lease follow million million million million million million company significant capital lease contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action vioxx litigation enhance litigation define separate assessment provide note opinion company unlikely resolution matter material company financial position result operation cash flow give preliminary nature litigation discuss include vioxx litigation enhance litigation complexity involve matter company unable reasonably estimate possible loss range possible loss matter company know factor claim survive dispositive motion practice extent claim include size potential class particularly damage specify indeterminate iii discovery process affect litigation settlement posture party litigation factor material effect litigation company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable company decision obtain insurance coverage dependent market condition include cost availability exist time decision result number factor product liability insurance available cost increase significantly company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance certain product liability effective august include liability legacy merck product sell date company continue evaluate insurance need cost availability benefit product liability insurance future table content vioxx litigation product liability lawsuit previously disclose merck defendant approximately federal state lawsuit allege personal injury economic loss result purchase use vioxx remain case coordinate multidistrict litigation district court eastern district louisiana vioxx mdl judge eldon fallon action discuss paragraph lawsuit collectively refer vioxx product liability lawsuit vioxx product liability lawsuit try currently schedule trial merck previously disclose outcome vioxx product liability lawsuit try prior posttrial appeal resolve december texas supreme court deny plaintiff petition review ernst merck merck previously disclose detail associate ernst case lawsuit pende court putative class action purportedly bring behalf individual purchaser user vioxx seek reimbursement allege economic loss vioxx mdl proceed approximately class action remain june merck move strike class claim judgment pleading master complaint include abovereference case briefing motion complete september vioxx mdl court hear oral argument merck motion october take advisement missouri state court certify class missouri plaintiff seek reimbursement outofpocket cost relate vioxx trial schedule begin addition indiana plaintiff file motion certify class indiana vioxx purchaser case pende circuit court marion county indiana april kentucky state court deny merck motion summary judgment certify class kentucky plaintiff seek reimbursement outofpocket cost relate vioxx trial court subsequently enter amend class certification order january merck appeal order kentucky court appeals february kentucky court appeal reverse trial court amend class certification order deny certification class kentucky plaintiff merck name defendant lawsuit bring behalf government entity suit bring state attorney general bring behalf county action vioxx mdl proceeding action allege merck misrepresent safety vioxx suit seek recovery expenditure vioxx governmentfunde health care program medicaid relief penalty attorney fee action bring attorney general kentucky seek penalty allege consumer fraud act violation judge fallon remand kentucky case state court january merck appeal decision lawsuit bring county putative class action file santa clara county california behalf similarly situate california county merck move judgment pleading case bring santa clara county september court hear oral argument motion january addition merck move dismiss case bring attorney general oklahoma december march judge fallon partially grant partially deny merck motion summary judgment louisiana attorney general case trial remain claim judge fallon complete april judge fallon find favor merck june dismissing louisiana attorney general remain claim prejudice louisiana attorney general file notice appeal fifth circuit dismiss appeal prejudice pursuant scheduling rule october louisiana attorney general request stay appeal shareholder lawsuit previously disclose addition vioxx product liability lawsuit putative class action individual lawsuit federal security law state law file merck current officer director vioxx security lawsuit vioxx security lawsuit coordinate multidistrict litigation district court district new jersey judge table content stanley chesler consolidated purpose august judge chesler grant deny merck motion dismiss fifth amend class action complaint consolidate security action thing claim base statement voluntary withdrawal vioxx september dismiss october defendant answer fifth amend class action complaint discovery currently proceed accordance court scheduling order scheduling order plaintiff class certification motion file april fact discovery complete march previously disclose individual security lawsuit file foreign institutional investor consolidate vioxx security lawsuit october plaintiff file amend complaint pende individual security lawsuit october new individual security lawsuit file district new jersey foreign institutional investor case consolidate vioxx security lawsuit january defendant file motion dismiss individual lawsuit abp lawsuit stipulation order defendant require respond complaint remain individual security lawsuit resolution motion dismiss abp lawsuit addition previously disclose putative class action file federal court employee retirement income security act erisa merck certain current officer director vioxx erisa lawsuit case consolidate judge chesler august party reach agreement principle merck pay million settle vioxx erisa lawsuit november judge chesler grant final approval settlement dismiss vioxx erisa lawsuit prejudice international lawsuit previously disclose addition lawsuit discuss merck name defendant litigation relate vioxx australia brazil canada europe israel collectively vioxx foreign lawsuit follow trial representative action instance judge federal court australia enter order dismiss claim merck regard mercks australian subsidiary merck sharp dohme australia pty ltd msd australia court dismiss certain claim award applicant court find suffer myocardial infarction ingest vioxx approximately month base statutory claim vioxx fit purpose merchantable quality court reject applicant claim merck msd australia know ought know prior voluntary withdrawal vioxx september vioxx materially increase risk court determine finding fact law common claim group member individual claim proceed reference finding msd australia appeal adverse finding federal court court hear appeal crossappeal august october court allow msd australia appeal set aside judgment favor applicant dismiss action court hold vioxx prove cause applicant msd australia liable applicant damage negligence trade practice act court affirm instance decision favor msd australia applicant statutory defect claim hold msd australia state art defense prove base development scientific knowledge time effect decision claim remain group member remain determined applicant seek leave appeal court judgment high court australia january merck announce enter agreement canada settlement agreement resolve claim include certain class action putative class action relate vioxx canada agreement pende approval court canadas province canada settlement agreement approve specify condition include right merck terminate optout meet condition set forth certain merck termination right accordingly waive merck merck payment aggregate minimum approximately million dollar december maximum approximately million dollar december canada settlement exact canada settlement depend number individual submit table content document claim determine meet certain threshold gate relate alleged injury event allege usage vioxx addition payment eligible claimant experience diagnose sudden cardiac death diagnose ischemic stroke settlement include fix payment province territory class counsel fee administrative expense involve implementation canada settlement agreement approve legal fee administrative expense exceed specify amount excess pay fund eligible claimant derivative claimants company record reserve fourth quarter settlement canada settlement agreement provide merck denie allegation deny damage payable concede admit liability merck payment pay notice dissemination cost certain administrative cost approval court canadas province secure termination right expire merck terminate canada settlement agreement entirety merck certain right terminate canada settlement agreement relation province territory ontario quebec insurance company director officer insurance coverage applicable vioxx security lawsuit remain state upper limit approximately million result previously disclose insurance arbitration additional insurance coverage claim available need upperlevel excess policy provide coverage variety risk dispute insurer availability company insurance coverage claim likely additional dispute amount actually recover policy discuss paragraph state upper limit investigation previously disclose merck receive subpoenas department justice doj request information relate merck research marketing selling activity respect vioxx federal health care investigation criminal statute previously disclose march merck receive letter attorney office district massachusetts identify target grand jury investigation vioxx company establish million reserve vioxx liability reserve connection anticipate resolution dojs investigation november company announce reach resolution federal state authority matter pende court approval civil settlement agreement sign united states individually state district columbia merck pay approximately twothird vioxx liability reserve resolve civil allegation relate vioxx result united states participate state release merck civil liability relate government allegation sale promotion vioxx company agree plead guilty count misdemeanor misbranding vioxx federal food drug cosmetic act promote drug treatment rheumatoid arthritis prior fda approval indication april company pay fine approximately onethird vioxx liability reserve federal government plea agreement december district court district massachusetts conduct hear regard resolution hearing party advise court nature resolution core document comprise resolution court schedule subsequent hearing march court issue ruling concern accept merck plea resolution reserve company believe meritorious defense vioxx product liability lawsuit vioxx security lawsuit vioxx foreign lawsuit collectively vioxx lawsuit vigorously defend view inherent difficulty predict outcome litigation particularly claimant claimant seek indeterminate damage company unable predict outcome matter time reasonably estimate possible loss range loss respect remain vioxx lawsuit note company establish vioxx liability reserve reserve table content respect canada settlement agreement company establish liability reserve respect vioxx litigation unfavorable outcome vioxx litigation material adverse effect company financial position liquidity result operation product liability litigation fosamax previously disclose merck defendant product liability lawsuit unite states involve fosamax fosamax litigation december approximately case include approximately plaintiff group file pende merck federal state court include case seek class action certification damage andor medical monitoring approximately action plaintiff allege thing suffer osteonecrosis jaw onj generally subsequent invasive dental procedure tooth extraction dental implant andor delay healing association use fosamax addition plaintiff approximately action generally allege sustained femur fracture andor bone injury association use fosamax case allege onj andor jaw relate injury august judicial panel multidistrict litigation jpml order certain fosamax product liability case pende federal court nationwide transfer consolidated multidistrict litigation fosamax mdl coordinated pretrial proceeding fosamax mdl transfer judge john keenan district court southern district new york result jpml order approximately case judge keenan judge keenan issue case management order amendment thereto set forth schedule governing proceeding focus primarily resolve class action certification motion complete fact discovery initial group case october fosamax mdl trial boles merck fosamax mdl court declare mistrial person jury reach unanimous verdict bole case retry june result verdict favor plaintiff million merck file posttrial motion seek judgment matter law alternative new trial october court deny merck posttrial motion sua sponte order remittitur reduce verdict million plaintiff reject remittitur order court request new trial damage schedule place september merck intend appeal verdict bole new trial damage conclude fosamax mdl trial maley merck jury return unanimous verdict merck favor february judge keenan select new bellwether case judith grave merck replace fleming merck bellwether case fosamax mdl court dismiss grant summary judgment favor merck november second circuit affirm court grant summary judgment favor merck fleming case grave jury return unanimous verdict favor merck november jury secrest merck return unanimous verdict favor merck october trial schedule fosamax mdl raber merck subsequently dismiss addition february judge keenan order bellwether trial conduct fosamax mdl spano merck schedule try jellema merck schedule try dismiss plaintiff replacement case select quarter case try begin november outside fosamax mdl trial florida anderson merck schedule begin june florida state court postpone trial date new date set january trial ready date carballo merck continue august april ward merck case schedule try june addition july application atlantic county superior court new jersey request fosamax case pende new jersey consider mass tort designation centralize management judge new jersey october new jersey supreme court order pende future action file new jersey arise use fosamax seek damage table content exist dental jawrelate injury include onj solely seek medical monitoring designate mass tort centralize management purpose judge carol higbee atlantic county superior court december approximately onj case pende merck atlantic county new jersey july judge higbee enter case management order amendment thereto set forth schedule contemplate complete fact expert discovery initial group case review trial february jury rosenberg merck trial new jersey coordinated proceeding return verdict merck favor trial sessner merck case commence february flores merck case schedule try jointly sessner merck february judge higbee sever flore case sessner trial flore trial reschedule california party review claim plaintiff carrie smith merck case claim pedrojetti merck case plaintiff expect try mid discovery ongoing fosamax mdl litigation new jersey coordinated proceed remain jurisdiction fosamax case pende company intend defend lawsuit case allege femur fracture andor bone injury december approximately case allege femur fracture andor bone injury file new jersey state court pending judge higbee atlantic county superior court party select initial group case review fact discovery plaintiff subsequently dismiss advise dismiss seven case select discovery remain case continue trial date new jersey state femur fracture case set march merck submit motion transfer jpml seek federal case allege femur fracture bone injury consolidate multidistrict litigation coordinate pretrial proceeding motion transfer grant federal case involve allegation femur fracture bone injury transfer district new jersey fosamax mdl site judge garrett brown initially assign preside second fosamax mdl proceeding judge joel pisano assign preside litigation november judge browns retirement case management order enter require party review case later reduce case fact discovery deadline july expert discovery deadline november project trial date case try march petition file seek coordinate femur fracture case file california state court single judge orange county california petition grant judge ronald bauer appoint preside coordinate proceeding expect replace judge steven perk scheduling order enter additionally femur fracture case pende state court femur fracture case pende federal court outside mdl case pende state court massachusetts florida alabama georgia pende federal court texas osteonecrosis hip case pende federal court idaho discovery ongoing federal state court femur fracture case pende company intend defend lawsuit nuvare previously disclose beginning number complaint file jurisdiction assert claim company subsidiarie organon usa inc organon pharmaceuticals usa inc organon international collectively organon scheringplough arise organon marketing sale nuvare combine hormonal contraceptive vaginal ring plaintiff contend organon scheringplough thing fail adequately design manufacture nuvare fail adequately warn allege increase risk venous thromboembolism vte pose nuvare andor downplay risk vte plaintiff seek damage injury allegedly sustain product use include alleged death heart attack stroke majority case currently pende federal multidistrict litigation nuvaring mdl venue missouri coordinated proceed new jersey state court table content december approximately nuvare case case approximately pende nuvare mdl district court eastern district missouri judge rodney sippel approximately pende coordinated discovery proceeding bergen county superior court new jersey judge brian martinotti additional case pende state court pursuant order judge sippel nuvare mdl party originally select pool case prepare trial pool narrow case trial nuvare mdl select pursuant judge martinottis order new jersey proceeding party select trial pool case prepare trial party complete fact discovery originally select trial pool case jurisdiction company anticipate expert discovery complete trial pool case summer certain case original trial pool voluntarily dismiss case judgment enter merck favor result certain replacement trial pool case remain fact discovery january party new jersey coordinated proceeding select additional trial pool case completion fact discovery company anticipate status conference hold coordinate proceeding follow completion expert discovery summer determine methodology select case try time party discuss time frame filing motion relate admissibility expert testimony causation company intend defend lawsuit propeciaproscar previously disclose merck defendant product liability lawsuit unite states involve propecia andor proscar december approximately lawsuit involve total approximately plaintiff instance spouse join suit allege experience persistent sexual effect follow cessation treatment propecia andor proscar file merck lawsuit early stage pende federal court new jersey washington washington florida illinois colorado missouri ohio state court new jersey certain federal plaintiff petition jpml federal lawsuit consolidate pretrial purpose certain new jersey state court plaintiff petitioned consolidation new jersey state court case resolution motion remain pende company intend defend lawsuit governmental proceeding effective august merck department health human service office inspector general hhsoig execute unified corporate integrity agreement unify cia replace individual cia sign merck scheringplough prior merger unify cia incorporate certain requirement individual cia merck scheringplough similar identical legacy cias merck assume compliance obligation unify cia february effective november merck hhsoig execute new corporate integrity agreement new cia replace unified cia term year previously disclose merck receive civil investigative demand cid issue doj address inspire pharmaceuticals inc company acquire merck cid advise relate false claim act investigation concern allegation inspire cause submission false claim federal health benefit program drug azasite marketing treatment indication approve fda company cooperate government investigation previously disclose company receive subpoena doj request information relate company marketing selling activity respect integrilin avelox january june civil federal health care investigation company previously disclose receive subpoena request information relate company marketing selling activity respect temodar pegintron intron january present federal health care investigation criminal statute company cooperate dojs investigation table content previously disclose company receive letter doj sec seek information activity number country reference foreign corrupt practice act company cooperate agency request believe inquiry broad review pharmaceutical industry practice foreign country regard company receive continue receive additional request information doj sec vytorinzetia litigation previously disclose april merck shareholder file putative class action lawsuit federal court consolidated district new jersey federal security lawsuit caption merck inc vytorin security litigation amend consolidated complaint file october name defendant merck merckscheringplough pharmaceutical llc certain company current officer director complaint allege merck delay release unfavorable result enhance clinical trial efficacy vytorin merck false misleading statement expect earning know result enhance study release sale vytorin decline merck earning suffer december merck defendant move dismiss lawsuit ground plaintiff fail state claim relief grant september court deny defendant motion dismiss june lead plaintiff file motion leave amend consolidated complaint grant february party currently brief lead plaintiff motion class certification similar consolidated putative class action security lawsuit pende district new jersey file scheringplough shareholder scheringplough chairman president chief executive officer fre hassan caption scheringplough corporationenhance security litigation amend consolidated complaint file september name defendant scheringplough merckscheringplough pharmaceutical certain company current officer director underwriter participate august public offering scheringplough common prefer stock december scheringplough defendant file motion dismiss lawsuit ground plaintiff fail state claim relief grant september court deny defendant motion dismiss party currently brief lead plaintiff motion class certification previously disclose april member merck erisa plan file putative class action lawsuit merck certain company current officer director alleging breach fiduciary duty erisa time similar erisa lawsuit file merck district new jersey lawsuit consolidate caption merck inc vytorin erisa litigation consolidate amend complaint file february name defendant merck current member company board director plaintiff allege erisa plan investment merck stock imprudent merck earning dependent commercial success cholesterol drug vytorin defendant know know result scientific study cause medical community turn expensive drug cholesterol management april merck defendant move dismiss lawsuit ground plaintiff fail state claim relief grant september court deny defendant motion dismiss similar consolidated putative class action erisa lawsuit currently pende district new jersey file member schering plough erisa plan scheringplough certain current officer director alleging breach fiduciary duty erisa caption scheringplough corp enhance erisa litigation consolidate amend complaint file october name defendant scheringplough thencurrent member scheringploughs board director thencurrent member committee scheringploughs board director november company defendant file motion dismiss lawsuit ground plaintiff fail state claim relief grant motion deny june november party reach agreement principle settle matter november party inform court submit motion preliminary approval settlement table content classwide basis november court order case dismiss cost prejudice right good cause show day seek reopen action settlement consummate january court extend day period additional day november stockholder company file shareholder derivative lawsuit local international brotherhood electrical worker pension fund clark local district new jersey behalf nominal defendant company shareholder company company certain company officer director allege insider certain predecessor company officer director allege insider allege breach fiduciary duty waste unjust enrichment gross mismanagement similar shareholder derivative lawsuit cain hassan file scheringplough stockholder district new jersey lawsuit company scheringplough thencurrent board director certain company thencurrent officer director allege insider plaintiff local cain hassan allege defendant withhold enhance study result false misleading statement deceive cause harm company scheringplough respectively invest public unjustly enrich insider waste corporate asset plaintiff local voluntarily dismiss suit prejudice july july intervenorplantiff cain hassan action file second amend complaint defendant move dismiss second amend complaint october december party cain hassan execute stipulation settlement terminate litigation plaintiff move approval settlement propose settlement include payment monetary consideration immaterial legal fee plaintiff counsel hearing hold february motion approval settlement november company shareholder file derivative lawsuit state court new jersey case caption rise hassan assert claim substantially identical claim allege cain hassan april defendant rise hassan move stay case dismiss prejudice favor federal derivative action august new jersey state court dismiss rise hassan prejudice september plaintiff rise hassan file notice appeal january plaintiff move additional day file appeal brief event cain hassan settlement approve discovery federal lawsuit refer section collectively enhance litigation coordinate substantially complete company believe meritorious defense enhance litigation intends vigorously defend lawsuit company unable predict outcome matter time reasonably estimate possible loss range loss respect enhance litigation unfavorable outcome result enhance litigation material adverse effect company financial position liquidity result operation insurance company director officer insurance coverage applicable vytorin shareholder lawsuit bring legacy scheringplough shareholder state upper limit approximately million company fiduciary insurance vytorin erisa lawsuit state upper limit approximately million dispute insurer availability company insurance coverage claim likely additional dispute amount actually recover policy discuss paragraph state limit commercial litigation awp litigation previously disclose company andor certain subsidiary remain defendant case bring state allege manipulation pharmaceutical manufacturer average wholesale price awp public private payor calculate provider reimbursement level outcome lawsuit include substantial damage imposition substantial fine penalty injunctive administrative remedy table content company settle certain awp case bring states utah south carolina alaska idaho kentucky pennsylvania mississippi wisconsin iowa massachusetts certain new york county company andor certain subsidiary continue defendant case bring state kdur antitrust litigation previously disclose june january scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle respectively relate generic version kdur scheringploughs longacte potassium chloride product supplement cardiac patient lederle upshersmith file abbreviate new drug application anda follow commencement administrative proceeding united states federal trade commission ftc allege anticompetitive effect settlement resolve scheringploughs favor putative class nonclass action suit file behalf direct indirect purchaser kdur scheringplough upsher smith lederle consolidated multidistrict litigation district court district new jersey suit claim violation federal state antitrust law state statutory common law cause action seek unspecified damage april indirect purchaser voluntarily dismiss case february special master recommend district court dismiss remain lawsuit summary judgment march district court adopt recommendation grant summary judgment defendant dismiss matter entirety plaintiff appeal decision circuit court appeal defendant simultaneously appeal december decision district court certify certain direct purchaser plaintiff claim class action patent litigation time time generic manufacturer pharmaceutical product file andas fda seek market generic form company product prior expiration relevant patent own company protect patent right company file patent infringement lawsuit generic company certain product company market agreement company currently involve patent infringement litigation united states include azasite cancidas nasonex nexium noxafil vytorin zetia similar lawsuit defend company patent right exist country company intends vigorously defend patent believe valid infringement generic company attempt market product prior expiration patent litigation assurance outcome adverse result significantly shorten period exclusivity product respect legacy scheringplough product potentially significant intangible asset impairment charge azasite patent infringement suit file united states sandoz inc sandoz respect sandozs application fda seek prepatent expiry approval market generic version azasite lawsuit automatically stay fda approval sandozs anda october adverse court decision whichever occur early cancidas november patent infringement lawsuit file united states teva parenteral medicines inc tpm respect tpm application fda seek prepatent expiry approval sell generic version cancidas lawsuit dismiss right grant tpm march patent infringement lawsuit file united states sandoz respect sandozs application fda seek prepatent expiry approval sell generic version cancidas june sandoz amend challenge mercks cancida patent state seek fda approval early expiry patent occur july sandoz maintain challenge cancida patent expire september lawsuit continue fda approve sandozs application early july integrilin february patent infringement lawsuit file jointly millennium pharmaceuticals inc united states tpm respect tpm application fda seek approval sell generic version integrilin prior expiry expire list patent october party enter settlement agreement allow tpm sell generic version integrilin begin june table content nasonex december patent infringement suit file united states apotex corp apotex respect apotexs application fda seek prepatent expiry approval market generic version nasonex lawsuit automatically stay fda approval apotexs anda adverse court decision whichever occur early trial expect place nexium november patent infringement lawsuit file jointly astrazeneca united states ranbaxy laboratories ltd ranbaxy respect ranbaxys application fda seek prepatent expiry approval sell generic version nexium previously disclose astrazeneca merck ranbaxy enter settlement agreement provide ranbaxy entitle bring generic esomeprazole product market united states company astrazeneca receive cid ftc july settlement agreement ranbaxy company cooperate ftc respond cid march patent infringement lawsuit file jointly astrazeneca ivax pharmaceuticals inc ivax later acquire teva pharmaceuticals inc teva respect ivax application fda seek prepatent expiry approval sell generic version nexium january astrazeneca merck tevaivax enter settlement agreement provide tevaivax entitle bring generic esomeprazole product market united states patent infringement lawsuit file united states reddys laboratories reddys sandoz lupin ltd lupin respect respective application fda seek prepatent expiry approval sell generic version nexium january astrazeneca merck reddys enter settlement agreement provide reddys entitle bring generic esomeprazole product market united states june astrazeneca merck sandoz enter settlement agreement provide sandoz entitle bring generic esomeprazole product market united states january astrazeneca merck lupin enter settlement agreement provide lupin entitle bring generic esomeprazole product market united states february patent infringement lawsuit file jointly astrazeneca united states hamni usa inc hamni respect hamnis application fda seek prepatent expiry approval sell generic version nexium august patent infringement lawsuit file jointly astrazeneca united states hetero drugs ltd unit iii hetero respect heteros application fda seek prepatent expiry approval sell generic version nexium january patent infringement lawsuit file jointly astrazeneca united states torrent pharmaceuticals ltd torrent respect torrent application fda seek pre patent expiry approval sell generic version nexium patent infringement lawsuit file jointly astrazeneca february united states sun pharma global fze sun pharma respect application fda seek prepatent expiry approval sell generic version nexium october astrazeneca merck sun pharma enter settlement agreement provide sun pharma entitle bring generic esomeprazole product market united states january noxafil patent infringement suit file united states sandoz respect sandozs application fda seek prepatent expiry approval market generic version noxafil lawsuit automatically stay fda approval sandozs anda september adverse court decision whichever occur early nuvare february patent infringement suit bring merck international trade commission itc femina pharma incorporate femina respect product nuvaring complaint allege nuvaring infringe patent own femina feminas itc complaint seek exclusion order importation nuvare united states hearing begin itc proceeding january january femina withdraw complaint terminate action addition november femina bring patent infringement lawsuit merck eastern district virginia assert nuvaring infringe patent case stay pende outcome itc proceeding company believe femina intend pursue litigation eastern district virginia propecia december patent infringement lawsuit file united states hetero drugs limit hetero respect heteros application fda seek prepatent expiry approval sell generic version propecia march company settle lawsuit hetero agree allow hetero sell generic finasteride product begin july table content temodar july patent infringement action file jointly cancer research technology limited crt united states barr laboratories barr later acquire teva respect barrs application fda seek prepatent expiry approval sell generic version temodar january court issue decision find crt patent unenforceable ground prosecution lache inequitable conduct november appeal court issue decision reverse trial court find december barr file petition seek rehear banc appeal petition deny june barr file petition review supreme court deny virtue agreement barr launch product appeal process company agree barr launch product august september patent infringement lawsuit file jointly crt united states sun pharmaceutical industries inc sun respect sun application fda seek prepatent expiry approval sell generic version temodar lawsuit automatically stay fda approval sun anda february adverse court decision whichever occur early november patent infringement lawsuit file jointly crt united states accord healthcare inc accord respect application fda seek prepatent expiry approval sell generic version temodar lawsuit automatically stay fda approval accord application april adverse court decision whichever occur early company crt enter agreement sun accord stay respective lawsuit pende outcome supreme court appeal process barr lawsuit light supreme courts denial barr petition sun accord agree withdraw challenge temodar patent respective lawsuit withdraw vytorin december patent infringement lawsuit file united states mylan pharmaceuticals inc mylan respect mylan application fda seek prepatent expiry approval sell generic version vytorin lawsuit automatically stay fda approval mylan application adverse court decision whichever occur early trial mylan jointly respect zetia vytorin conduct december decision expect february patent infringement lawsuit file united states teva respect tevas application fda seek prepatent expiry approval sell generic version vytorin july patent infringement lawsuit dismiss teva agree sell generic version zetia vytorin companys exclusivity right expire april certain circumstance august patent infringement lawsuit file united states impax laboratories inc impax respect impaxs application fda seek pre patent expiry approval sell generic version vytorin agreement reach impax stay lawsuit pende outcome lawsuit mylan october patent infringement lawsuit file united states actavis inc actavis respect actavis application fda seek prepatent expiry approval sell generic version vytorin lawsuit automatically stay fda approval actavis application adverse court decision whichever occur early zetia march patent infringement lawsuit file united states glenmark pharmaceuticals inc usa parent corporation collectively glenmark respect glenmark application fda seek prepatent expiry approval sell generic version zetia glenmark agree settlement virtue glenmark permit launch generic product united states december subject receive final fda approval june patent infringement lawsuit file united states mylan respect mylan application fda seek prepatent expiry approval sell generic version zetia lawsuit automatically stay fda approval mylan application december adverse court decision whichever occur early trial mylan jointly respect zetia vytorin conduct december decision expect september patent infringement lawsuit file united states teva respect tevas application fda seek prepatent expiry approval sell generic version zetia july patent infringement lawsuit dismiss right grant teva litigation pende legal proceeding involve company principally product liability intellectual property lawsuit feasible predict outcome proceeding opinion table content company likelihood loss remote reasonably possible loss associate resolution proceeding expect material company financial position result operation cash flow individually aggregate legal defense reserve legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate environmental matter company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability minimis final cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial position result operation liquidity capital resource company company take active role identify provide cost amount include reduction anticipate recovery cleanup cost site owner operator recalcitrant potentially responsible party previously disclose approximately plaintiff file amend complaint merck defendant district court eastern district california assert claim clean water act resource conservation recovery act negligence nuisance suit seek damage personal injury diminution property value medical monitoring allege real personal property damage associate groundwater surface water soil contamination find site merck subsidiary merce california certain defendant suit settle plaintiff aspect plaintiff claim lawsuit proceeding phase manner jury trial commence february jury ask certain factual finding contamination move offsite area plaintiff expose contamination amount defendant phase trial include merck original defendant march phase jury return mixed verdict find favor merck defendant plaintiff claim specifically jury find contamination site enter affect plaintiff municipal water supply well private domestic well jury find plaintiff expose contamination air emission prior surface water form storm drainage channel adjacent irrigation canal include flood april response posttrial motion merck defendant september court table content enter order set aside phase jury finding favor plaintiff specifically court hold plaintiff expose contamination surface flood water april flood fact time later merck motion reconsideration remainder jurys phase verdict adverse merck deny follow retirement judge handle case september case assign judge david carter district court central district california judge carter select plaintiff claim review depend outcome merck anticipate summary judgment motion possibly try early previously disclose doj environmental protection agency epa notify company pursue civil penalty merck excess million allege violation air water waste regulation result epas multimedia inspection merck west point riverside pennsylvania facilities merck subsequent information submission epa stipulation settling matter file district court middle district pennsylvania september pursuant company deny allege violation agree civil penalty million follow court approval stipulation november merck pay civil penalty united states claim merck dismiss prejudice management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year equity merck certificate incorporation authorize share common stock share prefer stock authorize share prefer stock series share designate mandatory convertible preferred stock mandatory convertible prefer stock connection merger holder scheringplough preferred stock receive preferred stock right substantially similar right scheringplough prefer stock accordance merck restate certificate incorporation result merger prefer stock subject makewhole acquisition provision prefer stock effective november makewhole acquisition conversion period end november prefer stock convertible makewhole conversion rate share prefer stock convert period holder receive cash merck common share holder receive dividend makewhole payment share depend date conversion total share prefer stock convert share merck common stock cash payment approximately million holder convert addition makewhole dividend payment million holder convert represent present value remain future dividend payment conversion date mandatory conversion date august discount rate stipulate term prefer stock august remain outstanding mandatory convertible preferred stock automatically convert term right receive cash share merck common stock share mandatory convertible preferred stock holder receive cash share merck common stock result conversion approximately million pay holder approximately million merck common share issue table content capital stock summary common stock treasury stock transaction share millions follow common treasury common treasury common treasury stock stock stock stock stock stock balance january mandatory conversion convertible prefer stock issuance share connection merger issuance purchase treasury stock cancellation treasury stock balance december issuance primarily reflect activity sharebase compensation plan pursuant merger agreement certain merck treasury share cancel noncontrolle interest connection restructure ami merck assume billion par value prefer stock obligation dividend rate annum carry kbi include noncontrolle interest astrazeneca exercise share option note preferred stock obligation retire sharebase compensation plan company sharebase compensation plan employee nonemployee director employee certain company equity method investee grant option purchase share company common stock fair market value time grant addition stock option company grant performance share unit psus restrict stock unit rsus certain management level employee plan approve company shareholder result merger scheringplough stock incentive plan scheringplough sip amend restate sharebased compensation instrument remain available future grant scheringplough sip merck employee employee scheringplough prior merger outstanding sharebased compensation instrument sharebase compensation instrument available future grant legacy merck legacy scheringplough incentive plan result merger certain sharebased compensation instrument previously grant scheringplough sip legacy scheringplough incentive plan exchange merck replacement awards awards relate precombination service payable cash fair value replacement award attributable precombination service million include calculation consideration transfer note significant portion legacy scheringplough award vest opening balance sheet time merger scheringplough share base compensation instrument immediately vest completion merger exchange merck replacement award generally vest basis original grant scheringplough legacy incentive plan immediately vest employee terminate company year merger certain circumstance fair value merck replacement award attribute postcombination service recognize compensation cost subsequent merger requisite service period award december million share collectively authorize future grant company sharebase compensation plan prior merger employee sharebase compensation award settle primarily treasury share subsequent merger award settle newly issue share treasury share table content employee stock option grant purchase share company stock fair market value time grant award generally vest onethird year threeyear period contractual term year rsus stock award grant employee entitle holder share common stock award vest fair value stock option rsu award determine fix grant date base company stock price psus stock awards ultimate number share issue contingent company performance preset objective set objective fair value psu determined date grant base company stock price rsus certain psus grant december employee participate dividend basis common share dividend nonforfeitable holder rsus psus issue january dividend declare vest period payable employee vest fair value stock option rsu psu replacement award determine fix time merger psu performance period number share stock expect issue adjust base probability achievement performance target final compensation expense recognize base ultimate number share issue rsu psu distribution share company stock end vest performance period generally year subject term applicable award total pretax sharebase compensation cost record million million million respectively relate income tax benefit million million million respectively company use blackschole option pricing model determine fair value option grant apply model company use historical datum current market datum estimate fair value option blackschole model require assumption include expect dividend yield riskfree interest rate volatility term option expect dividend yield base historical pattern dividend payment risk free rate base rate grant date zerocoupon treasury notes term equal expect term option expect volatility estimate blend historical imply volatility historical component base historical monthly price change imply volatility obtain market datum company trade option expect life represent time option grant expect outstanding base historical forecast exercise behavior weight average exercise price option grant option respectively weight average fair value option grant option respectively determine follow assumption year end december expect dividend yield riskfree interest rate expect volatility expect life year summarize information relative stock option plan activity option thousand follows weight weight average average remain aggregate number exercise contractual intrinsic option price term value outstanding january grant exercise forfeit outstanding december exercisable december table content additional information pertain stock option plan provide table year end december total intrinsic value stock option exercise fair value stock option vest cash receive exercise stock option fair value stock option vest exclude fair value option vest result merger attributable precombination service summary nonveste rsu psu activity share thousand follow rsus psus weight weight average average number grant date number grant date share fair value share fair value nonveste january grant vested forfeited nonveste december december million total pretax unrecognized compensation expense relate nonveste stock option rsu psu award recognize weight average period year segment report sharebased compensation cost unallocated expense pension postretirement benefit plan company define benefit pension plan cover eligible employee united states certain international subsidiary pension benefit united states base formula consider final average pay year credit service addition company provide medical dental life insurance benefit principally eligible retiree similar benefit dependent postretirement benefit plan december change company benefit plan approve discuss company use december yearend measurement date pension plan postretirement benefit plan net periodic benefit cost net periodic benefit cost pension postretirement benefit plan consist follow component pension benefit postretirement benefit year end december service cost interest cost expect return plan asset net amortization termination benefit curtailment settlement net periodic benefit cost table content high cost compare primarily incremental cost associate merger net periodic benefit cost attributable pension plan include table million million million connection restructuring action note termination charge record pension postretirement benefit plan relate expand eligibility certain employee exit merck connection restructuring activity curtailment record pension postretirement benefit plan addition settlement record certain domestic international pension plan obligation fund status summarize information change plan asset benefit obligation fund status amount record december follow postretirement pension benefit benefit fair value plan asset january actual return plan asset company contribution merger acquisition divestiture effect exchange rate change benefit pay settlement fair value plan asset december benefit obligation january service cost interest cost merger acquisition divestiture actuarial loss gain benefit pay effect exchange rate change plan amendment curtailment termination benefit settlement benefit obligation december fund status december recognize asset accrue current liability defer income taxis noncurrent liability table content fair value pension plan asset include precede table billion billion december respectively project benefit obligation pension plan billion billion respectively approximately company pension project benefit obligation december relate international define benefit plan individual plan significant relative total project benefit obligation december accumulate benefit obligation billion billion respectively pension plan billion billion respectively relate pension plan pension plan project benefit obligation excess plan asset december fair value plan asset billion billion respectively benefit obligation billion billion respectively plan accumulate benefit obligation excess plan asset december fair value plan asset billion billion respectively accumulate benefit obligation billion billion respectively plan asset entity require use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset value determine pricing model discount cash flow methodology similar technique significant unobservable input instrument determination fair value require significant judgment estimation december million million respectively approximately company pension investment year end categorize level asset input measure financial asset fall level describe categorization base low level input significant fair value measurement instrument table content fair value companys pension plan asset december asset category follow fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total asset cash cash equivalent investment fund large cap equitie smallmid cap equity nonus develop market equity nonus emerge market equity government agency obligation corporate obligation fix income obligation real estate equity security large cap smallmid cap nonus develop market fix income security government agency obligation corporate obligation mortgage assetbacke security investment insurance contract derivative liability derivative plan level investment real estate generally value market appraisal plan level investment insurance contract generally value credit rate approximate market return invest underlying security market value unobservable determine pricing model discount cash flow methodology similar technique table content table provide summary change fair value include transfer andor financial asset measure fair value significant unobservable input level company pension plan asset insurance real insurance real contract estate total contract estate total beginning balance january actual return plan asset relate asset hold december relate asset sell year purchase sale transfer level end balance december fair value company postretirement benefit plan asset december asset category follow fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total asset cash cash equivalent investment fund large cap equitie smallmid cap equity nonus develop market equity nonus emerge market equity fix income obligation equity security large cap smallmid cap nonus develop market fix income security government agency obligation corporate obligation mortgage assetbacked security fix income obligation total pension postretirement benefit plan asset exclude fair value hierarchy include interest receivable payable receivables relate purchase sale investment respectively company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard table content deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest nonus pension plan target investment portfolio vary base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline expect contribution contribution pension plan postretirement benefit plan expect approximately million million respectively expect benefit payment expect benefit payment follow pension postretirement benefit benefit expect benefit payment base assumption measure benefit obligation include estimate future employee service amount recognize comprehensive income net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption net loss amount excess certain threshold amortize net pension postretirement benefit cost average remain service life employee follow amount reflect component oci postretirement pension plan benefit plan year end december net loss gain arise period prior service credit cost arise period net loss amortization include benefit cost prior service cost credit amortization include benefit cost estimate net loss gain prior service cost credit amount amortize aoci net pension postretirement benefit cost million million respectively pension plan million million respectively postretirement benefit plan table content actuarial assumption company reassesse benefit plan assumption regular basis weight average assumption determine pension plan pension postretirement benefit plan information follow pension pension plan postretirement benefit plan december net periodic benefit cost discount rate expect rate return plan asset salary growth rate benefit obligation discount rate salary growth rate net cost rate precede table include cost associate scheringplough benefit plan date merger december expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay determined country basis develop expect rate return country longterm historical return datum consider actual return plan asset capital market experience reference information longterm return expectation asset category weight average expect return countrys target portfolio develop accord allocation investment category expect portfolio performance reflect contribution active management appropriate company expect rate return range compare range pension postretirement benefit plan health care cost trend rate assumption postretirement benefit plan follow december health care cost trend rate assume year rate cost trend rate assume decline year trend rate reach ultimate trend rate percentage point change health care cost trend rate follow effect percentage point increase decrease effect total service interest cost component effect benefit obligation benefit plan change december compensation benefit committee company board director approve management proposal change merck primary define benefit pension plan benefit formula cash balance formula begin service january active participant plan december accrue pension benefit prospectively new cash balance formula base age service pay interest transition period january december participant earn great benefit calculate employee legacy final average pay formula new cash balance formula year service december participant earn future benefit cash balance formula change plan reduce pension benefit obligation table content december approximately million corresponding offset aoci largely attributable change final average pay career average pay amortize reduction net periodic benefit cost employee future service period approximately year december company approve change retiree healthcare plan include change certain employee contribution subsidy level eligibility criterion subsidize retiree medical coverage elimination certain retiree dental coverage reduce merck future cost relate plan change reduce company benefit obligation relate retiree healthcare plan december approximately million corresponding offset aoci amortize reduction net periodic benefit cost employee future service period approximately year saving plan company maintain define contribution saving plan unite states include plan assume connection merger company match percentage employee contribution consistent provision plan employee eligible total employer contribution plan million million million respectively income expense net year end december interest income interest expense exchange loss gain net increase interest income compare primarily reflect high average investment balance decline interest income increase interest expense compare largely attributable merger exchange loss reflect million loss venezuelan currency devaluation discuss net present table reflect million charge relate resolution arbitration proceeding involve company right market remicade simponi note million gain disposition company interest jjmcp joint venture note million gain sale certain manufacturing facility relate asset note net reflect million charge vioxx liability reserve note charge relate settlement certain pende awp litigation partially offset million income recognize astrazenecas asset option exercise note million income recognize settlement certain dispute royalty net primarily reflect billion gain result recognize merck previously hold equity interest msp partnership fair value result obtain control msp partnership merger billion gain sale merck interest merial note note exchange loss reflect loss relate venezuelan currency devaluation effective january venezuelan government devalue currency bsf dollar twotiere official exchange rate essential rate bsf dollar nonessential rate bsf dollar january company require remeasure local currency operation venezuela dollar venezuelan economy determine hyperinflationary company settle transaction essential rate remeasure monetary asset liability utilize essential rate december venezuelan government announce eliminate essential rate effective january transaction settle official rate bsf dollar result announcement company remeasure december monetary asset liabilitie new official rate table content interest pay million million million exclude commitment fee interest pay net million receive company termination certain interest rate swap contract year note taxis income reconciliation effective tax rate statutory rate follow tax rate tax rate tax rate statutory rate apply income taxis differential arise foreign earning federal state tax settlement tax rate change unremitte foreign earning iprd impairment charge amortization purchase accounting adjustment arbitration settlement charge restructure state taxis gain equity investment vioxx liability reserve health care reform legislation include tax effect contingency reserve research credit export incentive miscellaneous item tax rate reconciliation percentage reflect impact significant decline company income taxis result primarily year acquisitionrelate cost include iprd impairment charge restructure charge arbitration settlement charge charge vioxx liability reserve income taxis consist year end december domestic foreign table content taxis income consist year end december current provision federal foreign state defer provision federal foreign state defer income taxis december consist asset liability asset liability intangible inventory relate accelerated depreciation unremitte foreign earning equity investment pension postretirement benefit compensation relate unrecognized tax benefit net operating loss tax credit carryforward subtotal valuation allowance total defer taxis net deferred income taxis recognize deferred income taxis current asset asset income taxis payable deferred income taxis noncurrent liability company net operating loss nol carryforward jurisdiction december approximately million defer taxis nol carryforward relate foreign jurisdiction individually significant approximately million valuation allowance establish foreign nol carryforward addition company approximately million defer tax asset relate tax credit carryforward nol carryforward amount million expect fully utilize prior expiry table content income taxis pay billion billion million respectively stock option exercise significant impact taxis pay reconciliation begin end unrecognized tax benefit follow balance january addition relate current year position addition relate prior year position additon relate merger reduction tax position prior year settlement lapse statute limitation balance december reflect conclusion irs examination merck federal income tax return resolution interest rate swap dispute irs discuss company recognize unrecognized tax benefit billion december income tax provision reflect favorable net impact billion company examination numerous tax authority jurisdiction globally company believe reasonably possible total unrecognized tax benefit december decrease million month result audit closure settlement expiration statute limitation ultimate finalization company examination relevant tax authority include formal administrative legal proceeding significant impact time reversal unrecognized tax benefit company believe reserve uncertain tax position adequate cover exist risk exposure interest penalty associate uncertain tax position amount benefit expense million million million liability accrue interest penaltie billion billion december respectively april irs conclude examination merck federal income tax return result company require net payment approximately million company unrecognized tax benefit year examination exceed adjustment relate examination period company record net million tax provision benefit net benefit reflect decrease unrecognized tax benefit year examination partially offset increase unrecognize tax benefit year subsequent examination period result settlement company disagree irs treatment issue raise examination appeal matter irs administrative process previously disclose october canada revenue agency cra issue merck notice reassessment contain adjustment relate certain intercompany pricing matter february merck cra negotiate settlement agreement regard matter accordance settlement merck pay additional tax approximately million interest approximately million additional amount penalty assessment settlement account quarter merck previously establish reserve matter portion taxis pay expect creditable tax purpose addition previously disclose cra propose adjustment relate intercompany pricing matter july cra issue assessment miscellaneous audit issue tax year adjustment increase canadian tax approximately million plus approximately million interest december company disagree position take cra believe merit company continue contest assessment cra appeal process cra expect prepare similar adjustment later year management believe resolution matter material effect company financial position liquidity table content october internal revenue service irs auditor assert interest rate swap scheringplough enter unrelated party recharacterize loan affiliate company result additional tax liability tax year september schering plough payment irs million income taxis million interest company tax reserve adequate cover payment scheringplough file refund claim taxis interest irs december follow irss denial scheringplough claim refund scheringplough file suit district court district new jersey refund taxis interest decision favor government announce august affirm court appeal circuit june irs finalize examination scheringplough tax year audit cycle company reach agreement irs adjustment income relate intercompany pricing matter income adjustment reduce nols tax credit carryforward additionally company seek resolution issue raise examination irs administrative appeal process company reserve uncertain tax position adequate cover adjustment relate examination period irs begin examination tax year addition state foreign tax examination progress significant tax jurisdiction state foreign company income tax return open examination period december foreign earning billion retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability addition company subsidiary operate puerto rico singapore tax incentive grant begin expire earning share company calculate earning share pursuant twoclass method earning allocation formula determine earning share common stock participate security accord dividend declare participation right undistribute earning method earning distribute undistributed allocate common share participate security base respective right receive dividend rsus certain psus grant december certain management level employee note participate dividend basis common share dividend nonforfeitable holder result rsus psus meet definition participate security rsus psus issue january dividend declare vest period payable employee vest rsus psus meet definition participate security table content calculation earning share twoclass method follow year end december basic earning common share net income attributable merck inc income allocate participate security net income allocate common shareholder average common share outstanding earning common share assume dilution net income attributable merck inc income allocate participate security net income allocate common shareholder average common share outstanding common share issuable average common share outstanding assume dilution issuable primarily sharebased compensation plan million million million respectively common share issuable sharebased compensation plan exclude computation earning common share assume dilution effect antidilutive table content comprehensive income loss component comprehensive income loss follow pretax tax tax year end december net unrealized loss derivative net loss realization derivative net unrealized loss investment net gain realization investment benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment year end december net unrealized gain derivative net loss realization derivative net unrealized gain investment net gain realization investment benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment year end december net unrealized loss derivative net loss realization derivative net unrealized gain investment net gain realization investment benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment include cumulative translation adjustment pretax gain loss approximately million billion respectively relate translation impact intangible asset record conjunction merger table content component accumulate comprehensive loss follow december net unrealized gain derivative net unrealized gain investment pension plan net loss postretirement benefit plan net loss pension plan prior service cost postretirement benefit plan prior service credit cumulative translation adjustment segment reporting company operation principally manage product basis comprise operating segment pharmaceutical animal health consumer care alliance include revenue equity income company relationship azlp animal health consumer care alliance segment material separate reporting include table pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity large component pediatric adolescent vaccine sell center disease control prevention vaccine child program fund government additionally company sell vaccine federal government placement vaccine stockpile company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer additionally company consumer care operation develop manufacture market overthecounter foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet segment composition reflect certain managerial change implement consumer care product sale outside united states canada previously include pharmaceutical segment include consumer care segment segment disclosure prior year recast comparable basis table content accounting policy segment describe describe note revenue profit segment follow pharmaceutical total year end december segment sale segment profit include segment profit equity income affiliate depreciation amortization year end december segment sale segment profit include segment profit equity income affiliate depreciation amortization year end december segment sale segment profit include segment profit equity income affiliate depreciation amortization segment profit comprise segment sale certain element material production cost operating expense include component equity income loss affiliate depreciation amortization expense internal management reporting present chief operating decision maker merck allocate production cost standard cost research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit table content sale company product follow year end december pharmaceutical cardiovascular zetia vytorin integrilin diabete obesity januvia janumet diversify brand cozaarhyzaar zocor propecia claritin remeron vasotecvaseretic proscar infectious disease isentress pegintron cancidas primaxin invanz avelox noxafil crixivanstocrin rebetol victrelis neuroscience ophthalmology maxalt cosopttrusopt oncology temodar emend intron respiratory immunology singulair remicade nasonex clarinex arcoxia simponi asmanex proventil dulera vaccines gardasil proquadmmr iivarivax rotateq pneumovax zostavax womens health endocrine fosamax nuvare follistim implanon cerazette pharmaceutical total pharmaceutical segment sale segment sale total segment sale sale legacy scheringplough product include postmerger period addition prior merger substantially sale zetia vytorin recognize msp partnership result merck interest msp partnership record equity income affiliate result merger msp partnership wholly own company accordingly sale msp partnership product merger reflect table sale zetia vytorin reflect merck sale product latin america msp partnership sale product postmerger period amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate amount reflect supply sale sanofi pasteur msd pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately reflect nonreportable segment include animal health consumer care revenue company relationship azlp primarily relate sale nexium prilosec revenue azlp billion billion billion respectively revenue primarily comprise miscellaneous corporate revenue thirdparty manufacture sale sale relate divested product business supply sale include segment result table content consolidated revenues geographic area derive follow year end december united states europe middle east africa japan reconciliation total segment profit consolidate income taxis follow year end december segment profit profit loss adjustment unallocate interest income interest expense equity income affiliate depreciation amortization research development amortization purchase accounting adjustment restructure cost arbitration settlement charge vioxx liability reserve gain astrazeneca asset option exercise gain related msp partnership gain merial divestiture expense net profit loss primarily comprise miscellaneous corporate profit loss operate profit loss relate thirdparty manufacture sale divest product business supply sale adjustment represent elimination effect double count certain item income expense equity income affiliate include taxis pay joint venture level portion equity income report segment profit expense net include expense corporate manufacturing cost center miscellaneous income expense net property plant equipment net geographic area locate follow year end december united states europe middle east africa japan company disaggregate asset product service basis internal management report information present table content report independent register public accounting firm board director shareholders merck inc opinion accompany consolidated balance sheet relate consolidated statement income equity cash flow present fairly material respect financial position merck inc subsidiaries december december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion merck maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso merck management responsible financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include management report item responsibility express opinion financial statement merck internal control financial reporting base integrated audits conduct audits accordance standard public company accounting oversight board united states standard require plan perform audits obtain reasonable assurance financial statement free material misstatement effective internal control financial reporting maintain material respect audits financial statement include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp florham park new jersey february table content supplementary datum select quarterly financial datum contain condense interim financial datum table condense interim financial datum unaudite million share amount sale material production marketing administrative research development restructuring cost equity income affiliate income expense net income taxis net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder sale material production marketing administrative research development restructuring cost equity income affiliate income expense net loss income taxis net loss income attributable merck inc basic loss earning common share attributable merck inc common shareholder loss earning common share assume dilution attributable merck inc common shareholder amount include impact vioxx liability reserve note amount include net benefit relate settlement federal income tax audit note amount reflect income recognize astrazenecas asset option exercise note amount include charge relate resolution arbitration proceeding note amount reflect impact merger include amortization purchase accounting adjustment inprocess research development impairment charge note amount include impact restructuring action note table content item change disagreement accountant account financial disclosure applicable item control procedure management company participation chief executive officer chief financial officer evaluate effectiveness company disclosure control procedure base evaluation end period cover company chief executive officer chief financial officer conclude company disclosure control procedure define rule securities exchange act amend act effective management responsible establish maintain adequate internal control financial reporting term define rule act management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission coso base evaluation management conclude internal control financial reporting effective december pricewaterhousecooper llp independent register public accounting firm perform assessment effectiveness company internal control financial reporting attestation report include filing previously disclose company process multiyear implementation enterprisewide resource planning erp system company complete legacy merck erp deployment second quarter deployment erp canada major european market expect erp deploy additional market certain operation addition response business integration activity company continue align streamline design operation financial control environment responsive change business model management report management responsibility financial statement responsibility integrity objectivity company financial statement rest management financial statement report management stewardship company asset statement prepare conformity generally accept accounting principle accordingly include amount base management good estimate judgment nonfinancial information include annual report prepare management consistent financial statement assure financial information reliable asset safeguard management maintain effective system internal control procedure important element include careful selection training development operate financial manager organization provide appropriate division responsibility communication aim assure company policy procedure understand organization staff internal auditor regularly monitor adequacy application internal control worldwide basis ensure personnel continue understand system internal control procedure policy concern good prudent business practice company periodically conduct management stewardship program key management financial personnel program reinforce importance understand internal control review key corporate policy procedure system addition company compliance program include ethical business practice program reinforce company longstanding commitment high ethical standard conduct business financial statement financial information include annual report fairly present material respect companys financial condition result operation cash flow formal certification security exchange commission include filing table content management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule securities exchange act company internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle united states america management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear kenneth frazier peter kellogg chairman president executive vice president chief executive officer chief financial officer item information table content iii item director executive officer corporate governance require information director nominee incorporate reference discussion item election director company proxy statement annual meeting shareholder hold information executive officer set forth document page require information compliance section security exchange act incorporate reference discussion head section beneficial ownership report compliance company proxy statement annual meeting shareholder hold company adopt code conduct value standard applicable employee include principal executive officer principal financial officer principal accounting officer code conduct available company website wwwmerckcomaboutcodeofconductpdf company intend post website amendment waivers code conduct print copy send charge shareholder request write chief ethic officer merck inc merck drive whitehouse station require information identification audit committee audit committee financial expert incorporate reference discussion head board committee companys proxy statement annual meeting shareholder hold item executive compensation information require executive compensation incorporate reference discussion heading compensation discussion analysis summary compensation table compensation table grant planbase award table outstanding equity award table option exercise stock vest table retirement plan benefit relate pension benefit table nonqualifie defer compensation relate table potential payment termination change control include discussion subheading separation individual agreement change control footnote information table company proxy statement annual meeting shareholder hold require information director compensation incorporate reference discussion head director compensation relate director compensation table schedule director fee table company proxy statement annual meeting shareholder hold require information heading compensation committee interlock insider participation compensation benefit committee report incorporate reference company proxy statement annual meeting shareholder hold item security ownership certain beneficial owner management relate stockholder matter information respect security authorize issuance equity compensation plan set forth document information respect security ownership certain beneficial owner management incorporate reference discussion head security ownership certain beneficial owner management company proxy statement annual meeting shareholder hold item certain relationship relate transaction director independence require information transaction relate person incorporate reference discussion head related person transaction company proxy statement annual meeting shareholder hold table content require information director independence incorporate reference discussion head independence director company proxy statement annual meeting shareholder hold item principal accountant fee service information require item incorporate reference discussion audit committee beginning caption pre approval policy service independent register public accounting firm fee companys proxy statement annual meeting shareholder hold item